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Abstract 
BACKGROUND 
Rheumatic Heart Disease (RHD) is a post-infectious immune disease ascribed to an 
interaction between a rheumatogenic strain of group A streptococcus, a susceptible host who 
lives in poor social conditions with limited access to medical facilities.  The disease process 
begins with repeated group A streptococcal (GAS) infections, which, subsequently result in 
acute rheumatic fever (ARF).  In the absence of intervention, repeated bouts of ARF in 
turn, may result in progression to RHD, particularly in those ARF patients with cardiac 
involvement.  The prevalence of ARF and RHD in developed countries has shown 
considerable decline during the last century, largely attributed to improved living 
conditions and access to healthcare.  Epidemiological data from developing countries, 
while scant, indicate a continued high prevalence of GAS-positive pharyngitis and RHD.  
Furthermore, while much is known about the social factors and the microbial agent that 
predispose individuals to ARF, little progress has been made in elucidating genetic 
susceptibility factors that are r producible in different populations.   
 
AIMS OF THIS THESIS 
This thesis aimed to establish determinants of RHD as well as to document the prevalence 
of RHD in South African school children.  The specific objectives of each study 
component were as follows: 
o To derive quantitative estimates of the size of the genetic contribution to the risk of 
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o To determine the prevalence of GAS carriage and emm strains of GAS isolates 
among asymptomatic children enrolled in primary and secondary school. 
o To describe the epidemiology of GAS among 3- to 15-year old children with 
pharyngitis attending primary health care facilities.  
o To develop a clinical prediction rule for diagnosis of GAS throat infection that is 
valid for children aged 5-15 years in the primary care setting within the South 
African context. 
o To determine the prevalence of echocardiographically-proven rheumatic heart 
disease in school children. 
 
METHODS 
The systematic review method was used to investigate population-based twin studies on 
acute rheumatic fever and rheumatic heart disease for evidence for a genetic effect in 
disease susceptibility and/or progression (Study 1).  Langa and Bonteheuwel, two 
juxtaposed township communities of Cape Town with significant socioeconomic 
differences was the setting for all the primary studies.  Healthy children in primary and 
secondary schools were screened for GAS carriage by throat swab culture;  GAS isolates 
were subjected to emm typing to provide insight into vaccine development (Study 2).  The 
prevalence of RHD in healthy learners was established by echocardiography using 
specifically designed criteria (Study 5).  For the clinic-based study, children aged 5-15 
years with pharyngitis rendered throat swabs for microbiological culture (Study 3) while 
for developing the clinical prediction rule (CPR) (Study 4), a multivariate logistic 
regression model was constructed incorporating variables with evidence of association with 
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RESULTS AND DISCUSSION 
Meta-analysis of pooled data from 435 twin pairs from six studies revealed a strong 
concordance risk for ARF (OR 6.39; 95% CI, 3.39 to 12.06; p < 0.001) with an estimated 
heritability across all the studies of 60%.  The populations-based studies among healthy 
learners revealed a carriage estimate for GAS of 3.2% (95% CI:  2.13 – 4.39 %) with < 
50% of emm types in our carrier strains represented in the latest proposed 30-valent 
vaccine. The prevalence of echocardiographically-confirmed RHD was 28.7 per 1,000 
(95% CI, 22.7 – 35.7 per 1,000).  A strong socioeconomic gradient was evident with 
participants from the poorer community having higher rates of carriage and asymptomatic 
RHD.  The period prevalence of GAS pharyngitis in children attending primary heath 
care clinics was 21.6% while the incidence of pharyngitis and GAS pharyngitis was 
0.837/100 person-years and 0.180/100 person-years respectively.  Existing CPRs were 
found to have low applicability in our setting and subsequently, a South African CPR was 
developed. 
CONCLUSION 
The novel findings of this thesis provide evidence for genetic susceptibility for RHD, 
justifying genome wide association studies in RHD patients in the future.  This research 
also emphasises the need for primordial prevention measures to reduce the prevalence of 
GAS carriage and asymptomatic RHD.  Next, it presents the latest report of a rather 
unexpectedly low incidence of GAS pharyngitis in children from poorer communities.  
Finally, this thesis provides an attempt at clinical prediction of GAS pharyngitis in the 
absence of laboratory confirmation of GAS infection.  Once confirmed in other 
populations, the findings of this thesis will make a sizeable impact on reducing the 
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1 BACKGROUND TO THE THESIS 
	  
1.1 PATHOGENESIS AND COURSE OF RHEUMATIC HEART DISEASE 
 
Rheumatic Heart Disease (RHD) is a post-infectious immune disease that is associated with 
significant morbidity and mortality in children and young adults living in developing 
countries.  Acute rheumatic fever (ARF), the precursor to RHD is a multifactorial disorder 
that is caused by an interaction between a rheumatogenic strain of group A β-haemolytic 
Streptococcus and a susceptible host who lives in poor social (Azevedo et al., 2012).  Initially 
described as long as four centuries ago (Stollerman, 2001), and despite many advances of 
the twentieth century, RHD remains a fascinating yet challenging condition as regards the 
precise processes involved in the development of the disease.   
The pathogenesis of RHD is characterised by three stages namely, Group A streptococcal 
(GAS) infection, ARF and RHD (Figure 1.1).  The disease process begins with a GAS 
infection in a susceptible individual. Repeated GAS episodes subsequently result in the 
development of ARF in 0.3 - 3% of individuals which may or may not include cardiac 
involvement (Stollerman, 1995). Without intervention, cumulative attacks of ARF may, in 
due course, result in progression to established RHD, particularly in those ARF patients 
with cardiac involvement.  In this chapter, I discuss the determinants (i.e. agent and host), 
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1.2 THE AGENT:  INFECTION AND IDENTIFICATION OF GAS 
 
Infection with Group A β-haemolytic Streptococcus (Figure 1.2), a gram-positive bacterium 
also known as Streptococcus pyogenes, results in a variety of human such as pyoderma and 
pharyngitis, and invasive group A streptococcal diseases (Box 1.1).  Following the initial 
infection, repeated GAS pharyngeal and skin infections, despite being classified as 
superficial, might give rise to more serious GAS-related illnesses such as acute post-
streptococcal glomerulonephritis, ARF and RHD (Cunningham, 2000, Carapetis et al., 
2005b, Stollerman, 1975, Marijon et al., 2012).  Haemolytic streptococcal species, so-called 
due to the pattern of haemolysis (due to haemolysin streptolysin S) produced round 
colonies on blood agar plates following incubation, were suspected as the causative agent of 
ARF as long ago as at the turn of the previous century.  Subsequent clinical, 
bacteriological, and epidemiological contributions by a number of investigators, including a 
system of serological classification by Rebecca Lancefield, confirmed the causative role of 
Figure 1.2.  Electron micrograph of group A M type 24 streptococci.  
Clearly visible are the surface fimbriae or hairlike projections indicating 
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Streptococcus pyogenes, classified as GAS with the Lancefield serogrouping system, in the 
development of ARF (Stollerman, 1975).   
Box 1.1   Group A streptococcal-related diseases (Steer et al., 2007, 
Cunningham, 2000, Marijon et al., 2012). 
Pharyngitis and Scarlet Fever 
 
Pyoderma and Streptococcal Skin Infections 
 
Invasive Streptococcal Disease:  
      Streptococcal Toxic Shock Syndrome 
      Necrotizing Fasciitis 
      Septicaemia 
 
Post-Infectious Sequelae 
      Rheumatic fever  
      Acute post-streptococcal glomerulonephritis  
      Reactive arthritis  
      PANDAS† 
†PANDAS, Paediatric Autoimmune Neuropsychiatric Disorders Associated 
with Streptococcal infections 
 
1.2.1 Laboratory	  Aspects	  of	  GAS	  
 
In culture, GAS can be differentiated from normal throat flora by their distinct appearance 
as β-haemolytic colonies on 5% sheep agar incubated under anaerobic conditions (Figure 
1.3).  Differences in the cell-wall polysaccharide or lipoteichoic acid components of 
streptococci allow for the further differentiation of β–haemolytic streptococci (βHS) into 
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group A carbohydrate, composed of N-acetylglucosamine linked to a rhamnose polymer 
backbone (Cunningham, 2000, Lancefield, 1941).   
 
Other βHS serotypes include Groups B, C, F, and G.  Grouping antisera employing slide 
agglutination techniques, allow for accurate determination of subgroups following culture 
(Facklam, 1997).  In response to the time constraints of microbiological culture, which 
requires a number of days within which to isolate the bacteria, and the urgency to 
commence treatment, a number of rapid GAS identification tests have been developed 
over the years to assist the clinician in achieving a diagnosis at the point of care (Gerber 
and Shulman, 2004, Maltezou et al., 2008).   
Figure 1.3.  Pattern of haemolysis around streptococcal colonies distinguishing beta (1) with 
large zones of complete haemolysis around colonies from alpha (2) with its incomplete 
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1.2.2 Molecular	  Aspects	  of	  GAS	  	  
Earlier work by Rebecca Lancefield established a type-specific surface antigen on GAS, the 
M-protein, that enabled further classification into antigenically distinct pathogenic strains 
(Lancefield, 1941).  The M-protein, consisting of two polypeptide chains extending from 
the cell wall, comprises four blocks of amino acid residues (Fischetti, 1989) (Figure 1.4).  
Figure 1.4.  Schematic illustration of 
M protein. Individual M proteins form 
coiled coils, which extend from the 
bacterial surface. Two coils wind 
around each other, forming a dimer 
that is stabilized by intermolecular 
interactions between amino acids in 
both strands. The hypervariable N-
terminal region, lacking helical 
structure, is followed by the A, B, C 
and D repeat regions (Smeesters et 
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The variability within the N-terminal region allows for differentiating GAS strains (i.e. M-
typing) using specific M-typing antisera (Cunningham, 2000).   The M-protein is encoded 
by the emm gene and is the major target for the immune system (Scott et al., 1985).  Recent 
advances in molecular biology have resulted in DNA sequence-based methods (emm-
typing) making it possible to differentiate the more than 200 variations in the emm sequence 
(Beall et al., 2000, CDC Protocol for emm typing available at 
http://www.cdc.gov/ncidod/biotech/strep/M-ProteinGene_typing.htm).  The N-terminal 
region of the M-protein is the target for vaccine development, having been shown to evoke 
antibodies with the greatest bactericidal activity, while showing no cross-reaction with 
human tissues (Dale, 2008).   Amino acid sequences of M Proteins of 30 emm types have 
been included in the latest vaccine initiative and preliminary results indicate bactericidal 
killing of >40 % in over 90% of the vaccine serotypes and additional cross-opsonic activity 
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in	  vitro	  percentage	  killing	  in	  human	  whole	  blood	  
Figure 1.5.  Percentage killing by bactericidal antibodies evoked by the 30-valent 
vaccine. A. Vaccine serotypes.  B.  Non-vaccine serotypes  (Dale et al., 2011). 
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1.3  THE HOST: IMMUNE RESPONSE AND PREDISPOSING FACTORS  
The development of RHD is ascribed to an interaction between a rheumatogenic strain of 
group A streptococcus, a susceptible host and environmental factors (Figure 1.6) (Carapetis et 
al., 2005a).   In this section, I review the immunological sequence of events occurring in the 
host following an initial pharyngeal GAS infection, together with host susceptibility and 
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1.3.1 Host	  Response	  Mechanisms	  
Figure 1.7 illustrates the sequence of immunological events leading to the development of 
RHD (Guilherme et al., 2007).  The development of ARF and RHD following an episode 
of GAS pharyngitis is brought about through humoral and cellular mediated molecular 
mimicry whereby some degree of homology between the GAS M protein and host 
structures, result in the recognition, and subsequent damage of host tissues by B- and T-
lymphocytes (Guilherme et al., 2011).  Several cross-reactive epitopes between human 
proteins and the M protein B block have been documented including laminin in heart 
valvular tissue, cardiac myosin and vimentim (Cunningham, 2000, Guilherme et al., 2005). 
Binding to the endothelial surface of the valve by cross-reactive antibodies leads to 
inflammation,  cellular infiltration (supported by evidence for upregulation of the vascular 
cell adhesion molecule-1 (VCAM-1) ((Roberts et al., 2001) and valve scarring (Galvin et al., 
2000).  Further support for the involvement of the humoral immune system is seen in the 
recovery of anti-GAS antibodies from the sera of ARF patients (Carapetis et al., 1996). 
 
Figure 1.7.   Major events triggering rheumatic valvular lesions in RHD. Heart tissue cross-reactive antibodies 
bind to the surface of the valve endothelial and facilitate mainly CD4+ T-cell infiltration.  Streptococcal primed T 
cells trigger an autoimmune reaction  resulting in the production of inflammatory cytokines by mononuclear 
cells.  Regulatory IL4+ cells are found in the valvular tissue leading to the progression of valvular lesions.  
(Guilherme et al., 2007) 
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1.3.2 Genetic	  Predisposition	  in	  the	  Host	  
	  
Various studies suggest that host factors may play a role in individual susceptibility to ARF.  
As early as in the late 1800s, Walter Cheadle noticed that ARF appeared to occur in 
clusters in families (Stollerman, 1975).  Others have also since found a frequent familial 
prevalence of ARF as compared with matched control families (Honeyman and Davis, 
1971, Wilson and Schweitzer, 1937) leading some to conclude the possibility of simple 
recessive mendelian inheritance (Honeyman and Davis, 1971).  A five-year study of 
rheumatic and non-rheumatic families confirmed a high prevalence of ARF among 
individuals from rheumatic families who contracted ARF or developed RHD (Quinn and 
Federspiel, 1967).  Furthermore, familial predisposition has also been demonstrated in an 
evaluation of 19 multiplex families segregating for ARF (Hafez et al., 1985).   
Associations of ARF/RHD with various genes have been investigated.  The initial reports 
of HLA polymorphisms provided evidence of protective HLA class II gene alleles (e.g., 
DRB1*13, DQA1*0103) and susceptibility alleles ( e.g. DRB1*0701, DQA1*0201) to the 
risk of developing RHD (Guedez et al., 1999, Kudat et al., 2006).  A meta-analysis of 10 
studies investigating disease risk associated with HLA-DR antigen expression supported an 
association between major histocompatibility complex class II alleles and risk for RHD. 
(Carlquist et al., 1995).  Increased frequencies of specific HLA antigens in patients with 
ARF/RHD have been reported (Visentainer et al., 2000, Wani, 1997, Hernandez-Pacheco 
et al., 2003a).  There are also reports of non-HLA genes that may be associated with ARF 
including Toll-Like Receptor-2 (Berdeli et al., 2005), Fc fragments of immunoglobulin G 
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2005); and with RHD TNF-α (Hernandez-Pacheco et al., 2003b), Transforming growth 
factor-beta (Hernandez-Pacheco et al., 2003b, Chou et al., 2004a), mannose-binding lectin 
(Jin et al., 2001) and angiotensin I-converting enzyme (Chou et al., 2004b, Davutoglu and 
Nacak, 2005).   Recently, Guilherme and colleagues reviewed the gene polymorphisms 
associated with rheumatic fever in detail (Box 1.2) (Azevedo et al., 2012). 
The three study designs used for testing the level of genetic involvement in a disease     
include familial aggregation, twin, and adoption studies. The familial aggregation study 
assesses the familial recurrence of a condition, enabling for the evaluation of the prevalence 
of a disease within families (Khoury, 1998);  diseases having a genetic predisposition will 
have a higher rate of prevalence compared to the general population.   Thus, where 
relatives are affected with the disease, other family members are expected to have an 
increased risk of developing that disease.  In familial aggregation studies investigating 
ARF/RHD, non-diseased relatives of both probands and matched controls (according to 
age and gender), are observed for the presence or absence of ARF/RHD or rheumatic 
manifestations defined by the proband.  Comparisons according to the odds of exposure 
(i.e. positive family history) in the case subjects are compared to the odds of exposure in the 
control subjects. By using a two-by-two table; measures of association such as odds ratio 
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Box 1.2.  Gene polymorphisms associated with RF and/or its manifestations (Azevedo et al., 2012) 
MBL, mannose-binding lectin;  TLR2, toll-like receptor-2; FCN2, ficolin-2; TNFa, tumor necrosis factor-a;  TGFb,  
transforming growth factor-b;  CTLA-4, cytotoxic T-lymphocyte antigen-4; IL1RN, interleukin-1receptor antagonist gene;  
IL10, interleukin-10;  ACE, angiotensin-converting enzyme;  AoR, aortic regurgitation; MVL, multivalvular lesion; OCD,  
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Twin and adoption studies provide the opportunity to delineate the contribution of genetics 
versus environment to the development of diseases.  A comparison of the concordance 
rates between monozygotic (MZ) twins, who are genetically identical, and dizygotic twins 
who, on average, share 50% of their DNA, serves to indicate the role of genetics in the 
aetiology of a disease (Farrer LA, 1998).  Studies of twins have to date, provided compelling 
evidence of a genetic component in a number of diseases including psychosis (Allan et al., 
2009), stroke (Flossmann et al., 2004), breast cancer (Mack et al., 2002), osteoporosis 
(Miakotkin and Benevolenskaia, 2008) and familial Mediterranean fever (Shohat et al., 
1992). 
1.3.3 Role	  of	  Environment	  	  
During the last century, the prevalence of ARF and RHD in developing countries has not 
shown the decline observed in industrialised countries, which has largely been attributed to 
poor living conditions and reduced access to healthcare (Quinn, 1989).  A recent review 
presented evidence for the role played by socioeconomic factors such as overcrowding, 
nutrition and access to medical services in susceptibility to developing ARF (Steer et al., 
2002).  As can be expected, lower socioeconomic conditions predispose to a higher burden 
of GAS pharyngitis (Nandi et al., 2001). 
Contrasting views of the role of environment have also been presented.  In the earlier part 
of the previous century, Wilson reported no increased risk of ARF in rheumatic siblings 
living in poorer conditions as compared with those from wealthier environments (Wilson 
and Schweitzer, 1937).  Thus, environmental factors may only partially explain 
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1.4 THE DISEASE:  GAS PHARYNGITIS, ARF AND RHD 
1.4.1 GAS	  Pharyngitis	  
Pharyngitis, from Greek, ‘pharynx’, meaning throat and ‘-itis’, suffix meaning inflammation, 
refers to swelling accompanied by pain or discomfort in the throat, often resulting in 
difficulty with swallowing.  Most cases of sore throat are due to viral infections such as 
influenza, requiring symptomatic treatment before eventually self-resolving.  GAS 
pharyngitis specifically refers to sore throat resulting from an infection with GAS.  Surface 
streptococcal ligands on the bacterium bind to specific receptors on host pharyngeal cells 
thereby inducing ingestion (LaPenta et al., 1994) (Figure 1.8).  Failure to eradicate 
streptococci from the pharynx occurs in about 1/3 of non-treated cases, giving rise to the 
carrier status in those individuals harbouring intracellular GAS (Markowitz et al., 1993). 
Figure 1.8.  Electron micrograph (x12,700 magnification) demonstrating the 
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1.4.1.1 Symptoms and Diagnosis of GAS Pharyngitis  
The management of pharyngitis is of major public health concern and the appropriate use 
of antimicrobial therapy is an important strategy in the reduction of the incidence of ARF 
and RHD (Karthikeyan and Mayosi, 2009, Robertson et al., 2005a). GAS pharyngitis is 
characterised by throat pain with none or some of the symptoms of fever, chills, malaise, 
headache, abdominal pain, nausea, and vomiting (Wannamaker, 1972) (Box 1.3) (World 
Box 1.3   Clinical signs and symptoms of group A streptococcal upper respiratory tract infection, by 
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Health Organization., 2004) .   The number of national and local guidelines that have been 
developed over the years bears testimony to the importance of correctly identifying GAS 
pharyngitis to ensure timely treatment (Bisno et al., 1997, Wachtler and Chenot, 2011, 
Matthys et al., 2007, Marres, 2008, Kerdemelidis et al., 2009, Chiappini et al., 2012).  
While a number of rapid diagnostic tests has been developed in recent years, 
microbiological culture of throat swabs remains the gold standard for diagnosing the 
presence of GAS upon presentation of pharyngitis. 
1.4.1.2 Clinical Prediction Model Development 
Clinical prediction rules (CPRs) serve to aid diagnostic evaluation, particularly in low-
resourced settings where laboratory facilities may not be available. They are practical 
decision tools, incorporating a limited number of variables obtained at the time of 
examination, to derive a probability score for directing a course of action (Wasson et al., 
1985, Laupacis et al., 1997).  
 
Development of Clinical Prediction Rules 
The development of CPRs involves a preceding decision phase that will impact on the final 
model’s application to the disease of interest (Box 1.4).	   	   Selecting candidate variables 
generally follows a systematic review of the literature, taking into account pre-existing 
knowledge of clinical predictors of the disease of interest (Spiegelhalter, 1986).  It is often 
preferable to limit the number of variables, especially given that simpler models are easier 
to apply in practice (Laupacis et al., 1997).  Following enrolment and collection of the 
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quality, especially documenting the reasons for missing values and possibly excluding those 
predictors for which the cut-off threshold (usually < 5%) for missing data has been 
exceeded. 
Box 1.4   Decisions affecting CPR model development (Royston et al., 2009).   
1 Selecting clinically relevant candidate predictors for possible inclusion in the model 
2 Evaluating the quality of the data and judging what to do about missing values  
3 Data handling decisions such as combining or creating new variables 
4 Choosing a strategy for selecting the important variables in the final model  
5 Deciding how to model continuous variables  
6 Selecting measure(s) of model performance or predictive accuracy. 
 
 
Statistical Procedures in Developing a CPR 
A univariate analysis is conducted as the preliminary step to evaluate the potential 
contribution of the individual variables, based on their respective significance levels of 
association with the outcome of interest, to the final model.  Regardless of the univariate 
analysis results though, variables known to be associated with the disease of interest should 
be included in developing the final model.  The backward elimination technique is 
commonly used to derive the final model (Steyerberg et al., 2000);  in brief, a series of 
logistic regression procedures are conducted, initially incorporating all the candidate 
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significance level after each round of testing.  Overall performance of the prediction model 
is assessed using the receiver operating curve (ROC) where sensitivity is plotted against the 
false positive rate for different cut-off points of a parameter and the area under the curve is 
a measure of the distinguishing ability of the model, also known as the c-statistic (Zweig and 
Campbell, 1993). Values closer to 1 indicate relatively superior performance as compared 
with values of 0,5.  Following the derivation of the best-fit model, beta coefficients are 
generated using the ‘logit’ (in Stata®) command and transformed by multiplying by a 
factor, into points, which constitute the scoring chart. The final step is the validation of the 
prognostic model, where the model’s performance is evaluated in different groups of 
patients (Altman et al., 2009). 
1.4.1.3 Clinical Prediction Rules for GAS Pharyngitis 
In resource-limited settings, sending throat swabs for culture is not always feasible given the 
cost of the investigations and the waste incurred if patients do not return for follow up of 
results.  In addition to the guidelines provided by the World Health Organisation (WHO) 
(WHO, 1995) on empiric treatment with antibiotics in the absence of laboratory 
confirmation, various CPRs to predict streptococcal sore throat have been derived over the 
last decade, many of which were from developed country settings (Wald et al., 1998, 
McIsaac et al., 1998, Breese, 1977, Centor, 2009, Attia et al., 2001, Joachim et al., 2010).  
Table 1.1 contains some examples of well-known CPRs for GAS pharyngitis together with 
scores given to the presence or absence of specific variables. 
CPRs for the prediction of GAS-positive pharyngitis in children aged 3 to 18 years 
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2011).  Thirty-four studies (totaling 24,418 patients) from clinics and emergency 
departments from a number of resource settings were included. Five of the current 
prediction rules were inaccurate in providing a definitive diagnosis of streptococcal 
pharyngitis leading the authors to support rapid testing or throat culture in suspected GAS 
cases as suggested by the American Academy of Pediatrics, the American Heart 
Association, and the Infectious Disease Society of America. 
It is imperative to test and validate CPRs in local settings in different groups of patients 
before they are rolled out as standard practice of care (McGinn et al., 2000).  In fact, two of 
the rules included in the table above (Smeesters et al., 2006, Steinhoff et al., 2005) were 
developed in resource-constrained scenarios in response to poor performance of CPRs 
from developed country settings. The 3-variable Steinhoff rule, which presents a modified 
version of the Abu Reesh rule was developed in the Abu Reesh Hospital in Cairo following 
the enrolment of 410 participants aged 2 to 12 years who presented at the children’s 
hospital with pharyngitis, while the CPR developed by Smeesters prospectively included 
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Table 1.1  Summary of clinical prediction rules (modified from (Fischer Walker et al., 2006)). 
	   	   	   	  Rule	   Clinical	  signs/symptoms	   Score	  if	  present	   Score	  if	  absent	  
Abu	  Reesh	   Exudate	  or	  enlarged	  lymph	  nodes	  	   1	   0	  
Attia	  et	  al	   Moderate	  to	  severe	  tonsillar	  swelling	  	  
Moderate	  to	  severe	  large	  cervical	  nodes	  	  
Scarlatiniform	  rash	  	  






Breese	  et	  al	   Season	  	   1-­‐4	  
	  	  	   Age	  	   1-­‐4	  
	  
	  
White	  blood	  cell	  count	  	   1-­‐6	  
	  
	  
Fever	  (>100.5°F)	  	   4	   2	  
	  
Sore	  throat	  	   4	   2	  
	  
Headache	  	   4	   2	  
	  
Abnormal	  pharynx	  	   4	   2	  
	  
Abnormal	  cervical	  lymph	  nodes	  	   4	   2	  
	  
Cough	  	   2	   4	  
Centor	  et	  al	   Tonsillar	  exudate	  	   1	   0	  
	  
Swollen	  tender	  anterior	  cervical	  lymph	  nodes	   1	   0	  
	  
Cough	  	   0	   1	  
	  
History	  of	  fever	  	   1	   0	  
McIsaac	  et	  al	   Temperature	  >38°C	  	   1	   0	  
	  	   Cough	  	   0	   1	  
	  
Tender	  anterior	  cervical	  lymph	  nodes	   1	   0	  
	  
Tonsillar	  swelling	  or	  exudate	  	   1	   0	  
	  
Age	  in	  years	  3–14	  /	  15–44	  /	  ≥	  45	   1	  /	  0	  /	  -­‐1	   0	  
Smeesters	  er	  
al	  
Age	  ≤35	  /36-­‐59/≥60	  months	  
Viral	  signs:	  	  1/≥	  2	  	  
Bacterial	  signs:	  	  1	  /	  ≥	  2	  
20	  /	  6	  /	  2	  
7	  /	  10	  




Steinhoff	  et	  al	   Enlarged	  lymph	  nodes	  	   1	   0	  
(3-­‐variable)	   Rash	  	   0	   1	  
	  	   Rhinitis	  	   0	   1	  
Wald	  et	  al	   Age	  (5–15	  years)	  	   1	   0	  
	  
Season	  (November–May)	  	   1	   0	  
	   Fever	  (>38.3°C)	  	   1	   0	  
	  
Enlarged	  or	  tender	  lymph	  nodes	  	   1	   0	  
	  
Erythema,	  swelling,	  or	  exudate	  on	  pharynx	  or	  
tonsils	  
1	   0	  
	  
Upper	  respiratory	  tract	  symptoms	   0	   1	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1.4.1.4 Treatment of GAS pharyngitis in SA 
In South Africa, guidelines for the management of pharyngitis (including bacterial 
tonsillitis) are provided in the Department of Health publications, Standard Treatment 
Guidelines and Essential Drugs List (EDL) for South Africa, Primary Health Care 2003 Edition 
(Department of Health, 2006) and National Guidelines on the Primary Prevention and Prophylaxis of 
Rheumatic Fever and Rheumatic Heart Disease for Health Professionals at Primary Level (Department of 
Health, 1999) .  Clinical features suggestive of β-haemolytic streptococci group A are sore 
throat, inflamed tonsils with exudate, tender and enlarged cervical lymph nodes and often, 
sudden onset of fever as illustrated in Box 1.5.  
The widespread, often inappropriate use of macrolide antibiotics, which are often used in 
the treatment of sore throat as an alternative to penicillin, is adding to the growing problem 
of bacterial resistance to antimicrobials (Silva-Costa et al., 2012).  A recent study of 
prescribing in the South African private sector revealed that over 70% of consultations 
resulted in the prescription of an antimicrobial agent and that antimicrobials were 
prescribed, even when the cause of the illness was stated to be viral (Katende-Kyenda et al., 
2006). Elsewhere, healthy volunteers given azithromycin and clarithromycin showed a 
significant increase in the proportion of resistant streptococci in the pharynx within a few 
days, which remained high up to 180 days later (Malhotra-Kumar et al., 2007).  In many 
parts of the world, antimicrobial resistance to macrolides is increasing, an example being 
Greece where a prevalence of resistant GAS has been reported to be over 30% prevalence 
of (Syrogiannopoulos et al., 2004).  By comparison, only 60,6% of respiratory isolates of 
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geographical regions of South Africa were susceptible to erythromycin (Zietsman and A.J., 
2011). 
 
Box 1.5   South African EDL:  Diagnosis and Treatment of 




Viruses are the most common cause of acute pharyngitis and a cross-sectional study 
performed in South Africa in 1979 found that only 33.2% of patients who presented with 
sore throat had GAS on culture of throat swabs (van Zyl et al., 1981).  Therefore, given 
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pharyngitis, it would thus be ideal to correctly identify those patients with streptococcal 
pharyngitis who would benefit from antimicrobial therapy while avoiding antimicrobial use 
in pharyngitis.  There is no CPR for application in the South African population and thus, 
the diagnosis of streptococcal pharyngitis is made on suggestive clinical features and 
empirical antimicrobial therapy is prescribed (Brink et al., 2004).  This practice is endorsed 
in local guidelines, at least for the age group at high risk for ARF (Department of Health, 
1999). 
 
1.4.2 Acute	  Rheumatic	  Fever	  	  
ARF develops between one and six weeks following an episode of GAS pharyngitis that has 
been left untreated in susceptible children and adolescents aged 5-15 years (Rammelkamp 
and Stolzer, 1961, Quinn and Federspiel, 1967).  ARF is a multi-organ disease 
characterised by inflammation of joints, heart structures, central nervous system and skin. 
The revised, updated and modified Jones’ criteria (Special writing group of the committee 
on rheumatic fever, 1992), is recommended by the American Heart Association for 
diagnosing ARF, although Carapetis argues for considering the 2002 – 2003 WHO criteria 
(World Health Organization., 2004) (Box 1.6) which enhances the diagnosis of recurrent 
ARF in  patients with established RHD (Carapetis et al., 2005a).  Symptoms do however, 
vary, depending on the tissues involved, although polyarthritis is the most common 
(Cunningham, 2000).  Carditis, which is seen in 65% of patients, is the most serious 
complication of ARF given that ARF patients with carditis go on to develop RHD (Bland 
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Box 1.6   2002–2003 WHO criteria for the diagnosis of rheumatic fever and rheumatic heart 




Primary episode of RF.m 
Recurrent attack of RF in a patient without 
established rheumatic heart disease.b 
Recurrent attack of RF in a patient with 
established rheumatic heart disease. 
Rheumatic chorea. 
Insidious onset rheumatic carditis.b 
Chronic valve lesions of RHO {patients 
presenting for the firs t time wi th pure 
mitral stenosis or mixed mitral valve 
disease and/or aortic valve disease).d 
• Major manifestations 
•• Minor manifestations 
••• Supporting evidence of a preced ing 
streptococcal infection within the last 
45 days 
Criteria 
Two major ' or one major and two minor" 
manifestations plus evidence of a 
preceding group A streptococcal 
infection· .. . 
Two major or one major and two minor 
manifestations plus evidence of a 
preceding group A streptococcal infection. 
Two minor manifestations plu s evidence of 
a preceding group A streptococcal 
infection.c 
Other major manifestations or evidence of 
group A streptococcal i fection not 
required. 
Do not require any other criteria to be 





- erythema marg inatum 
- subcutaneous nodules 
- clinical: fever, polyarthralgia 
- laboratory: elevated acute phase 
reactants (erythrocyte sedimentation rate 
or leukocyte count) 
- electrocardiogram: prolonged P-R interval 
- elevated or rising antistreptolysin-O or 
other streptococcal antibody, or 
- a positive throat cul ture , or 
- rapid antigen test for group A 
streptococci, or 
- recent scarlet fever. 
• Patients may present with polyarthritis (or with only polyarthralgia or monoarthritis) and with several 
(3 or more) other minor manifestations, together with evidence of recent group A streptococcal 
infection. Some of these cases may later turnout to be rheumatic fever. It is prudent to consider them 
as cases of "probable rheumatic f,lVer" (once other diagnoses are excluded) and advise regular 
secondary prophylaxis. Such patients require close follow up and regular exam ination of the heart. 
This cautious approach is particularly suitable for patients in vulnerable age groups in high 
incidence settings. 
b Infective endocarditis should be e~cluded . 
C Some patients with recurrent attacks may not fulfil these criteria. 
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1.4.3 Rheumatic	  Heart	  Disease	  
	  
RHD is characterized by permanent valve damage resulting from the cumulative effects of 
recurrent attacks of ARF, although initial attacks can lead directly to RHD diagnosed in 
patients with no recollection of ARF (Carapetis et al., 2005a, Marijon et al., 2012).   More 
than one valve may be affected, although the most common lesion is mitral valve disease 
(Bland and Duckett Jones, 1951, Rashed et al., 2007).  On pathological examination, the 
mitral valve shows a deformed appearance with thickening of the leaflets as a result of 
cellular infiltration during the immunological response, which is also responsible for the 
diminished movement of the valve.  In addition, neovascularisation, the after-effect of 
inflammation, interstitial calcification, as well as the presence of Aschoff’s nodules, which 
comprises degenerated collagen surrounded by activated histiocytic cells and lymphoid 
cells, may also be noted (Veasy and Hill, 1997, Stollerman, 1975) (Figure 1.9).  The valve 
surface may also show ulceration and have fibrinous vegetations near the line of closure 
(Rashed et al., 2007).   Shortening and thickening of the chordae tendineae and papillary 
muscles result in the so-called “funnel-shaped valve” (Stollerman, 1975).  For the remaining 
valves, deformities rarely occur in isolation (Shrestha et al., 2012).  Tricuspid valve 
deformities in chronic RHD are rare, although the risk of tricuspid valve regurgitation 
increases following successful mitral valve surgery or development of pulmonary 
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1.4.3.1 Echocardiographic criteria for the diagnosis of RHD 
In diagnosing subclinical RHD, echocardiography has been shown to be significantly 
superior by as much as ten-fold as compared with traditional auscultation for a heart 
murmur (Figure 1.10) (Reeves et al., 2011, Marijon et al., 2012).  Recently, new 
standardized international echocardiographic guidelines, The World Heart Federation criteria 
for echocardiographic diagnosis of rheumatic heart disease, were developed with clear definitions for 
the diagnosis of RHD across three categories namely, ‘definite RHD’, ‘borderline RHD’, 
and ‘normal’ using assessment by 2D, continuous-wave and color-Doppler 
echocardiography (Remenyi et al., 2012).  Further subcategories are also defined within the 
‘definite RHD’ diagnosis (Box 1.7). 
Figure 1.9.  Light microscopy image of mitral valve from RHD patients undergoing 
surgery, showing neovascularization (NV), lymphocytes infiltration (LI) and 













Chapter	  1:	  	  Background	  to	  the	  thesis	  
PhD	  Thesis:	  	  Mark	  E	  Engel	  	   	   |	  Page	  28	  
 
Figure 1.10.  Rheumatic heart disease (RHD) prevalence rates in children: 
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Box 1.7   2012 WHF criteria for echocardiographic diagnosis of RHD (Remenyi et al., 2012) 
Echocardiographic criteria for individuals aged ≤20 years 
Definite RHD (either A, B, C, or D): 
A) Pathological MR and at least two morphological features of RHD of the MV 
B) MS mean gradient ≥ 4 mmHg* 
C) Pathological AR and at least two morphological features of RHD of the AV‡ 
D) Borderline disease of both the AV and MV§ 
Borderline RHD (either A, B, or C): 
A) At least two morphological features of RHD of the MV without pathological MR or MS 
B) Pathological MR 
C) Pathological AR 
Normal echocardiographic findings (all of A, B, C, and D): 
A) MR that does not meet all four Doppler echocardiographic criteria (physiological MR) 
B) AR that does not meet all four Doppler echocardiographic criteria (physiological AR) 
C) An isolated morphological feature of RHD of the MV (for example, valvular thickening) without 
     any associated pathological stenosis or regurgitation 
D) Morphological feature of RHD of the AV (for example, valvular thickening) without any associated  
     pathological stenosis or regurgitation 
Echocardiographic criteria for individuals aged >20 years 
Definite RHD (either A, B, C, or D): 
A) Pathological MR and at least two morphological features of RHD of the MV 
B) MS mean gradient ≥ 4 mmHg* 
C) Pathological AR and at least two morphological features of RHD of the AV, only in individuals 
     aged <35 years‡ 
D) Pathological AR and at least two morphological features of RHD of the MV 
Morphological features of RHD 
Features in the MV 
• AMVL thickening* ≥ 3 mm (age-specific)‡ 
• Chordal thickening 
• Restricted leaflet motion§ 
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Morphological features of RHD (cont’) 
Features in the AV 
• Irregular or focal thickening 
• Coaptation defect 
• Restricted leaflet motion 
• Prolapse 
Criteria for pathological regurgitation 
 
Pathological mitral regurgitation 
(All four Doppler echocardiographic criteria must be met) 
• Seen in two views 
• In at least one view, jet length ≥2 cm* 
• Velocity ≥3 m/s for one complete envelope 
• Pan-systolic jet in at least one envelope 
 
Pathological aortic regurgitation 
(All four Doppler echocardiographic criteria must be met) 
• Seen in two views 
• In at least one view, jet length ≥1 cm* 
• Velocity ≥3 m/s in early diastole 
• Pan-diastolic jet in at least one envelope 
 
*A regurgitant jet length should be measured from the vena contracta to the last pixel of regurgitant 
color (blue or red). 
*Congenital MV anomalies must be excluded. Furthermore, inflow obstruction due to non-rheumatic 
mitral annular calcification must be excluded in adults. ‡Bicuspid AV, dilated aortic root, and 
hypertension must be excluded. §Combined AR and MR in high prevalence regions and in the 
absence of congenital heart disease is regarded as rheumatic. Abbreviations: AR, aortic 
regurgitation; AV, aortic valve; MR, mitral regurgitation; MS, mitral stenosis; MV, mitral valve; RHD, 
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1.5 EPIDEMIOLOGY OF GAS, ARF AND RHD IN SCHOOL CHILDREN 
The prevalence of ARF and RHD in developed countries has shown considerable decline 
during the last century, largely attributed to improved living conditions and access to better 
healthcare (Quinn, 1989).  Figure 1.11 demonstrates the declining rates of death per 
100,000 due to ARF over the decades, highlighting significant milestones and achievements 
in medical science (Bonow and Braunwald, 2012).  
In contrast, epidemiological data from developing countries, while scant, indicate the 
continued high prevalence of GAS-positive pharyngitis and RHD.  Alarmingly, a 
resurgence of ARF/RHD has been observed in the former Soviet Union republics of 
Central Asia (Omurzakova et al., 2009).  In fact, a recent review on the worldwide 
epidemiology of ARF and RHD identified increasing trends in the prevalence of RHD for 
Figure 1.11.  Declining rates of death due to Rheumatic Fever.  Dotted 
arrows indicates dates of revision of Jones’ Criteria or World Health 
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each WHO region in the world except for Europe (Figure 1.12) (Seckeler and Hoke, 2011);  
these findings are probably attributed to better ascertainment  through the use of portable 
echocardiography, and better survival of cases of RHD. 
 
As regards Africa though, few studies on the epidemiology of ARF/RHD are reported 
particularly in South Africa and efforts are underway to ascertain the burden of disease in 
Africa and elsewhere through initiatives such the REMEDY study (Karthikeyan et al., 
2011).  Recently, Sliwa et al. estimated an annual incidence of 23.5 new cases of RHD per 
100,000 population aged >14 years in the areas surrounding Johannesburg.  This study, 
Figure 1.12.  Trends of rheumatic heart disease prevalence per 1000 persons for each WHO region, 
A) The Americas, B) Europe, C) Africa, D) Eastern Mediterranean, E) Western Pacific, and F) 
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conducted over 24 months in a cardiac clinic of a large hospital, documented all patients 
with a first-time diagnosis of heart failure due to RHD; all ages of patients were 
represented, thus confirming that RHD is present throughout the life course (Sliwa et al., 
2010).    
The epidemiology of GAS pharyngitis, ARF, and RHD is considered below, with 
particular emphasis on school children.  
 
1.5.1 Group	  A	  Streptococcus	  	  
1.5.1.1 Asymptomatic Pharyngeal Carriage  
Asymptomatic children can be a major reservoir of pharyngeal GAS.  A pooled GAS 
carriage prevalence of 12% (95% CI: 9% - 14%) in healthy children aged 5 – 17 years was 
reported in a recent review of 18 clinic- and school-based studies on streptococcal carriage 
in both industrialised and developing countries (Shaikh et al., 2010).  Amongst the seven 
studies on school-aged children included in the review, the prevalence of asymptomatic 
carriage ranged from 10% in Sweden to 21% in Iran.  
In another 16-month follow-up study conducted in community-based family medicine 
practices in Australia, seasonal carriage rates ranged from 8% - 16% amongst 160 
randomly selected families (Danchin et al., 2007), while in a prospective surveillance study 
conducted over 9 months in Fiji, a GAS carriage of 6.0% was observed amongst 685 
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Results from India show contrasting figures;  in Chennai, 8.4% of 1102 school children 
from overcrowded government or charity-aided schools in slum-like conditions harboured 
GAS (Lloyd et al., 2006) while in a rural community in Northern India, a prevalence rate 
of only 1.3 per cent was observed in 3385 children aged 5-15 years (Kumar et al., 2009a).  
Still within the region, a cross-sectional study across 4 schools in Nepal, isolated GAS from 
10,9% of 350 students 5-15 years of age (Dumre et al., 2009).  Elsewhere, in Grenada, a 
study conducted in randomly selected schools observed a GAS prevalence of 5.2% among 
1388 children aged 5-15 years (Noel et al., 2005).  
Data on GAS carriage from countries in Africa remain scant with only a few studies 
reporting on carriage.  In Ethiopia, Abdissa reported a 9.7% carriage rate in pharyngeal 
isolates from 937 healthy participants aged 6-14 years (mean age, 11 years) (Abdissa et al., 
2011).  An earlier study in Tunisia documented a rate of 9.0% from throat swabs taken 
from 155 controls (Mzoughi et al., 2004).  More recently, Sadoh reported a prevalence of 
almost 10% among asymptomatic school children in Nigeria (Sadoh and Omokhodion, 
2007).  Table 1.2 provides details of individual studies conducted outside of South Africa.   
Of particular interest is that a number of the studies failed to confirm the absence of recent 
infection by serology.  Most studies though, did note the symptoms at the time of the 
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Table 1.2.  GAS carriage among asymptomatic children in countries outside of South Africa 
Study Country Study Design Prevalence Serology Symptoms  
(Abdissa et al., 2011) Ethiopia Cross-sectional 9.7% ND Y 
(Danchin et al., 2007) Australia Longitudinal  8%-16% ND Y 
(Dumre et al., 2009) Nepal Cross-sectional 10.9% ND N 
(Kumar et al., 2009b) Northern India Cross-sectional  1.3% ND Y 
(Lloyd et al., 2006) Chennai, India Cross-sectional 8.4% ND Y 
(Mzoughi et al., 2004) Tunisia Longitudinal 9.0% UC UC 
(Noel et al., 2005) Grenada Cross-sectional 15.4% Y UC 
(Sadoh and 
Omokhodion, 2007) 
Nigeria Cross-sectional 10% ND Y 
(Steer et al., 2009) Fiji Longitudinal 6% ND Y 
ND, not done;  Y, yes;  N, no;  UC, unclear. 
 
In South Africa, there is a dearth of recent studies on GAS carriage rates in school-aged 
children, with only four studies conducted more than 25 years ago.  In a study of 12,050 
school children from largely lower-socioeconomic households in Soweto, isolation rates of 
5.2% were reported with a significantly higher rate of GAS isolation during the winter 
months and a peak incidence in fifth and sixth school grades (McLaren et al., 1975),  In 
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and 16.8% were reported in asymptomatic Black participants from a remote traditional 
community and an urban setting respectively (Van Staden et al., 1982).   In the same study, 
urban Whites had a carriage prevalence of only 3.4%.  A study conducted in the late 1970s 
in the densely overcrowded Hout Bay community of Cape Town reported an overall 
prevalence of 3.6% amongst 1150 children aged 6 – 17 years (Bundred, 1986).  The two 
schools surveyed had respective prevalence rates of 2.4% and 12%, the latter speculated to 
be reflective of the 10 km distance from the nearest primary health care polyclinic.  Finally, 
a study involving mostly grade 3 school children of either mixed or Indian ancestry 
reported GAS carriage rates >20% in summer and <5% in spring (Ransome et al., 1983). 
Few studies report on the distribution of emm types amongst asymptomatic GAS carriers; 
in Fiji, while not reporting specific emm types, Steer et al observed that 32% of GAS emm 
sequence types were shared between carriage and sore throat isolates (Steer et al., 2009).  
To date, only one study reports on the distribution of emm types amongst asymptomatic 
GAS carriers in Africa, indicating diversity in M strains (Abdissa et al., 2006). 
1.5.1.2 GAS Pharyngitis  
GAS-positive pharyngitis is among school-aged learners, with the peak age of incidence for 
GAS infections being between 5 and 15 years (WHO, 2004).  
Generally, developing countries have higher prevalence rates of GAS isolated from patients 
with pharyngitis compared with industrialised nations, except for impoverished populations 
within industrialised countries (Steer et al., 2007).  A recent review of 17 studies of GAS 
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sore throat from both industrialised and developing countries (Figure 1.13) (Shaikh et al., 
2010).  Of the studies included in the review, the prevalence rates ranged from 23% in the 
United States to 58% in a study from the Netherlands;  although, on closer inspection of 
the Netherlands study, the isolation of GAS was actually only 32% (Dagnelie et al., 1993).  
In the same review, two studies from developing countries reported rates of 45% (Sri 
Lanka) and 33% (Egypt/Croatia/Brazil) respectively.  
In a hospital-based study from Kolkata, GAS was isolated from 42 out of 100 throat swabs 
from patients of all ages presenting with pharyngitis, with a peak incidence observed in the 
5-15 years age group (Ray et al., 2010).  Elsewhere in India, a cross-sectional study 
Figure 1.13.  Prevalence of GAS Infection Among Children Presenting With Sore Throat (Shaikh 
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comprising 4249 children aged 5-15 years from 25 randomly selected villages in the 
Panchkula district of Haryana in northern India, reported respective prevalence rates for 
βHS and GAS of 25.7% and 2.8% from children with pharyngitis with rates of isolation 
being significantly higher in the winter months (Kumar et al., 2009a).  In the same study, 
the investigators observed pharyngeal βHS and GAS carriage rates of 15.4% and 1.3% 
respectively. 
 A number of studies have documented incidence of GAS pharyngitis.  Table 1.3 
summarizes the respective incidence rates of acute sore throat and GAS swab-positive 
pharyngitis, indicating the method of ascertainment of participants.  
 
Prevalence and incidence data on GAS pharyngitis from developing countries are largely 
lacking as compared with industrialised nations (Carapetis et al., 2005a), especially in 
Table 1.3.  Incidence of symptomatic GAS pharyngitis among children 
Study Country Method of 
Ascertainment 
Incid of sore throat / 
100 child-yrs 
Incid of GAS pharyngitis / 
100 child-yrs 
(Duben et al., 1979) (Former) Czechoslovakia Active 8.3 3.9 
(Nandi et al., 2001) Northern India Active 705 95 
(Danchin et al., 2007) Melbourne, Australia Active 33 13 
(Steer et al., 2009) Melbourne, Australia Active 162 14.7 
(McDonald et al., 2006) Darwin, Australia Active 8 0 
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South Africa.  A study conducted in Pretoria over 30 years ago on 232 unselected patients 
who presented with a complaint of sore throat reported an overall prevalence of 33.2% 
with a significant difference between rates for Blacks (45.5%) and Whites (23.2%) (van Zyl 
et al., 1981).  No variation in rates was observed by season and the overall background 
carriage rate of 165 controls was 12.1% (Blacks, 16.8%; Whites, 3.4%).  In another study of 
112 participants aged two to nineteen years of age conducted during the summer months 
at a hospital serving the Black community in Bloemfontein, 42% of throat swabs cultured 
returned a positive GAS result (Olivier and de Graad, 1978).   
 
1.5.2 Acute	  Rheumatic	  Fever	  
The ascertainment of true incidence rates of ARF is often hampered by the lack of active 
national control programmes to ensure adequate reporting and control through the use of 
registry-based systems (McDonald et al., 2005), a phenomenon also observed in South 
Africa (Robertson et al., 2005b). 
A recent systematic review included 14 papers on the burden of ARF, observing a global 
distribution in the incidence rates reported (Jackson 2011);  incidence and mortality rates in 
developed countries remain low, while for Sudan, an incidence of 826 per 105 amongst 
school children was reported, an incidence greater than 15 times the previous estimate of 
50 per 100 000 children in developing countries (Carapetis et al., 2005a).  Seckler and 
colleagues recently highlighted the global distribution of trends in the incidence of ARF, 
indicating increases in the Americas, Eastern Mediterranean countries and Southeast Asia 
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incidence of ARF reported in Africa is probably attributed to ascertainment bias in that 
episodes of ARF may often go unnoticed in poor countries with poor access to health care 
and health-seeking behaviour on the part of the patients (Karthikeyan and Mayosi, 2009). 
For South Africa, anecdotal information suggests that the incidence of ARF remains quite 
high and in fact, South Africa may be in the midst of an ARF epidemic (Department of 
Health, 2002b), despite national guidelines and recommendations for antibiotic prevention 
of the disease (Department of Health, 1999, Department of Health, 2006).  Practical 
experience indicates a high incidence of ARF and prevalence of RHD accounting for 2% 
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1.5.3 Rheumatic	  Heart	  Disease	  
	  
Data on RHD show variation across different regions of the world with prevalence rates 
from as low as 68 per 100,000 in India to as high 3320 per 100,000 in Tonga and mortality 
rates from 1.2 to 2.8 per 100,000 reported in a recent review (Jackson et al., 2011).  African 
data as regards RHD mortality remain scant, with no African studies available for inclusion 
into the review.  
While a number of school-based studies on the prevalence of RHD have been reported, the 
majority of these did not employ echocardiography for screening.  Instead, 
echocardiography was often only used to confirm clinical suspicion.  Thus, current 
estimates may well represent an under estimation of the prevalence, given that of late, a 
number of reports have shown echocardiography to be a more sensitive approach for 
screening than auscultation, detecting up to ten times more cases than auscultation in some 
studies (Marijon et al., 2008).   
Prevalence rates for echocardiographically-screened RHD amongst school children range 
from 2.7 per 1000 to 50 per 1000.  Table 1.4. illustrates the prevalence rates obtained by 
echocardiography-based screening and the criteria used for diagnosis.  When put into a 
meta-analysis, the pooled prevalence rate for definite or probable RHD as defined by 
WHO criteria (where it was possible to extract data from the original reports), is 15 per 
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Table 1.4.  Prevalence of RHD among asymptomatic school children (as extracted from original reports) screened by 
echocardiography 
Author Study Date Country Criteria N pr / 1000 (95% CI)  
(Anabwani et al, 1996) 1994 Kenya “Colour flow”  1115 2.7 (0.6 – 7.8)  
(Marijon et al., 2009) 2001 - 2 Cambodia “Consensus-based”  3677 21.5  (16.8 – 26.2) 
(Carapetis et al., 2008) 2003 - 4 Tonga Modified WHO 5053 33.2 (28.7 – 38.6) 
(Marijon et al., 2009) 2005 Mozambique “Consensus-based”  2170 30.4 (23.3 – 37.6) 
(Paar et al., 2010) 2006 - 9 Nicaragua WHO/NIH 3151 48 (35.0 – 60.0) 
(Bhaya et al., 2010) 2007 - 8 India WHO 1059 50.0 (39.0 – 66.0) 
(Beaton et al., 2012) 2010 Uganda WHO/NIH 4,869 14.8 (7.3 – 22.3) 
N, Number examined by echocardiography;  pr, prevalence;  CI, confidence interval 
Figure 1.14.  Pooled prevalence rates of echocardiographically-confirmed WHO-defined Definite or 
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1.5.3.1 Auscultation-­‐based	  School	  Screening	  for	  RHD	  in	  South	  Africa	  
There are four studies on the prevalence of RHD among school children in South Africa 
(Bundred, 1986, Maharaj et al., 1987, McLaren et al., 1975, Pocock et al., 1968).   
Two of the studies were conducted in school children from Soweto, Johannesburg;  Pocock 
and colleagues, who screened 428 children, reported a prevalence of between 5 and 10 per 
1000 at the Southern Africa Cardiac Society Conference, (Pocock et al., 1968).  The 
second study, conducted over 5 months in 1972, enrolled 12,000 randomly-selected 
children between the ages of 2 and 18 years across all grades (McLaren et al., 1975).  The 
participants were examined by ten cardiologists, three of whom needed to have agreement 
on a diagnosis of RHD following an independent examination of children having an 
abnormal heart.  An overall prevalence rate of 6.9 per 1000 was observed, although this 
figure went up to as high as 11 / 1000 in older children.  A preponderance of females to 
males of 1.6:1 was observed. The third study was conducted among 1150 school children 
from the lower income peri-urban fishing community of Hout Bay in Cape Town 
(Bundred, 1986).  Two schools, one being a Moravian Mission outreach project for 
children of the local farm labourers, participated in the survey.  Using auscultation for 
screening, and echocardiography for confirmation of abnormal cases, the group reported a 
combined prevalence rate of 6.9 per 1000.  The last study reported a prevalence of 1 per 
1000 using the WHO-defined auscultation criteria among 4408 school children aged 4 – 
18 years from the Inanda township community on the periphery of Durban (Maharaj et 
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1.6 PREVENTION OF ARF AND RHD  
1.6.1 Primary	  Prevention	  of	  Rheumatic	  Fever	  
Primary prevention of rheumatic fever is defined as the administration of adequate 
antibiotic treatment in individuals diagnosed with GAS pharyngitis so as to prevent ARF 
(World Health Organization., 2004).  A meta-analysis has provided firm evidence for a 
reduction in the risk of developing ARF resulting from the administration of antibiotics 
following a GAS pharyngitis episode, relative risk of 0.32 (95% CI = 0.21–0.48) (Robertson 
et al., 2005a).  Subgroup analysis of penicillin alone was associated with an even more 
effective outcome and thus, Robertson refutes the reservations of resistance to penicillin, 
especially given the rarity of anaphylactic reactions.   
The WHO recommended dosage for primary prevention is indicated in Box 1.8.  In South 
Africa, the Department of Health publications, Standard Treatment Guidelines and Essential 
Drugs List (EDL) for South Africa, Primary Health Care 2003 Edition (Department of Health, 2006) 
and National Guidelines on the Primary Prevention and Prophylaxis of Rheumatic Fever and Rheumatic 
Heart Disease for Health Professionals at Primary Level (Department of Health, 1999) provide the 
recommended management strategies.  Upon diagnosis, a single dose of benzathine 
benzylpenicillin should be administered intramuscularly according to the patient’s weight 
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benzylpen icill in 
Phenoxymethyl pen icill in 






• Modified in part from (24). 
Adm inistration 
Single intramuscular injection 
Orally 2-4 times/day for 10 
fu ll days 
Orally 2-3 times/day for 10 
fu ll days 
Orally 2-3 times/day for 10 
fu ll days 
Oral ly 4 times/day for 10 fu ll 
days 
Dose 
1200000 units intramuscularly; 
600000 units for children 
weighing <27kg. 
Children: 250mg bid or tid. 
Adolescents or adults: 250mg tid 
or qid, or 500mg bid. 
25-50mglkg/day in three doses. 
Total adu lt dose is 
750-1500 mg/day. 
Varies with agent. 
Varies with formulation. Avai lable 
as the stearate, ethylsuccinate, 
estolate or base. 
Comments 
Preferable to oral penic illin because of 
patient adherence problems. 
Pen icill in resistance by group A 
streptococci has never been reported. 
Acceptable alternative to oral penicil li n 
because of the taste. 
Acceptable alternative for oral 
penicillin. d 
Alternative drug for patients al lergic to 
penicillin. Should not be used in areas 
where group A streptococci have high 
rates of macrolide resistance . 
o In some countries, macrolides have been approved for an abbreviated course of therapy (shorter than 10 days), but the elficacy of this treatment is 
controversiat and it cannot be recommended at present. Also, trimethoprim, sullonamides and tetracyclines are not effective antibiotics for eradicating 
Group A streptococci and are not indicated for the primary prevention 01 RF. 
e These agents should not be used in patients who have had immediate-type hypersensitivity to beta-Iactam antibiotics. 
o This has been used in some patients who have either a poorly documented history of penicil lin al lergy, but should not be used for patients with immediate 
hypersensitivity react ions to penicill in (e.g. anaphylaxis or hives). About 5% of those who have even a mild al lergic reaction to penicillin may also have a 
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1.6.2 Secondary	  Prevention	  of	  Rheumatic	  Heart	  Disease	  
Secondary prevention refers to the uninterrupted administration of antibiotic therapy for 
an extended period of time following the diagnosis of ARF so as to prevent recurrences of 
ARF and progression to RHD.  Box 1.9 details the WHO regime for secondary prevention 
of ARF (World Health Organization., 2004).  
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1.6.3 Current	  Standard	  of	  Care	  in	  South	  Africa	  	  
National guidelines exist for the management of upper respiratory tract infections and the 
prevention of rheumatic fever (Department of Health, 1999).  In South Africa, ARF was 
listed as a notifiable condition in 1989, with notification commencing in 1990.  Although 
previously included, the initial diagnosis of RHD was removed and only recently, moves 
are afoot to have it reinstated on the list.  A recent evaluation of rheumatic fever 
notification showed a fall in the number of RF cases and inconsistencies in the reporting 
mechanisms at various levels (Nkgudi et al., 2006).  Furthermore, a study by Robertson et 
al showed a lack of awareness of the guidelines amongst health practitioners (Robertson et 
al., 2005b). 
The current standard of care targets two populations:  children aged 3-15 years for primary 
prevention and children up to 21 years/adults up to 35 years for prophylaxis of 
ARF/RHD.  Patients aged 3-15 presenting with a sore throat are treated with penicillin if 
there are no signs of viral infection.  In children with a previous history of ARF, penicillin 
treatment is continued until she/he attains 21 years of age.  Those patients with established 
RHD remain on penicillin treatment until 35 years old.  Oral erythromycin is administered 
to patients allergic to penicillin.  All antibiotics are provided by the state health department 
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1.7 SUMMARY AND CONCLUSIONS OF THE LITERATURE REVIEW 
 
There has been a considerable amount of research on the pathogenesis of RHD as regards 
the host, agent and disease with elucidation of the aetiology and mechanisms involved in 
the disease process;  however, a few questions remain unanswered. 
1. Much is known about the social factors and the microbial agent that predispose to 
ARF.  However, while it is widely accepted that a genetic effect may play a role in 
susceptibility to contracting ARF, the size of the genetic effect is unknown.  Thus, 
there is a need to quantify the heritability of ARF in order to determine whether 
additional studies, such as whole genome scans, are justifiable.   
2. Current data on GAS carriage rates among asymptomatic school children in South 
Africa remain scant, with no school-based studies undertaken across the complete 
spectrum of age groups.  Recently, advancement in molecular methods has enabled 
the characterisation of GAS strains through M-typing of the emm gene.  There is a 
need to document GAS carriage in school children of all ages, which, together with 
molecular characterisation of strains harboured in the pharynx of carriers, will help 
to ascertain the extent to which disease strains are prevalent amongst carriers.  This 
information could potentially contribute to the development of the putative vaccine, 
and the monitoring of its efficacy within the South African population. 
3. There is considerable heterogeneity amongst epidemiological studies on GAS 
pharyngitis in terms of participant selection, study setting and duration of 
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participants are enrolled only at the time of presenting to the clinic or health 
facility, thereby reducing the risk of selection bias.  Furthermore, few studies extend 
much beyond a year in duration, making it difficult to make conclusive judgements 
on seasonality.  
An understanding of the incidence of GAS pharyngitis among children within a 
local context is crucial to inform appropriate primary prevention measures.  Given 
that there exists no data on the incidence of GAS pharyngitis among children with 
pharyngitis attending primary health care clinics in South Africa, a prospective 
surveillance study of sufficient duration (> 3years) is required. 
4. Most of existing clinical prediction rules (CPRs) were developed in industrialised 
countries with none having been evaluated in sub-Saharan Africa.  It is preferable 
that a CPR is validated within a local context, especially given the poor 
performance of CPRs in populati ns different from those in which they were 
developed.  Thus, there is a need to test the generalizability of currently 
recommended CPRs within the South African context and, in the event of poor 
performance thereof, to develop an appropriate CPR from local data.  A robust 
CPR will facilitate the primary prevention of ARF. 
5. There is no contemporary studies of the prevalence of RHD among asymptomatic 
school children in South Africa.  The use of echocardiography in screening may 
reveal the true burden of asymptomatic disease, and assist in the development of 
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1.8 SCOPE AND OBJECTIVES OF THE THESIS 
 
1. To identify and summarize all studies reporting on the concordance of 
ARF and RHD in monozygotic compared to dizygotic twins in order to 
derive quantitative estimates of the size of the genetic contribution to the 
risk of the condition. 
2. To determine the prevalence of group A streptococcal (GAS) isolates 
among asymptomatic children in primary and secondary school-aged 
children (asymptomatic carriage). 
3. To describe the prevalence and incidence of GAS  among  3- to  15- year 
old  children with pharyngitis living in the Vanguard community 
(Bonteheuwel/ Langa), Cape Town, South Africa.  
4. To evaluate the sensitivity and specificity of existing clinical prediction 
rules when applied to patients with GAS pharyngitis in our setting. 
5. To develop a clinical prediction rule for diagnosis of GrAS throat infection 
that is valid for children aged 5-15 years in the primary care setting within 
the South African context. 
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2 RATIONALÉ AND DESIGN OF THE STUDIES 
2.1 THE STOP RHD A.S.A.P. PROGRAMME IN SOUTH AFRICA 
	  
This	   section	   have	   been	   published	   in	   part	   in	   the	   following	   peer-­‐reviewed	   article:	  	  	  
ME	  Engel,	  L	  Zühlke,	  K	  Robertson.	  	  A.S.A.P.	  Programme	  in	  Rheumatic	  Fever	  and	  Rheumatic	  
Heart	  Disease:	  	  Where	  are	  we	  now	  in	  South	  Africa?	  	  SA	  Heart	  2009;	  6:270-­‐3	  	  
	  	  
	  
In October 2005, the Pan African Society of Cardiology (PASCAR) convened the 1st All 
Africa Workshop on Rheumatic Fever (RF) and Rheumatic Heart Disease (RHD) in 
Drakensberg, South Africa.  Attended by delegates from various parts of Africa and the rest 
of the world, the event concluded with the adoption of the Drakensberg Declaration, a 
statement proposing an action plan targeting RF and RHD in Africa (Mayosi et al., 2006).   
Four key areas	  had been identified as needing attention: awareness, surveillance, advocacy, 
and prevention and the programme was thus aptly named the A.S.A.P. Programme (Box 
2.1).  Essentially, the A.S.A.P. Programme aims to effect simple strategies within a 
comprehensive approach for RF/RHD control, beginning with the establishment of 
sentinel or demonstration sites across the continent. Awareness-raising is concerned with 
maximising case detection in communities through educating health professionals and 
members of the public about the signs and symptoms of RF and RHD as well as about the 
preceding streptococcal pharyngeal and skin infections.  Success of this aspect of the 
programme requires an evaluation of different strategies of delivering key audience-
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Box 2.1   Strategy of the A.S.A.P Programme in RF and RHD 
o raise public and health professional awareness 
o establish surveillance systems 
o advocacy for increased resources for treatment 
o promoting the prevention of RF/RHD in African nations 
 
address the lack of reliable prevalence data and the absence of reports on RF outbreaks 
from developing countries (Robertson et al., 2006).  The approach requires demonstration 
sites to create and maintain RF/RHD registers, conduct prospective RF incidence and 
cross-sectional RHD prevalence surveys, and establish the epidemiology of streptococcal 
throat and skin infections.  Advocacy at the level of government is essential to reverse the 
trend of rising numbers of cases of RF/RHD in developing countries (Carapetis et al., 
2005b).   Admittedly, the global burden of other diseases tends to overshadow RF/RHD, 
but it is hoped that together with the surveillance component, increasing attention will be 
placed on the devastating effects of RF/RHD on the health of children worldwide 
(Robertson et al., 2006).  Finally, the A.S.A.P. Programme proposes a focus on primary 
and secondary prevention, both for which there is sufficient evidence for their efficacy and 
cost-effectiveness (Robertson et al., 2005a, Manyemba and Mayosi, 2003, Karthikeyan and 
Mayosi, 2009).   
The A.S.A.P programme collaborates with other similar programmes of the World Heart 
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Panel as one of six global programmes.  Following this meeting, there has been renewed 
interest among cardiologists, other medical and public health professionals, the community 
and most importantly, government to be proactive in combating RF and RHD. 
2.1.1 The	  Establishment	  of	  the	  Vanguard	  Community	  Demonstration	  Site	  
Brief overview 
In South Africa, the A.S.A.P. Programme has designated the Vanguard Community in 
Cape Town as its demonstration site.  The area comprises two peri-urban suburbs of Cape 
Town, namely Bonteheuwel and Langa, which lie on either side of the Vanguard Road 
(thus ‘Vanguard Community) approximately 17 kilometres from Cape Town city centre, 
Figure 2.1.  Langa is the oldest township, having been officially opened in 1927 to 
accommodate black people forcibly removed from other areas of the Cape Peninsula.  It is 
characterized by a mixture of household units, ranging from brick structures to informal 
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dwellings located on vacant municipality property. Bonteheuwel is a coloured township 
created in the 1960s as a repository for coloured people subjected to forced removals under 
the Group Areas Act. Both Bonteheuwel and Langa are faced with major challenges of 
poverty such as crime, unemployment and	  overcrowding.  To date, the A.S.A.P. team has 
been conducting awareness-raising presentations amongst parents, teachers and 
community members.  In addition, we have held seminars for health professionals to 
enable them to recognize and diagnose streptococcal sore throat, and make valid 
management decisions.   
Customisation of the mobile vehicle 
The recent acquisition of a customized mobile echo-surveillance unit has enabled the 
launch of the surveillance component of the programme, where school-aged participants 
can be screened for the prevalence of RHD (Figure 2.2).  
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2.1.2 The	  Study	  Population	  
At last estimate in 2001, the South African population was 40,8 million of whom 4.5 
million reside in the Western Cape (Statistics South Africa, 2003);  population estimates for 
the Bonteheuwel and Langa are around 55,707 and 49,667 respectively living in 26,913 
households. (Statistics South Africa, 2003).  The communities are considered to be of lower 
socioeconomic status and comprise mainly black African (Langa) and people of mixed 
ancestry (Bonteheuwel).  They are plagued with social problems such as poverty, 
unemployment, crime, drug and alcohol abuse, poor housing and overcrowding.  Informal 
dwellings with limited, or no access to ablution facilities and running water, comprise 
11,5% and 49,7% of the housing units in Bonteheuwel and Langa, respectively. Table 2.1 
summarises characteristics of the two communities based on the 2001 census data (Statistics 
South Africa, 2003). 
Table 2.1  Vanguard Demonstration Site:  Demographic characteristics with respect to suburb.  
Parameter 
Bonteheuwel Langa Chi2 
Count Total % Count Total %  
Male school learners 7012 13869 50,6% 4501 9439 47,7% <0.05 
High School completed 951 33357 2,9% 701 32522 2,2% <0.05 
Non-brick dwelling 1303 11368 11,5% 7729 15545 49,7% <0.05 
Water in dwelling 9561 11373 84,1% 5498 15548 35,4% <0.05 
Electricity 11322 11373 99,6% 10301 15548 66,3% <0.05 
Employment 14911 22549 66,1% 13118 25862 50,7% <0.05 
Household income <US$ 
200 /month 4107 11368 36,1% 11119 15545 71,5% <0.05 
        
 
The two areas contrast considerably as regards some of the indicators of socio-economic 
status;  employment is around 58% of the adult population with more than half of the 
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Approximately 20% of the population census is 5 to 15 years of age (Table 2.2);  school 
attendance is compulsory and reported to be relatively high  (Mr Paulsen Personal 
Communication).   
Table	  2.2:	  Age	  distribution	  amongst	  Vanguard	  children 
Age	  in	  years Frequency Percentage 
5 1827 9.1 
6 1863 9.3 
7 1893 9.5 
8 1697 8.5 
9 1860 9.3 
10 1888 9.4 
11 1890 9.5 
12	   1879	   9.4	  
13	   1764	   8.8	  
14	   1646	   8.2	  
15	   1787	   8.9	  
Total	   19994	   100	  
 
Mortality data for 2001 for the whole of Cape Town and for the Central sub-districts 
(including Langa) and Tygerberg West  (including Bonteheuwel) reveal that the leading 
causes of mortality in the sub-districts are HIV/AIDS, homicides, tuberculosis, ischaemic 
heart disease, road traffic accidents, and diabetes.  Among infants low birth weight and 
lung disease, HIV/AIDS, diarrhoea, and lower respiratory infections are leading causes of 
death. The infant mortality rate per 1000 live births in 2002 was 31 and 20 respectively for 
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2.2 GENETICS STUDY:  SYSTEMATIC REVIEW OF TWIN STUDIES ON 
ARF AND RHD 
2.2.1 General	  Description	  of	  the	  Study	  
Systematic reviews use a rigorous method to summarise data from a collection of studies, 
specifically giving increased power to detect an association between risk factors and the 
outcome of interest.  Using the systematic review method, we investigated population-
based twin studies on ARF and RHD for evidence for a genetic effect in disease 
susceptibility and/or progression. The systematic review process was based on the 
guidelines set out in the Cochrane Handbook for Systematic Reviews (Higgins et al., 2009),  
the methods of the Human Genome Epidemiology Network (Little and Higgins, 2006). and 
of those of the PRISMA Statement (Moher et al., 2009) (See Appendix 10.1). 
2.2.2 Specific	  Objective	  of	  the	  Genetics	  Study	  
Following the identification of all primary studies reporting on the incidence of ARF and 
the prevalence of RHD in monozygotic and dizygotic twins, we determined the extent to 
which the variation of ARF and RHD between monozygotic and dizygotic twin pairs is 
due to genetic effects.   
2.2.3 Methods	  of	  the	  Systematic	  Review	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2.3 CLINIC-BASED STUDY:  VANGUARD, NETREG AND LANGA HEALTH 
CENTRES 
2.3.1 Study	  Design	  and	  Setting	  	  	  	  
 
We conducted this prospective observational study in the paediatric outpatient 
departments of the three primary health care clinics serving the Vanguard community.  
The provincial authority, called the Metro District Health Service, delivers all primary 
health care services to the people of Cape Town, of which the Metropole is divided into 8 
sub-districts.  The Vanguard Community Health Centre, which is situated on the border of 
Bonteheuwel and Langa, opened in June 2000 and has 24-hour access with comprehensive 
medical services including emergency facilities, obstetrics and gynaecology and dentistry.   
The Netreg and Langa community clinics are based within the Bonteheuwel and Langa 
communities respectively, providing vaccination, TB and HIV treatment amongst other 
services. There is a dedicated child health service that is integrated into the rest of the 
health service.  Clinical nurse practitioners run the well baby clinic daily and a 
paediatrician from Red Cross War Memorial Children’s Hospital visits once a week to deal 
with major problems.  Family planning services are provided at flexible hours to 
accommodate working mothers.  In addition, there are ten private general practitioner 
clinics in this area, who did not participate in the study. To our knowledge, there were no 
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2.3.2 Specific	  Objectives	  of	  the	  Clinic-­‐based	  Study	  
o To describe the prevalence and incidence of throat isolates of GAS among 3- to 15-
year-old children with pharyngitis living in the Vanguard community of Cape 
Town. 
o To develop a clinical prediction rule for diagnosing GAS pharyngitis that is valid 
for the South African population. 
2.3.3 Sampling	  Procedures	  
 
Study participation was offered to all unscheduled, walk-in paediatric patients aged 3 – 15 
years who presented with symptomatic pharyngitis seeking medical care at one of the three 
community clinics serving the Vanguard area (Section 2.1).  Patients were first triaged by 
clinic staff and then seen by our study nurse.  We excluded patients who had received a 
recent prescription of antibiotics, the last dose of which was taken within 30 days prior to 
enrolment, or were unable or unwilling to participate.  The clinic-based studies presented 
in this thesis used the same participants (Study 3, chapter 5; Study 4, chapter 6). 
	  
2.3.4 Ethics	  Matters	  
	  
The study was performed with the approval of the University of Cape Town’s institutional 
review board and the relevant department of health, and informed consent was obtained in 
writing from a parent or legal guardian of each participant.  The consent forms were 
provided in the local languages of Afrikaans, English and isiXhosa.   In addition, children 
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Potential Risks 
According to the guidance provided by the Office of Human Research Protections, 
participation in this study involves a research activity that presents no more than minimal 
risk for the volunteers (US Department of HHS.) Taking a throat swab is a routine clinic 
procedure; throat swabbing may lead to brief gagging and could potentially induce 
vomiting.  The risks of a breach of confidentiality of data are minimal given our safeguards 
and the nature of the study. 
 
Known Potential Benefits 
Participants in this study were examined by the study research nurse;  all management 
decisions, however, were made by respective clinic staff based on clinical assessment. While 
patient management decisions were not dependent on microbiological information, the 
results of the throat swab were, nevertheless, made available by the study coordinator to 
the clinic staff as soon as possible.  Participants were not paid for participating in the study. 
 
2.3.5 Summary	  of	  Study	  Evaluations	  
The research nurse attended a training session in clinical assessment and procedures under 
the guidance of the study clinician.  At each clinic, the nurse prospectively collected basic 
demographic information including recent antibiotic prescription history onto the study 
case record form (See Appendix 10.3), conducted a physical examination and, obtained a 
throat swab specimen for microbiological processing in the microbiology laboratory within 










Chapter	  2:	  	  Rationale	  and	  design	  of	  the	  studies	  
PhD	  Thesis:	  	  Mark	  E	  Engel	  	   	   |	  Page	  61	  
(based on on the best-performing clinical prediction rules in an Egyptian prospective study 
(Steinhoff et al., 2005), with the addition of “absence of candidiasis”. 
 
o Cough (a negative point against the diagnosis of GAS) 
o Rhinorrhoea (a negative point against the diagnosis of GAS) 
o Hoarseness (a negative point against the diagnosis of GAS) 
o Observed fever (T> 38ºC) 
o Tonsillar erythema 
o Tonsillar swelling 
o The presence of exudates on the pharynx 
o The presence of exudates on the tonsils 
o The presence of oro-pharyngeal candidiasis (a negative point against the 
diagnosis of GAS) 
o Tenderness of an anterior cervical node on palpation 
o The presence of an anterior cervical lymph node greater than 1.5cm in 
diameter 
o Rash (a negative point against the diagnosis of GAS) 
These data informed the results of Study 3 (Longitudinal Study of GAS pharyngitis in the Vanguard 
Demonstration Site) and, 
 
Study 4 (Streptococcal pharyngitis in children presenting with sore throat:  evaluation of existing clinical 
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2.3.6 Specimen	  Collection,	  Transport	  and	  Handling	  
Collection of specimens  
All throat swab specimens were collected by the study nurse according to a standard 
procedure. Sterile individual cotton swabs were used for all cultures. For each throat 
specimen, a single swab was slowly swiped across one tonsil or tonsillar fossa, then across 
the posterior pharynx, and finally across the opposite tonsil or tonsillar fossa with care 
taken not to touch the tongue or the mouth with the swab. Swabs with liquid media tips 
were used (Culturette or equivalent). The standard operating procedure for collection of 
throat specimens is found in Appendix 10.4.  
Transport of specimens 
Swabs collected at clinical sites were transported to the National Health Laboratory 
Service (NHLS) microbiology laboratory at Groote Schuur Hospital for processing on the 
same day, with specimens kept in an insulated bag for transport.  
Handling of specimens  
Swabs were received by the microbiology laboratory and logged according to routine 
procedures. Briefly, specimens were plated onto 4% sheep blood agar plates in a standard 
fashion. Effort was made to place specimens in an incubator no later than 4 hours from the 
time of collection. Time of collection and time of plating were recorded. Plates were 
inverted and incubated anaerobically at 35°C.  After 18 to 24 hours, the plates were read 
by the microbiology technician, under the supervision of the study microbiologist.  All 
cultures of beta-haemolytic colonies were further identified by Gram stain, catalase, and 
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sub-cultured for purity. Pure colonies of beta-haemolytic streptococci identified as group A, 
C or G were removed from the plates in a sterile fashion and placed in trypticase soy broth 
with glycerol for storage.  
Laboratory results were downloaded from the database of the NHLS laboratory.  Reports 
containing the microbiologic data indicating the presence or absence of beta haemolytic 
streptococci (group A, C or G in particular) and the storage identification number were 
affixed to the case report form (CRF) for simultaneous entry into the database.  Specially 
designed batch-flow sheets were used to track the specimens and forms from the time of 
screening to filing after data entry was completed.  
2.3.7 Data	  Handling	  And	  Record	  Keeping	  
	  
Source documentation comprised information initially captured on a paper CRF at the 
clinic and laboratory reports extracted from the NHLS laboratory’s website. Forms were 
filed in individual patient folders in the Mayosi Research Group’s data entry centre in a 
fire-proof lockable cabinet.   
Data-entry was performed by research assistants based in the Department of Medicine at 
the University of Cape Town.  A purpose-designed database (Epi Info™ software package) 
was used for data management and analysis.   All data were double-entered (i.e., entry 
performed independently on two separate occasions) into the database once all the source 
documents had been obtained. Copies of the source documents were maintained in the 
participant’s medical chart or study file at the site, and were readily available for review.  
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centre and the clinics as well as database comparisons of the double-data entry.  In 
addition, the project was subjected to external monitoring as mandated by the sponsor. 
 
2.3.8 Statistical	  Considerations	  
2.3.8.1 Outcome	  Measures	  
	  
o The proportion of children with pharyngitis from whom GAS was isolated. 
o The minimal incidence of GAS pharyngitis in children based on annual cases per 
100 children in the catchment area. 
o The age-, gender- and suburb-specific minimal incidence rates of GAS pharyngitis 
in children living in the catchment area 
o Identification of the clinical signs and symptoms of pharyngitis which are most 
strongly associated with GAS infection. 
 
2.3.8.2 Sample	  Size	  Considerations	  
 
Epidemiology of Streptococcus pyogenes pharyngitis 
The number of cultures positive for GAS was expected to be directly proportional to the 
number of participants enrolled in the study.  Given the surveillance system that we were to 
put in place to identify as many of the pharyngitis cases as possible, the incidence of GAS 
pharyngitis was based on our estimate of the number of children that would seek care 
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According to most recent census data, the population of the target area was approximately 
100,000, of which we estimate that approximately 20,000 were children aged 3-15 
(Statistics South Africa, 2003).  Based on a 30% recovery rate, 420 cultures positive for 
GAS were expected each year.  The study included only those who were symptomatic and 
presented to the community health centre with sore throat.  
 
Clinical Prediction Rule development 
Given the expected prevalence of GAS in patients with pharyngitis of 30%, and to 
demonstrate a 95% sensitivity of our prediction rule with a 95% confidence interval of 
91% to 99%, we needed 115 GAS cases for which at least 383 patients needed to be 
recruited.  Thus, our chosen sample size was set at 400 participants to create the CPR. 
Information on a further 400 participants was desirable to validate the proposed CPR.  
The sample size required for the derivation and validation of the CPR was therefore 800 
participants.   
 
2.3.8.3 Analysis	  Plan	  
 
Demographic data and a summary of all clinical signs and symptoms recorded at 
enrolment are presented descriptively for all children enrolled as well as for those with 
positive cultures for GAS.  Based on data from a South African study conducted in a 
different province which found an overall GAS positivity of 33.2% in patients presenting 
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obtained per annum.  In addition, the overall annual rate of incident cases of GAS 
pharyngitis is presented according to gender, age and ethnicity using an estimate of the 
number of children three to fifteen years old in the catchment areas based on the most 
recent census.  Significance was accepted at the two-sided level of 0.05.  
 
Statistical Analysis used in the creation of the Clinical Prediction Rule 
 
The reference standard in this study for diagnosis of GAS throat infection is a throat swab 
culture. A chi-squared test for association between each clinical symptom and sign and the 
result of throat swab culture were calculated together with the odds ratios and 
accompanying 95% confidence intervals for each sign and symptom. A multivariate logistic 
regression model was constructed incorporating vari bles with evidence of association with 
throat swab culture result on univariate analysis.  The weighting of each variable in the 
final model was used to determine the weighting of each criterion in the CPR.  We had 
expected the CPR to be derived based on the first 400 cases with a further 400 participants 
to be enrolled to validate the rule with no interruption between recruitment and validation, 
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2.4 SCHOOL-BASED STUDY:  SCREENING FOR GAS AND RHD  
2.4.1 Study	  Design	  and	  Setting	  	  	  	  
 
We conducted this cross-sectional school-based study amongst healthy learners attending 
primary and secondary schools within the Vanguard Demonstration site of the A.S.A.P. 
Programme (Section 2.1.) from January 2008 until March 2012 following an initial pilot 
study conducted at a primary school within the research area, to establish the suitability of 
the protocols in May 2007.  Schooling is compulsory and free, and uptake is estimated to 
be around 90% (Mr Paulsen Personal Communication).  A school health service operates 
within the community, having one of its focuses as “an assessing the health needs of the school 
community” (Department of Health, 2002a).  These are mainly directed at learners entering 
the school system at grades 0 and 1 to identify barriers to learning. Assessments thus 
include hearing assessment, vision screening, speech impairment and physical examination 
for gross locomotor dysfunction, oral health checks, anthropometric assessment, and on 
occasion, identifying and responding to intentional injuries and child abuse, and mental 
health assessments.  No screening is done for RHD as part of the school health system. 
2.4.2 Specific	  Objectives	  of	  the	  Population-­‐based	  Study	  
o To determine the prevalence of echocardiographic RHD in school-aged children 
living in the “Vanguard” Area (Langa and Bonteheuwel) of Cape Town. 
o To describe the prevalence of pharyngeal group A streptococcal carriage amongst 
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2.4.3 Sampling	  Procedures	  
 
Study participants were selected from all primary and secondary schools within the 
Vanguard Demonstration site.  We employed an adaptation of Probability Proportional to 
Size (PPS) Cluster Sampling (European Social Survey Education Net.) using classrooms as 
the sampling frame.  PPS has various advantages over simple random sampling including 
an assurance of spread of participants across all strata (in this case, grades and area) and 
eliminates the need for finding replacements in the event of learners not turning up for the 
examination.  The random selection of the classrooms ensures control for selection bias.   
Using the Department of Education’s database, we compiled a list of all the schools and 
their respective enrolment figures in the area.  Figure 2.3 shows the distribution of schools 
in Langa and Bonteheuwel.   
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Schools were approached individually and through principals’ fora to glean interest in 
participating in the study, after which a final list was compiled. Class lists were used to 
determine the number of learners enrolled in each school.  
The sampling method consisted of three stages: 
1. Stratification by municipality 
2. Stratification by grade 
3. Simple random selection 
 
Stage 1:  Stratification by municipality 
 
The sample size within each municipality of Langa and Bonteheuwel was calculated in 
proportion to the number of learners in each stratum 
Stage 2:  Stratification by grade 
 
Within each stratum (municipality), the sample size within each grade was in proportion to 
the average number of children in the grade (sub-stratum) 
Stage 3:  Simple random selection 
 
Within each municipality and grade, according to the average class size in the grade, we 
calculated the number of classes needed (rounding up where necessary).  Classrooms were 
then randomly selected within a grade, regardless of school.  All eligible learners within a 
selected classroom were invited to participate, and the parents/caregivers were asked to 
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Participants enrolled in Study Two: Carriage Rates And Genotypic Characteristics Of Group A 
Streptococci In Asymptomatic School children Of The Vanguard Communities Of Cape Town, South Africa 
as reported in this thesis was enrolled from within the larger surveillance screening project 
by convenience sampling over the three-year period from February 2009 – November 
2011.  
	  
2.4.4 Ethics	  Matters	  
 
The study was performed with the approval of the University of Cape Town’s institutional 
review board and the relevant departments of health and education.  Informed consent was 
obtained in writing from a parent or legal guardian of each participant following an in-class 
demonstration of the examination procedures in  relaxed atmosphere.  Information 
brochures and consent forms were provided in the local languages of Afrikaans, English 
and isiXhosa.   In addition, children aged 8 years and older were required to provide 
assent, Appendix 10.6. 
Potential Risks 
According to the guidance provided by the Office of Human Research Protections (US 
Department of HHS.), participation in this study involves a research activity that presents 
no more than minimal risk for the volunteers (US Department of HHS.)  All participants 
were subjected to echocardiography, together with routine height and weight 
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Known Potential Benefits 
Participants in this study were investigated by the study echocardiographer.  The potential 
benefits of participating in the study are that children with previously undiagnosed RHD 
would be referred to a tertiary center for prophylaxis, potentially preventing them from 
progression to life-threatening RHD.  Participants were not paid for participating in the 
study. 
 
2.4.5 Summary	  of	  Study	  Evaluations	  
 
The research assistant verified parental / legal guardian consent permission, and in 
addition, obtained assent from participants 8 years of age or older.  Each participant was 
assigned a unique number and cross-referenced in the enrolment log register.  All 
evaluations were conducted in the purpose-built mobile echo surveillance unit parked on 
school grounds.  A standard CRF was used (See Appendix 10.7).  Enrolled participants 
were interviewed by the study researcher to determine general health, past history of 
rheumatic fever, frequency of sore throats, and symptoms of ARF at the time of the study 
examination.  Heights and weights were also recorded at the time of the interview. 
2.4.5.1 Throat Swab Collection 
 
A selection of participants, regardless of physical findings were swabbed for microbiological 
investigation for GAS pharyngeal carriage.  The throat swab procedure and processing was 
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2.4.5.2 emm Typing 
 
GAS isolates were submitted to the Division of Microbiology for emm typing which involves 
a number of steps.  Briefly, following DNA extraction, PCR amplification is performed 
using recommended primers.  The PCR products are separated and visualized using 
agarose gel electrophoresis and purified.  After sequencing, a comparison is made with emm 
sequences in the existing databases housed at the Centres for Disease Control and 
Prevention (CDC), at which time the sequence is assigned its corresponding sequence 
number.   More detail is provided in Appendix 10.8.   
2.4.5.3 Echocardiography 
 
All echocardiographic studies were performed in the left lateral decubitus position, initially 
using a Vivid i machine (GE Ultrasound, South Africa), equipped with a 3S probe and 
tissue Doppler technology.  Other machines used included the Philips® CX50  with an S5-
1 phased-array  transducer probe and the Sonosite®  M-Turbo with the P10 probe.  
Simultaneous electrocardiography was used to correlate timing of electrical events with 
mechanical events.  No sedation was used.   
Echocardiography was performed by experienced cardiac ultrasonographers who had 
received extensive training in adult and paediatric echocardiography at teaching hospitals 
in Cape Town. Standard approaches to trans-thoracic echocardiography were adopted.  
All M-mode measurements were taken and recorded at least twice, while the Doppler 
velocity of greatest value and intensity was recorded.  Measures found to be abnormal in 
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Echocardiograms were reviewed by a cardiologist blinded to the original 
echocardiographer’s preliminary diagnosis. Where there was a difference of opinion or any 
uncertainty, the opinion of a second cardiologist was sought, and decisions were based on 
consensus between all three individuals. Initial analysis of our echo data was done using the 
NIH/World Health Organization expert consultation criteria for diagnosis of RHD 
published in 2006 (Carapetis JP et al., 2006).   
The criteria initially used to report school screening echocardiograms were based on a 
combination of clinical and echocardiographic findings.	  Study patients were classified as 
definite, probable, or possible RHD, congenital cardiac disease, or normal.  This approach 
however, implied that a fully trained cardiologist needed to be present in order to 
auscultate each patient.  We developed and used a new set of criteria which focused on the 
echocardiograph as a screening tool without the concomitant use of clinical examination in 
the screening phase.  (Figure 2.4) (Zuhlke and Mayosi, 2009).  
The most recent development however, has been the publishing of the evidence-based 
World  Heart  Federation  guidelines  for  echocardiographic diagnosis of  RHD, but these 
only became available after completing this study. 
 
2.4.6 Data	  Handling	  And	  Record	  Keeping	  
Demographic data, collected at the time of screening by the field site coordinator, were 
entered directly into a customised database (Epi Info™ software package).  For the 
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all participants as normal, probable RHD or definite RHD as per the echocardiographic 
criteria according to the Zühlke criteria (Zuhlke and Mayosi, 2009).  These findings are 
captured into the database at the Data Entry Centre in the offices of the Mayosi Research 
Group.  After the confirmatory examination by the cardiologist, those participants with 
definite or borderline RHD are referred to their primary care clinic with appropriate 
documentation for follow-up and secondary antibiotic prophylaxis.   Data were reviewed 
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on a regular basis and queries were referred to the field site coordinator for comment.  All 
CRFs and related query documents and data quality reports are filed in a fire-proof 
lockable cabinet.  
 
2.4.7 Statistical	  Considerations	  
2.4.7.1 Outcome	  Measures	  
 
o The proportion of school-going children with echocardiographic features of RHD 
o The age-, gender- and suburb-specific background rates of GAS pharyngeal 
carriage in school-going children living in the Vanguard area of Cape Town 
2.4.7.2 Sample	  Size	  Considerations	  
GAS pharyngeal carriage  
The sample size for this nested study was based on published studies in similar South 
African communities (McLaren et al., 1975, Ransome et al., 1983) allowing for estimation 
of at least 5% difference of GAS carriage across the two communities within a precision of 
5%;  in addition, we assumed a 5% non-response rate. Therefore, at least 451 participants 
needed to be examined per community.  
Prevalence of RHD 
A necessary minimum total sample size of 2875 subjects was calculated, anticipating a 
frequency of 3% of RHD.  This sample size also assumes a rejection rate of 5%.   With this 
sample, we would be able to estimate the prevalence of RHD within 0.7 percentage points 
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original sample size) to account for clustering in the sampling design is assumed between 
the participants coming from the same classroom.  The 3% was taken from a recent 
screening carried out among school children in Mozambique (Marijon et al., 2007).  Our 
total school population was 16,771 pupils. 
In South Africa, a previous prevalence survey estimated the prevalence of RHD in school 
children from poor households as 10-15 per 1,000 (Maharaj et al., 1987).   Table 2.3 shows 
the total number of participants in each municipality and the expected sample distribution 
among the two juxtaposed peri-urban townships, Langa and Bonteheuwel, forming the 
Vanguard area, reaching the total sample size of 2875. 
 
2.4.7.3 Analysis	  Plan	  
We estimated the prevalence of RHD in Vanguard with the corresponding 95% 
confidence interval. The estimate of the standard error for this estimate accounted for 
clustering effects and was considered in the confidence interval computation. Similar 
estimates are provided by region, gender, and selected age groups.  We also describe the  
background characteristics and other clinical features of RHD cases collected in this study. 
Table 2.3. Expected sample size distribution by region 
Municipality Total (%) Sample Required 
Langa 8034	  (47.9) 1377 
Bonteheuwel 8737 (52.1) 1498 
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3 HOST DETERMINANTS:  STUDY ONE 
 
SUSCEPTIBILITY TO DEVELOPING RHEUMATIC HEART DISEASE:   
A SYSTEMATIC REVIEW OF THE GENETIC EVIDENCE FROM  
TWIN STUDIES 
The	  data	  presented	  in	  this	  section	  have	  been	  published	  in	  the	  peer-­‐reviewed	  article:	  
Engel,	  ME;	  Stander,	  R;	  Vogel,	  J;	  Adeyemo,	  AA;	  Mayosi,	  BM.	  Genetic	  susceptibility	  to	  acute	  





The role of host factors is discussed in the literature review (Section 1.3).  As mentioned, 
while much is known about the social fact rs and the microbial agent that predispose to 
ARF, little progress has been made in elucidating genetic susceptibility factors that are 
reproducible in different populations (Bryant et al., 2009). 
Several twin and family aggregation studies have suggested a genetic effect, but they have 
not provided a quantitative estimate of the magnitude of the genetic contribution in ARF 
and RHD. Furthermore, the molecular genetic studies of human leukocyte antigen (HLA) 
and non-HLA factors have been characterized by small studies with inconsistent and 
conflicting findings (Bryant et al., 2009).  A quantitative assessment of the genetic effect in 
twin or adoption studies, which provide a reliable estimate of genetic effect in familial 
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‘global genome analysis’ studies of the condition that have been recommended recently 
(Bryant et al., 2009)  Higher concordance rates between monozygotic twins compared with 
dizygotic twins indicate a greater role for genetic factors in the development of a disease 
given that monozygotic twins are genetically identical, versus dizygotic twins who, on 
average, share 50% of their genes, Conversely, concordance of a similar magnitude in both 
monozygotic and dizygotic twin pairs suggests the involvement of factors not pertaining to 
genes (Ahlbom et al., 1997).  It would thus be prudent to invest scarce resources on genetic 
studies of conditions with good evidence of genetic determination particularly in resource-
poor countries where ARF is prevalent.    
We have conducted a systematic review and meta-analysis of the concordance rate and 
heritability of ARF in monozygotic and dizygotic twin pairs as reported in observational 
studies. The primary aim of this study in the thesis was to determine the extent to which 




The systematic review process was based on the guidelines set out in the Cochrane 
Handbook for Systematic Reviews (Higgins et al., 2009) and the methods of the Human 
Genome Epidemiology Network in this review to summarise all studies reporting on 
occurrence of ARF in monozygotic and dizygotic twins (Little and Higgins, 2006).  
Independent reviewers assisting with study selection and data extraction is a pre-requisite 
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process which was governed by a review protocol.  The PRISMA Statement for reporting 
systematic reviews was used as a guide in writing up this review (Moher et al., 2009). 
 
3.2.1 Data	  Sources	  and	  Search	  Strategy	  	  	  
Using the terms ((RHEUMATIC FEVER OR RHEUMATIC HEART) AND (FAMIL* 
OR TWIN OR ADOPTION)), we searched PubMed/MEDLINE, EMBASE, Thomson 
Reuters ISI Web of Science and Google Scholar for all reports of original research from 
the inception date of each database to 31 January 2011, without any language restriction. 
Predefined criteria were used to identify studies examining the concordance for ARF and 
RHD in monozygotic versus dizygotic twins.  The literature search was performed 
independently by the three reviewers (MEE, RS, and JV).  In addition, an independent 
search specialist conducted an EMBASE search. This process was complemented by 
reviewing the reference list of all articles identified, and by scanning abstracts from 
conference proceedings. The search strategy for Medline and EMBASE appears in 
Appendix 10.9 
 
3.2.2 Inclusion	  Criteria	  	  
We included reports that met the following criteria: 
1. Twin studies reporting on the concordance for ARF and/or RHD in 
monozygotic versus dizygotic twins (i.e., comparative group used);  
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3. Clear indication of how zygosity was established; and  
4. Diagnostic assessment of relatives preferably performed with investigators blind 
to the affection status of the proband. 
The first three criteria were an absolute requirement for inclusion of a report in the study.  
Three observers (MEE, RS, and JV) independently evaluated the titles and abstracts of 
search outputs, and thereafter compiled a list of articles deemed to be potentially relevant.  
Full-text articles were subsequently retrieved and evaluated against the inclusion criteria.   
 
3.2.3 Validity	  Assessment	  of	  Included	  Studies	  
We assessed studies in terms of case definition and determination of twin zygosity wherever 
recorded by the authors.     
 
3.2.4 Data	  Abstraction	  	  	  
From each study, reviewers independently recorded the year of publication, origin and 
demographic details of participants, matching procedures for zygosity, diagnostic criteria 
for ARF and RHD, and information on disease. The supervisor served as arbitrator where 
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3.2.5 Quantitative	  Methods	  
Concordance or twin similarity was assessed by calculation of two concordance rates: the 
pairwise concordance rate and the probandwise concordance rate.  The pairwise 
concordance rate is given by the formula:  
Number of pairs where both twins are affected 
Total number of twins. 
 
The probandwise concordance rate is given by the formula:  
Number of probands whose co-twins are affected 
Total number of probands. 
 
The advantage of the probandwise concordance rate is that it is independent of 
ascertainment.  We also calculated aggregate pooled probandwise concordance by 
combining raw data from each of the studies.  Heritability was estimated by estimating the 
variance components using structural equation modeling techniques as implemented in the 
MX software package (http://www.vcu.edu/mx/).  We considered an “ACE” variance 
components (VC) model incorporating parameters for additive genetic (A), common 
(shared) environmental (C), and individual specific (unshared) environmental (E) 
components of the total variance (V). The A, C, and E parameters were estimated by 
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of the total variance that is attributable to the genetic variance; i.e. h2=A/V.  Odds ratios 
from separate studies were combined by random-effects meta-analysis according to the 
Mantel-Haenszel method to evaluate association between zygosity status and concordance.  
Heterogeneity between studies was evaluated with the χ2 Q statistic, which was considered 
significant for p < 0.1.  STATA software version 11 (STATA Corporation, College Station, 
Texas, USA) was used to perform the meta-analysis and produce the forest plots using the 
‘metan’ routine, which automatically adds 0·5 to all zero-containing cells of the 2×2 table 
before analysis (Sterne JAC et al., 2001). 
 
3.3 RESULTS 
3.3.1 Flow	  of	  included	  studies	  	  
The electronic literature search yielded 685 articles for consideration (Figure 3.1). Titles 
and abstracts were reviewed and together with the articles identified by hand searching, 
twenty-three publications were selected for possible inclusion; however, three non-English 
language papers were excluded due to unavailability of the full text of the articles from the 
authors and library archives (Strusberg et al., 1968, Uribarri et al., 1965, Zajicek and 
Gajova, 1966) [4,5,6].  Of the remaining 20 articles, a further 14 were excluded for the 
following reasons: no twins reported (n=10) (Benevolenskaia et al., 1973, Benevolenskaia 
and Miakotkin, 1980, Bobylev and Men'shova, 1972, Giannini and Romani, 1967, Paul, 
1941, Paul and Salinger, 1931, Prasad, 1967, Quinn and Federspiel, 1967, Spagnuolo and 
Taranta, 1968), having rheumatoid arthritis as the outcome (n=1) (Dixon, 1969)[17], or 
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did not distinguish between types of twins (Honeyman and Davis, 1971) (Table 3.1).  We 
did not discover any unpublished studies nor did we find any twin studies of RHD that met 
the inclusion criteria. 
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Table 3.1:  Studies that were excluded from the systematic review 
Author Year Reason for exclusion 
Benevolenskaia 1973 No distinction between MZ and DZ  twins  
Benevolenskaia 1980 No twins reported in sample  
Bobylev 1972 No distinction between MZ and DZ  twins  
Denbow 1999 No comparison group 
Dixon 1969 Different Diagnosis (Rheumatoid Arthritis) 
Giannini 1967 No twins reported in sample  
Honeyman 1971 No distinction between MZ and DZ  twins  
Horne 2004 No twins reported in sample  
Paul(a)  1931 No twins reported in sample  
Paul(b) 1931 No twins reported in sample  
Perry 1940 Case study, no comparison group 
Prasad 1969 No twins reported in sample  
Quinn 1967 No twins reported in sample  




Strusberg 1968 Spanish 
Uribarri 1965 Spanish 
Zajicek 1966 Czech 
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3.3.2 Characteristics	  of	  Included	  Twin	  Data	  Sets	  
Six studies published between 1933 and 1964 and contributing a total of 435 twin pairs 
were included in the analysis, Table 3.2 (Kauffman and Schreerer, 1938, Reed, 1964, 
Stevenson and Cheeseman, 1953, Irvine-Jones, 1933, Wilson and Schweitzer, 1937, 
Taranta et al., 1959).  Two of the included datasets (Kauffman and Schreerer, 1938, Reed, 
1964) were retrieved from Perry (Perry, 1940) and Honeyman (Honeyman and Davis, 
1971) respectively, while another was reported as a conference abstract (Taranta et al., 
1959).  Where indicated by the authors, studies were conducted in North America (Irvine-
Jones, 1933, Wilson and Schweitzer, 1937) and Ireland (Stevenson and Cheeseman, 1953).  
One study (Taranta et al., 1959) specifically focused on twins, while in the others, twin 
pairs formed part of larger cohorts.  Wilson used previous records of children attending a 
pediatric cardiac clinic to obtain twin samples (Wilson and Schweitzer, 1937).   
In all six studies the outcome measured was the concordance of acute rheumatic fever in 
monozygotic and dizygotic twin pairs. Defining characteristics of the studies are presented 
in Table 3.3.  Only two studies provided information on how zygosity was determined 
(Stevenson and Cheeseman, 1953, Taranta et al., 1959);  methods included evaluation of 
blood groups, similarity of dermatoglyphics, hair and eye colour.  Information on age and 
gender was incomplete or not specified:  one study comprised only females in the MZ 
group while the DZ twin sets included both females and mixed gender (Stevenson and 
Cheeseman, 1953).  Another study consisted of mixed and same sex twin sets in a 3:5 ratio 
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Table 3.2:  Observational studies of zygosity and concordance for rheumatic fever 
Study ID No of twin pairs Type of zygosity Occurrence of acute rheumatic fever 
   Concordance Disconcordance 
Irvine-Jones 1933 7 MZ 2 0 
  DZ 0 5 
Wilson 1937 6 MZ 2 0 
  DZ 2 2 
Kaufmann 1938  72 MZ 5 22 
  DZ 1 44 
Stevenson 1953 10 MZ 1 0 
  DZ 0 9 
Taranta 1959 56 MZ 3 13 
  DZ 1 39 
Reed 1964 284 MZ 36 91 
  DZ 11 146 
Totals 435 MZ 49 126 
  DZ 15 245 
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Table 3.3:  Possible sources of bias:  defining characteristics in individual studies 
Study ID ARF case definition  Gender of twin pairs Zygosity Determination 
Irvine-Jones 1933 ARF, chorea, joint pain, fever absent, mitral 
stenosis  
nd nd 
Wilson 1937 New York TB and Heart Association  nd nd 
Kaufmann 1938 nd nd nd 
Stevenson 1953 ARF, chorea, mitral stenosis, death from 
RHD, rheumatic conditions with mitral 
involvement 
MZ:F;  DZ: 6=same sex, 
3=mixed   
nd 
Taranta 1959 Jones’ criteria MZ:nd;  DZ: 23=same sex, 
17=mixed   
blood group, hair and eye-colour, 
similarity of dermatoglyphics,  
Reed 1964 nd nd nd 
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either using the criteria of the Heart Committee of New York Tuberculosis and Health 
Association, Inc or the Jones Criteria (Stevenson and Cheeseman, 1953, Taranta et al., 
1959, Wilson and Schweitzer, 1937, Irvine-Jones, 1933).   
3.3.3 Relationship	  between	  Zygosity	  and	  Concordance	  Rates	  of	  ARF	  	  
Probandwise concordance rates ranged from 31% to 100% for monozygotic twins, and 
from 0% to 67% in dizygotic twins in individual studies.  The pooled probandwise 
concordance rate was 44% for monozygotic twins and 12% for dizygotic pairs.  Random-
effects meta-analysis confirmed the strong association between zygosity and concordance 
for acute rheumatic fever in twins (OR, 6.39; 95% CI, 3.39 to 12.06; P<0.001) (Figure 3.2).  
 
Figure 3.2. Odds ratio of concordance for acute rheumatic fever according to type of 
zygosity 
Horizontal lines, 95% confidence interval; CI, Confidence interval; MZ, monozygotic; 
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If the two studies with no events among dizygotic twins are excluded, the pooled OR = 
5.78 (95% CI, 3.02 to 11.05; P<0.001). No statistical heterogeneity was present between 
studies (χ 2 2=2.56; P=0.768).  Heritability estimated by fitting VC models is shown in 
Table 3.4. Study-specific heritability estimates of acute rheumatic fever from the three 
larger studies varied from 0.54 to 0.73. The heritability across all the studies was 0.603 
(95% confidence interval 0.413, 0.805).   
The comprehensive literature search revealed no twin studies of concordance of rheumatic 
heart disease. 
3.4 DISCUSSION 
To the best of our knowledge, this meta-analysis of 175 monozygotic and 260 dizygotic 
twin pairs represents the largest quantitative assessment of the heritability of acute 
rheumatic fever to date.  This study shows that the risk of acute rheumatic fever in a 
monozygotic twin with a history of acute rheumatic fever in the co-twin is increased by 
more than six times compared to that of dizygotic twins.  The heritability estimate was 
60%, which confirms the importance of genetic factors in acute rheumatic fever. These 
findings provide a strong justification for embarking on whole genome mapping of genetic 
susceptibility variants for acute rheumatic fever in large appropriately designed cohorts 
(Bryant et al., 2009).  
Twin studies provide the appropriate framework for assessing the extent to which the 
familial occurrence of acute rheumatic fever is due to genetic and environmental factors. 
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Table 3.4: Results of fitting the ‘ACE’ threshold model to estimate genetic and environmental components of 
variance* Study ID No of twin pairs Additive genetic Common environment Unique environment 




72 0.728 0.000 0.272 
  (0.134-0.856) (0.000-0.503) (0.144-0.454) 
Taranta 1959(Taranta 
et al., 1959) 
56 0.714 0.018 0.268 
  (0.017-0.887) (0.000-0.565) (0.114-0.513) 
Reed 1964(Reed, 
1964) 
284 0.540 0.275 0.185 
  (0.315-0.781) (0.051-0.474) (0.135-0.246) 
All studies** 435 0.603 0.209 0.188 
  (0.413-0.805) (0.023-0.378) (0.144-0.239) 
‘ACE’, Additive genetic factors, Common environment, and unique Environment; No, number 
*Limited to studies with sufficient numbers (> 50) of twin pairs  
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phenotypic similarity in monozygotic twins that is greater than that of dizygotic twins is 
due to their greater genetic similarity (Phillips, 1993).  To compare the different studies, we 
used the probandwise concordance rate to derive the proportion of affected co-twins for an 
affected proband in a particular study; the probandwise concordance rate has the 
advantage of providing the opportunity to compare studies irrespective of their 
ascertainment method, and provide an overall estimate of twin concordance rates for a 
particular condition. The important role which genetic susceptibility studies can play in 
informing the prioritization of research resources is illustrated in the unraveling of genes 
involved in breast cancer, where monozygotic twin pairs carry a risk of almost three times 
of developing the disease compared with dizygotic twins or first-degree relatives (Mack et 
al., 2002). 
Acute rheumatic fever is a complication of untreated streptococcal pharyngitis for which 
only affects 3-6% of the general population is at risk. It is not possible at present to predict 
the individuals who are at risk of developing acute rheumatic fever following an episode of 
streptococcal pharyngitis. The identification of genetic variants that reliably predict risk of 
development of acute rheumatic fever may be used to identify individuals who may benefit 
from prophylaxis with penicillin or vaccination against invasive streptococcal infection. 
This study suggests that genetic factors may have a high predictive power for the 
development of acute rheumatic fever, and as such may be of clinical utility in predicting 
disease risk. Therefore, the identification of all genetic susceptibility factors for acute 
rheumatic fever through whole genome analysis may lead to the development of a useful 
predictive genetic risk score for the disease. 
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the phenotype given that we used the clinical definition of acute rheumatic fever provided 
by the authors.  Three of the studies were published before the original Jones criteria for 
the diagnosis of acute rheumatic fever were formulated in 1944, and relied on the clinical 
judgment of the investigators.  Thus, given that the criteria for the diagnosis of acute 
rheumatic fever have evolved over the years, the generalizability of our findings to the 
present may be limited.  Secondly, there was incomplete information on the age and 
gender of the twins included in this review. It is therefore not possible to assess the effects of 
age of onset or gender on genetic susceptibility to acute rheumatic fever in this work. 
Thirdly, there is a lack of data on the methods of determining zygosity status in four of the 
studies, which may cast doubt on the reliability of the findings. Although no twin studies were 
found for RHD, it is likely that these findings apply to cases of RHD nonetheless, which is a 
consequence of repeated attacks of ARF.  Finally, it must be acknowledged that the results of 
twin studies cannot automatically be generalized beyond the population in which they were 
derived, and heritability is specific to a particular population in a particular environment. 
Furthermore, these studies were carried out over 45 years ago mainly in industrialized 
countries where endemic rheumatic fever has since been eradicated through improved 
living conditions and the availability of penicillin;  today acute rheumatic fever is largely a 
disease of poor communities in developing countries.  No studies of familial aggregation of 
the disease have been done within the developing country setting, which possibly reflects 
the relative neglect of this disease by the research community (Watkins et al., 2009)  It is 
interesting, however, to note that the proportion of people at risk of development of acute 
rheumatic fever following untreated streptococcal pharyngitis remains the same in all 
ethnic groups of the world (Bryant et al., 2009).  It is likely therefore, that there are no 
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human populations. It follows therefore, that the apparent ethnic variation between racial 
groups are more likely to be due to confounding by socio-economic factors, especially given 
that socioeconomic factors are difficult to measure completely (Kaufman et al., 1997) 
In summary, this meta-analysis of 435 twin pairs with acute rheumatic fever shows that the 
monozygotic twin concordance substantially exceeds the dizygotic twin concordance, and 
thus implicates genetic factors as playing a significant role in the etiology of the condition. 
These results should provide renewed impetus to the establishment of large-scale studies to 
unravel the genetic architecture of acute rheumatic fever and rheumatic heart disease. 
Finding reliable and reproducible genetic susceptibility variants for acute rheumatic fever 
will not only assist in elucidating the pathophysiological mechanisms of the disease, but also 











Chapter	  4:	  	  Background	  Carriage	  of	  the	  Agent	  
PhD	  Thesis:	  	  Mark	  E	  Engel	  	   	   	  	  	  |	  Page	  94	  
4 PHARYNGEAL CARRIAGE OF THE AGENT:  STUDY TWO 
 
CARRIAGE RATES AND GENOTYPIC CHARACTERISTICS OF  
GROUP A STREPTOCOCCI IN ASYMPTOMATIC SCHOOL CHILDREN OF 
THE VANGUARD COMMUNITIES OF CAPE TOWN, SOUTH AFRICA 
4.1 INTRODUCTION    
The epidemiology of pharyngeal carriage of GAS has been reviewed in the Background to the 
Thesis, Section 1.5.1.2.  Data on GAS carriage from African countries remain scant with a 
few studies reporting a prevalence of about 10% in pharyngeal isolates from healthy 
participants (Abdissa et al., 2011, Mzoughi et al., 2004, WHO, 2004).   In South Africa, 
four studies conducted in various race groups in the 1970s reported carriage rates varying 
from 3.6% to over 20% in urban settings where overcrowding, amongst other factors, was 
identified as a possible predisposing factor to high carriage rates (McLaren et al., 1975, 
Ransome et al., 1983, Van Staden et al., 1982, Bundred, 1986).  
Determining the background prevalence of GAS carriage could aid in identifying risk 
factors associated with carriage in school-aged children and influence the planning and 
evaluation of management programmes in the screening of pharyngeal carriers (Lloyd et 
al., 2006).  Also, knowledge of the pretest probability influences assessment of the posttest 
probability of GAS pharyngitis, so as to minimise unnecessary diagnostic testing in children 
(Shaikh et al., 2010).  Finally, in the light of recent advances towards a streptococcal 
vaccine (Dale et al., 2011) and given that asymptomatic carriers have been shown to 
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2004), identification of the DNA sequencing pattern of the 5’ hypervariable region of the 
cell-surface M-protein (so called emm typing (Beall et al., 1996)) may be able to inform 
vaccine development and later, for assessing the impact of vaccination and monitoring 
serotype changes. 
This study was conducted in order to determine GAS carriage rates among asymptomatic 
school children in the two peri-urban school districts of Bonteheuwel and Langa, Cape 
Town, South Africa.  In particular, we sought to determine the extent to which 
rheumatogenic strains used for candidate vaccine development were being carried in 
asymptomatic children.  Also, we characterised the emm types of the isolates in order to 
establish whether some strains were more prevalent than others as well as to contribute to 
the knowledge base informing the development of appropriate GAS vaccines. 
 
4.2 MATERIALS AND METHODS 
4.2.1 Study	  Design	  and	  Setting	  
This cross-sectional study formed part of a larger school-based study on the prevalence of 
RHD amongst healthy school children in the Vanguard area of Cape Town  (See Section 
2.1).  The area, situated about 14 km from the Cape Town CBD, covers approximately 6.3 
km2 and comprises two lower socio-economic communities of largely black African and 
mixed ancestry.  Approximately 20% of the population is 5 – 15 years of age (Statistics 
South Africa, 2003).  Further detail as regards some of the indicators of socio-economic 
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Recruitment and Sample Size 
The sample comprised asymptomatic children between the ages of 5 and 21 years whose 
parents provided informed consent for participation in the study.   The sample size was 
based on published studies in similar South African communities (McLaren et al., 1975, 
Ransome et al., 1983) allowing for estimation of at least 5% difference of GAS carriage 
across the two communities within a precision of 5%;  additionally we assumed a 5% non-
response rate. Therefore, at least 451 participants per community were needed to be 
examined over the three-year (school) period from February 2009 to November 2011.  A 
purpose-built database on the Epi Info (version 3.5.2) platform was used to manage the 
data.     
4.2.2 Study	  Procedure	  
The throat swab sample was taken by swabbing the tonsillar and posterior pharyngeal 
areas; samples were transferred in transport media for processing by the Microbiology 
Laboratory of the National Health Laboratory Service located at Groote Schuur Hospital.  
Briefly, each throat swab was inoculated onto 4% sheep blood agar plates according to the 
standard protocol, inverted and incubated anaerobically at 35 oC for 24-48 hours. All 
cultures of beta-hemolytic colonies were further identified by Gram stain, catalase, and 
serogrouping, as appropriate.  
The emm typing procedure was performed according to established protocols (Beall et al., 
1996).  Briefly, DNA was extracted from single colonies of GAS and subjected to PCR-
amplification using primers targeting the N terminal of the emm gene.  The PCR product 
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http://www.cdc.gov/ncidod/biotech/strep/M-ProteinGene_typing.htm) using ABI 
Prism® BigDyeTM Terminator Cycle Sequencing kit (Applied Biosystems, USA) and 
analysed using BioEdit v7.0.9 (Ibis Biosciences, USA). Sequences were submitted 
electronically to the S. pyogenes emm sequence database centre at CDC, which assigned the 
emm types and subtypes.   
4.2.3 Ethical	  Approval	  
The study was performed with the approval of the University of Cape Town Faculty of 
Health Sciences Research Ethics Committee, and informed consent was obtained in 
writing from a parent or legal guardian of each participant.  In addition, children aged 8 
years and older were required to provide assent.   
4.2.4 Statistical	  Analysis	  
Statistical analyses were performed using STATA version 11.0 (SPSS Inc., Chicago, IL, 
USA).  Comparisons were made using chi-square test or Fisher’s exact test. A p-value of 




Over the three school years (2009 – 2011) of our study, 950 healthy learners attending 
schools within the two communities of our demonstration site were enrolled into our study.  
The mean and median ages of the participants were 11.4 years and 10 years respectively 
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Table 4.1. Comparison of some of the characteristics with respect to GAS status, of the asymptomatic 
school children recruited into the study during February 2009 – November 2011 
  
βHS (+) (%) βHS (-) (%) Total 
GAS + (%) GAS – (%)   
Age (mean (sd);  [range]) 11.1 (3.6); [6-21] 11.6 (4.0); [4-19] 11.4 (4.0); [3-24] - 
 < 9 years 7 (3.1) 8 (3.57) 210 (93.3) 225 (23.7) 
 ≥ 9 years 24 (3.3) 43 (5.9) 658 (90.8) 725 (76.3) 
Gender     
 Female 15 (2.8) 35 (6.4) 493 (90.8) 543 (57.2) 
 Male 16 (3.9) 16 (3.9) 375 (92.2) 407 (42.8) 
School District     
 Bonteheuwel 8 (1.6)* 25 (5.1) 454 (93.2) 487 (51.3) 
 Langa 23 (5.0) 26 (5.6) 414 (89.4) 463 (48.7) 
Season     
 Winter 18 (4.1) 14 (3.2) 406 (92.7) 438 (46.1) 
 Summer 13 (2.5) 37 (7.2) 462 (90.2) 512 (53.9) 
 Total 31 (3.3) 51 (5.4) 868 (91.4) 950 (100) 
βHS, βeta Haemolytic Streptococcus;  GAS, group A streptococcus;  (+), positive;  (-), negative; %, percentage;   
sd, standard deviation.  * P value < 0.05 for association between school district and having a GAS (+) status 
 
4.3.2 β-­‐haemolytic	  streptococci	  isolation	  	  
β-haemolytic streptococci (βHS) were identified in swabs from 82 of 950 participants (8.6% 
(95% Confidence Interval [CI]: 6.84 – 10.4 %)).  There was no association between βHS 
isolation and gender (p=0.47), age < 9 years vs age ≥ 9 years (p=0.23) or winter vs summer 
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seasons (p=0.18).  More βHS were isolated from participants in the Langa school district 
(10.6%) than from those in Bonteheuwel (6.7%), (p=0.037).   
4.3.3 Group	  A	  Streptococci	  Isolation	  	  
Group A Streptococci (GAS) was isolated from 37.8% of all βHS isolates (31/82) 
corresponding to a carrier rate of 3.26% (95% CI:  2.13 – 4.39 %) among healthy school-
aged learners (Table 4.1).  GAS was recovered from almost all ages of learners (Figure 4.1)   
 
(mean age = 11.09 years (sd ± 3.6 yrs)  with  no  association  of  GAS status with age 
(p=0.628).  Winter vs summer showed no significant association with GAS recovery as did 
neither gender.  Considering school district, there was a statistically significant difference in 














Age	  in	  years	  
Chapter	  4:	  	  Background	  Carriage	  of	  the	  Agent	  
PhD	  Thesis:	  	  Mark	  E	  Engel	  	   	   |	  Page	  100	  
the isolation rates of GAS by school district, with pupils from Langa, having a significantly 
increased odds of having the organism isolated (O.R 3.129, 95% CI 1.38 – 7.09). 
4.3.4 Non-­‐Group	  A	  Streptococci	  Isolation	  	  
The carrier rates amongst the non-Group A βHS isolates were 3.5% (33/950) for group C 
(GCS) and 1.5% (14/950) for group G streptococci (GGS).  Other βHS recovered included 
group F (3 isolates) and group D (1 isolate) (Table 4.2). 
 
Table 4.2.  Seasonal distribution of beta haemolytic streptococci isolates from asymptomatic school children 
Climate GRP-A GRP-C GRP-D GRP-F GRP-G Total 
Winter 18 10 0 0 4 32 
Summer 13 23 1 3 10 50 





4.3.5 emm	  Typing	  of	  Streptococcal	  Isolates	  
We managed to sequence 25/31 of the GAS isolates in the time available for this study.  
There was a variety of emm types represented, and the most common types were emm 4 
(12%) and emm 9 (12%) (Figure 4.2).  Of the 25 isolates investigated, 14 are represented in 
the putative GAS 30-valent vaccine (Dale et al., 2011).   
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4.4 DISCUSSION 
This study investigated GAS carriage in a population of South African school children in 
order to determine carrier rates, prevalent serotypes and emm strains, and their association, 
if any, with a number of demographic factors. Carriers of GAS may represent a potential 
source of the acquisition of infections for other children and adults.  A longitudinal study 
over 44 months demonstrated the persistence of carrier strains during repeated episodes of 
GAS infection in 50% of participants (Martin et al., 2004).  Thus, GAS carriage reflects the 
reservoir of circulating strains, which are relevant to disease such as pharyngitis 
Microbiological evidence of βHS carriage was found in 8.6% of pharyngeal swabs taken 
from 950 healthy school-aged children.  The proportion of GAS carriage was observed to 
be 3.3% among the 950 healthy school-aged children, with no difference in the prevalence 
rates for male and female school children.  Prevalence rates of GAS carriage of ≥ 10% 
have been reported in school settings in both industrialised and developing countries 
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(Gunnarsson et al., 1997, Jasir et al., 2000, Kim and Lee, 2004).  A meta-analysis 
comprising 18 studies conducted in clinic and school settings in both developed and 
developing countries reported a pooled prevalence of GAS carriage of 12% (95% CI: 9%–
14%).  Our present rate of GAS carriage is below previously reported carriage rates from 
South Africa;  furthermore, we did not observe the seasonal variation between winter and 
summer isolation rates, which may be related in part, to the climatic differences between 
Cape Town  and the other regions in South Africa where the respective studies were 
conducted (Ransome et al., 1983).  
In our study, carriage of group A streptococci in the Vanguard Community, a community 
with apparently high rates of rheumatic fever and rheumatic heart disease, is remarkably 
low (overall3.3%).  A similar low carriage rate (3.7%) of GAS was reported in a study from 
the Northern Territory of Australia (McDonald et al., 2006). GAS carriage was 
significantly associated with the Langa school district;  learners from Langa were found to 
have more than three times the odds of GAS carriage (p=0.038).  While both Bonteheuwel 
and Langa school districts are considered as being of low SES, of the two, Langa rates 
poorly in a number of key indicators of SES.  Thus, the statistically significant higher 
prevalence observed in Langa may be explained by socioeconomic factors such as 
overcrowding and lack of suitable housing.  This finding corroborates those of earlier 
studies conducted in South Africa amongst urban Black communities (Van Staden et al., 
1982, McLaren et al., 1975), historically known to have resided in overcrowded poverty-
stricken conditions.   
Rates of carriage for GCS and GGS were 3.5% and 1.5% respectively.  The potential 
pathogenicity of non-GAS organisms is not well understood with there being some 
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evidence for an association with pharyngitis and other diseases (Turner et al., 1997, 
Tiemstra and Miranda, 2009, Zaoutis et al., 2004).  However, these findings were not 
confirmed in a study conducted in the South Pacific (Steer et al., 2009).   
This is only the second study to document the molecular epidemiology of GAS isolates 
from asymptomatic carriers in Africa.  The 25 isolates recovered from asymptomatic school 
children in our study represents 15 emm types;  although emm 4 accounted for the largest 
proportion, there was no predominant subtype.  Our isolates have only seven emm types in 
common with those reported from asymptomatic carriers in Ethiopia (Abdissa et al., 2006).  
Interestingly, our most abundant emm type, emm 4, was absent from their cohort .  We 
considered our emm types in light of the putative vaccine under development by Dale and 
colleagues; only forty-six per cent of our emm types are listed among those in the 30-valent 
vaccine (Dale et al., 2011).  
This study screened sufficient participants in terms of the size required for this study.  
However, there are a number of limitations:  while we are certain that we only sampled 
healthy children, we nevertheless had to rely on participants’ self-reporting as regards 
recent pharyngitis and antibiotic history given that we did not serologically confirm the 
absence of a recent episode of GAS.  We were also limited by the short summer school 
terms due to holidays, and thus seasonal variation across all four seasons could not be 
adequately captured in terms of when swabs were taken. Given that only 25 isolates were 
sequenced, it is difficult to draw firm conclusions regarding dominant emm types.  No 
serology testing was undertaken, thus reducing the discriminatory power to distinguish 
between cases and carriers.  
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In conclusion, we have shown that among asymptomatic school children from Cape Town, 
GAS carriage was higher in Langa than Bonteheuwel.  Furthermore, there is a diversity in 
emm type distribution of which more than 50% are not included in the putative 30-valent 
vaccine.  Further research needs to be conducted to elucidate the possible role of GAS 
carrier strains in episodes of acute GAS pharyngitis. 
.
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5 EPIDEMIOLOGY OF GAS PHARYNGTIS:  STUDY THREE  
 
LONGITUDINAL STUDY OF GAS PHARYNGITIS IN THE  
VANGUARD COMMUNITY DEMONSTRATION SITE:  
INCIDENCE AND PREVALENCE IN CHILDREN AGED 3 TO 15 YEARS 
 
5.1 INTRODUCTION 
As discussed in Section 1.4, GAS pharyngitis in childhood has been shown to be 
associated with the subsequent development of ARF in up to 3% of patients, following an 
autoimmune response in untreated patients (Rammelkamp et al., 1952).  Furthermore, 
subsequent GAS infections increase the risk of having a recurrent episode of ARF to as 
high as 75% (Denny, 1987). 
The incidence of GAS pharyngitis is estimated to be 616 million cases per year amongst 
all ages across the world based on a systematic review of population-based data using 
United Nations population data as the denominator;  in more developed countries, 
approximately 15% of school-aged children will suffer an episode of GAS pharyngitis 
each year, whereas in less-resourced countries, the incidence may be more than five times 
greater (Carapetis et al., 2005b).  Previous studies have reported varying incidence rates 
of acute sore throat ranging from 8,3 to 705 cases per 100 child-years and GAS swab-
positive pharyngitis from 3,9 to 95 cases per 100 child-years (see Section 1.5).  Only two 
studies have reported on the prevalence of GAS in participants with pharyngitis in South 
Africa.  Throat swab culture returned a positive culture in 33% and 42% in each study 
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respectively, conducted in Pretoria (van Zyl et al., 1981) and Bloemfontein (Olivier and 
de Graad, 1978) more than 30 years ago. 
An understanding of the incidence of GAS pharyngitis in children within a local context 
is an important component of any ARF and RHD control programme (World Health 
Organization., 2004).  Addressing GAS pharyngitis through appropriate primary 
prevention measures (as discussed in Section 1.6) and treating all symptomatic GAS sore 
throats with a course of oral or parenteral penicillin (Robertson et al., 2005a) presents the 
opportunity for primary intervention of RHD (Karthikeyan and Mayosi, 2009), thereby 
reducing the economic and major public health consequences associated with disease 
burden (Pfoh et al., 2008, Danchin et al., 2004).  
The primary aim of this study was to determine the incidence and prevalence of GAS 
pharyngitis among children of the Vanguard community of Cape Town over a four-year 
period.  
5.2 PATIENTS AND METHODS 
The methods are described previously in detail in Section 2.3 ‘Rationalé and Design of 
the studies”.   
5.2.1 Study	  Design	  	  	  
We conducted a 4-year prospective, clinic-based study from May 2008 – April 2012.  A 
research nurse identified children with symptoms of sore throat among attendees of the 
three community-based clinics.  
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5.2.2 Setting	  and	  Participant	  Recruitment	  
Participants aged 5 – 15 years were enrolled, following informed consent, according to a 
standard protocol from one of the three clinics serving the Vanguard community of Cape 
Town.  Children >7 years also provided assent to their participation in the study.  The 
two communities of Bonteheuwel and Langa within Vanguard differ significantly with 
respect to a number of socio-economic status indicators (Section 2.1). Each participant 
was designated a unique identifying code.  Prior to obtaining the throat swab specimen, 
the research nurse performed a physical examination of the pharynx and recorded, in 
addition to the demographic characteristics of participants, recent antibiotic usage, which 
was verified by folder review;  patients who had received antibiotics in the preceding 30 
days were not enrolled in the study. The symptoms and signs were documented in a 
database.  A repeated episode of sore throat was treated as a new case. 
5.2.3 Treatment	  of	  Pharyngitis	  
The research study did not interfere with the routine standard of care at the respective 
institutions.  Thus, patients were treated according to the clinic protocols for sore throat 
management.  A copy of the laboratory culture results of all study participants was placed 
in the clinic folder. 
5.2.4 Laboratory	  Methods	  	  
Specimen Collection, Transport and Handling are outlined in Section 2.3.6.  Briefly, all 
throat swabs were placed in individual sealed specimens and delivered to the 
microbiology laboratory as soon as possible following collection (usually by midday).  A 
batch flow form was used to track specimens and accompanying CRFs.  On arrival at the 
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laboratory, specimens were plated onto 4% sheep blood agar plates, incubated 
anaerobically at 35°C, and read within 18 to 24 hours.  Patients were characterized as 
GAS positive if beta-haemolytic colonies were confirmed as Streptococcus pyogenes by Gram 
stain.  A single colony was picked off with a sterile wire loop, and sub-cultured for purity.  
Pure colonies of beta-haemolytic streptococci identified as group A, C or G were removed 
from the plates in a sterile fashion and placed in trypticase soy broth with glycerol for 
storage.  
5.2.5 Statistical	  Analyses	  and	  Denominator	  Figures	  for	  Incidence	  Calculations	  
Statistical considerations are discussed in Section 2.3.8;  about 420 cultures were expected 
per annum at the clinics collectively. I compared categorical data according to 
demographic and clinical profiles using !2 or Fisher’s exact test (for small numbers) with 
calculation of odds ratios (OR) and 95% confidence intervals (CI) as appropriate.  To 
facilitate comparisons, I generated new variables:  AgeCat:  for age categories of < 9 vs ≥ 
9 years of age, Season:  corresponding to the wet winter months (June–August), spring 
(September – November), the dry summer months (December – February) and autumn 
(March – May).  I further analysed the GAS results according to the residence of the 
participants (as opposed to by clinic) given that patients do not necessarily attend the 
clinic nearest to their homes.  
The annual rate of incident cases of GAS pharyngitis was calculated on a gender- and 
community-specific basis using an estimate of the number of children aged five to fifteen 
years in the catchment areas based on census data for the Vanguard population (Statistics 
South Africa, 2003) – see Section 2.1.  Incidence data are thus presented for the 5 – 15 
age groups residing within the Bonteheuwel and Langa communities.    We revised the 
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yearly population total for each year of the study taking into account an annual 
population growth of 1% per annum (World Bank, 2012).  Significance was accepted at 
the two-sided level of 0.05.  Statistical analyses were performed using STATA version 
11.0 (SPSS Inc., Chicago, IL, USA).  
5.2.6 Ethical	  Approval	  	  
The University of Cape Town’s Human Research Ethics Committee approved the study.  
We also received permission from the various local departments of health as well as from 
the management of each facility. 
 
5.3 RESULTS 
5.3.1 Enrolment	  and	  Demographics	  
From May 2008 to April 2012, 902 children were evaluated for eligibility to participate in 
the study.  Following exclusion due to recent antibiotic use (n=35), age ineligibility (n=1),  
refusal on the part of the parent or child (n=16) or incomplete data (n=10), 840 
participants were enrolled over the 4-year period (Table 5.1).  Female children were in 
the majority with 468 cases (56%). The mean age amongst all participants was 8.17 years 
(range 3 – 15 years).  Children under the age of nine years presenting with sore throat to 
the community clinics were more likely to be female (O.R 1.41, 95% CI 1.07-1.86).   
The majority of participants (72.1%) was enrolled from Bonteheuwel, 18% from Langa 
and 9.8% from outside the Vanguard area.  Of the three clinics, the Vanguard 
Community Health Centre with 639 patients had the highest number enrolled while the 
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TABLE 5.1   Demographic Data for Enrolled Participants According to Clinic 
 Demographic  Clinic 
  Total Vanguard Langa Netreg 




468  (56) 































Mean (+/- 2sd) 
                   3 - 8 



















1.  May 08 – Apr 09 
2.  May 09 – Apr 10 
3.  May 10 – Apr 11 































Winter (June – Aug) 211 (25) 190 (30) 9 (10) 12 (11) 
Spring (Sept – Nov) 240 (29) 170 (26) 36 (39) 34 (31) 
Summer (Dec – Feb) 147 (17)   94 (15) 23 (25) 30 (28) 
Autumn (Mar – May) 242 (29) 185 (29) 24 (26) 33 (30) 
n, number;  y, years; sd, standard deviation;  
 §P value was significant for !2 test assessing difference in distribution of age category w.r.t gender (p = 0,0138)  
§§ Seasons are designated according to the local climate with summer and winter being the driest and wettest seasons 
respectively 
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Netreg clinic had the highest female to male ratio (female to male ratio 1.7:1).  Over the 
four years of the study, overall enrolment was highest during the first year of the study 
(May 2008 – April 2009).  Netreg clinic’s recruitment, though, was the most in the third 
year of study.  Peak season of enrolment for the Langa and Netreg clinics was spring, 
while for Vanguard, winter had the highest numbers recruited. 
5.3.2 Period	  prevalence	  of	  GAS	  Pharyngitis	  
Table 5.2 shows the demographic and GAS status of the laboratory cultures investigated 
over the study period.  Overall, GAS was positive in 181 of the 840 patients (21.6%) 
presenting with pharyngitis as a symptom to the community clinics with no significant 
differences found with respect to age categories (< 9 or ≥ 9) or gender.  Isolation rates for 
GAS were similar across the three communities ranging from 21% to 23%.  The highest 
proportion of GAS isolates occurred during the third study period (2010 – 2011) with 55 
participants (28%) being positive from the 197 enrolled.   Autumn had the highest 
proportion (27%) of GAS isolates while in Winter, only 15% of throat swabs were positive 
for the organism.  There was no plausible explanation for the drop in the numbers of 
children enrolling year by year;  the study is ongoing and trends will continue to be 
monitored in the coming years.  
5.3.3 Recurrent	  Episodes	  of	  Culture–Positive	  Pharyngitis	  
Fifty-four children had repeated episodes of pharyngitis with 46, 5 and 3 children having 
2, 3 and 4 episodes of pharyngitis, respectively. Of these, 6 children had two episodes of 
GAS positive pharyngitis. 
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TABLE 5.2  Comparison of GAS-Positive Throat Cultures According to Community  
Demographic Total Bonteheuwel Langa Other 






   Male 
103/468 (22) 
78/372 (21) 
69/335 (21)  
59/270 (22) 






y 3 - 8 















1.  May08 – Apr09 
2.  May09 – Apr10 
3.  May10 – Apr11 









































n, number;  y, years;  § P value was significant for !2 test assessing difference in distribution of gender in Langa participants w.r.t. GAS 
positivity (p=0,022) 
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5.3.4 Period	  prevalence	  of	  Streptococcal	  Groups	  other	  than	  GAS	  	  
Non-GAS streptococcal isolates were recovered from 62 children:  these included group C 
(32), group D (1), group F (5) and group G (24). 
5.3.5 Demographic	  Associations	  Culture-­‐Positive	  Sore	  Throat	  
There were no significant associations between demographic variables and GAS positivity 
with one exception:  females from Langa were more likely to have a GAS-positive throat 
culture than male children (O.R 2.568, 95% CI 1.11-5.94), Figure 5.1;  this was observed 
in three of the four years of the study period.  In the second year of the study, there was a 
significantly higher rate of GAS isolation from participants from Bonteheuwel compared 















Bonteheuwel	   Langa	   Other	  
(p	  =	  0,022)	  
FEMALE	  (n=103)	   MALE	  (n=78)	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with Langa, p=0.037.  The analysis of GAS isolation by season across the four study years 
is presented in Table 5.3.  Overall, there was no significant difference in the rates of  
isolation on a year-by-year basis, p values = 0.132, 0.190, 0.203 respectively.  When 
considering seasons, autumn  had  the highest proportion of  GAS  isolated  ranging  from 
20.7 - 37.3% over each of the first three years of the study (Figure 5.2.).  During year 4, the 
highest percentage of GAS was isolated in summer 10/33 (30.3%). 
 
Figure 5.2.   Seasonal variation in the proportion of culture-positive GAS isolated in the Vanguard 
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TABLE 5.3  Comparison of GAS-Positive Throat Cultures According to Study Year 
Year 
No of  
Children (%) 
No (%) of  
GAS-positive cultures  
P-value 
2008 - 2012 840 181 (22)  
















































































No, number;   P value for !2 test assessing difference in distribution year on year 
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5.3.6 Incidence	  Rates	  for	  Sore	  Throat	  and	  GAS	  Pharyngitis	  
Based on the number of cases and age-specific population data, the incidence of new cases 
of pharyngitis for the population of the Vanguard community aged 5-15 years was 
estimated to be 0.837 cases/100 person-years (Table 5.4).  The incidence of sore throat 
varied according to age, being higher among 5-9 years of age than among those aged 10-
15 years (IRR 2.341, 95% CI 2.00-2.74). 
The incidence of GAS pharyngitis for the population of the Vanguard Demonstration site 
aged 5-15 years was 0.18 cases/100 py.  GAS sore throat incidence ranged from 0.14 – 
0.21 per 100 py over the respective years of the study. A significantly higher incidence of 
GAS pharyngitis was observed in the younger age group (I.R.R 2.265, 95% CI 1.61-3.21), 
a trend seen throughout each year of the study period (Figure 5.3).    
 
Figure 5.3.   Estimated incidence of GAS culture-positive pharyngitis in 
Bonteheuwel and Langa children  
Age:	  5-­‐9	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TABLE 5.4   Estimated Incidence of Sore Throat and Primary Cases of GAS Culture-Positive Pharyngitis  
Parameter Sore Throat  
GAS Pharyngitis 
 Cases,  
n 





95% CI  Cases,  
n 
Time at risk, 
py 
Incidence per 
100 py  
95% CI 
Overall 728 87040 0.836 0.77 – 0.89 157 87040 0.180 0.15 – 0.21 
Age, y 
 
    5 – 9 
 











1.11 – 1.33 











0.21 – 0.31 


























1.17 – 1.48 
0.59 – 0.83 
0.63 – 0.86 

















0.16 – 0.29 
0.11 – 0.22 
0.15 – 0.28 
0.099 – 0.201 
n, number;  py, person-years;  CI, confidence interval;  y, years; 
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5.4 DISCUSSION 
To the best of my knowledge, this is the first prospective incidence study of sore throat and 
GAS pharyngitis in Africa. Participants for this study were enrolled over four years from 
the three state-funded facilities in the Cape Town suburbs of Bonteheuwel and Langa. The 
incident rate per 100 py for sore throat presentation was 0.836 cases and 0.180 for GAS 
pharyngitis.  
We calculated incidence rates using population-based regional census data.  Our study 
presents incidence rates noticeably lower than those previously reported.  The incidence 
rates of GAS pharyngitis episodes among 5 to 15 year-olds ranged from 0.157 to 0.215 per 
100 py over the individual years of the study.  Incidence rates of GAS pharyngitis from 
North India were estimated to be 950 / 103 py (Nandi et al., 2001), Czechoslovakia, 39 / 
1,000 py (Duben et al., 1979) and Melbourne, 130 / 1,000 py (Danchin et al., 2007) and 
140.7 / 1,000 py cases (Steer et al., 2009).  The lower incidence in our study may indicate 
that, either episodes of group A streptococcal pharyngitis are exceedingly uncommon in 
the Vanguard Community or that presentation with this condition is exceedingly 
uncommon.  Either way, this finding has important implications for policy, especially as 
regards whether the focus of prevention efforts for rheumatic fever should be on primary 
prevention.  It is likely that our incidence rates are an underestimate of the true effect, 
especially given that our denominator potentially included children who do not use the 
state facilities;  our study has not accounted for the small proportion of children who attend 
private general practitioners for care.  
The period prevalence of GAS pharyngitis in patients with sore throat was 22% across the 
three participating clinics.  GAS isolation rates were similar for participants irrespective of 
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place of residence;  despite significant differences in SES indicators between the two 
suburbs of Langa and Bonteheuwel.  Other studies have also reported a negligible effect of 
SES on GAS results (Nandi et al., 2001, Danchin et al., 2007).  In an earlier study in 
Pretoria, South Africa, 33,2% of cases of pharyngitis in 5-25 year old patients were GAS-
positive and the notable difference noted between the GAS isolation rates between black 
and white participants were postulated to be attributed to the differences in the socio-
economic conditions across race groups within South Africa at the time (van Zyl et al., 
1981).   We could not explain the higher rate of GAS recovery amongst female children as 
compared with male children residing in Langa, a finding not consistent with results from 
other studies.  Concerning isolates other than GAS, we found a low period prevalence of 
non-GAS isolates among our cohort.  Unfortunately, the numbers are too low to 
investigate any associations between clinical parameters examined and the type of 
organism isolated.   
Children aged 5 – 9 years had incidence and period prevalence rates of more than twice 
those of children aged 10 years or older.  This is in keeping with data reported elsewhere 
for both sore throat (Nandi et al., 2001, Duben et al., 1979) and GAS-positive pharyngitis 
(Steer et al., 2009, Danchin et al., 2007).   
The rates of GAS isolation was highest in the autumn months for three of the four years of 
the study period, with summer having the peak prevalence in the remaining year.  While 
this finding differs from reports of high prevalence being frequently associated with the wet 
winter months, when children are more likely to spend time indoors in crowded 
surroundings, thus increasing the probability of transmission of infection (Sarkar et al., 
1988), others have reported GAS isolates being recovered across all the seasons.  
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Our study has a number of strengths:  The participants were enrolled at the time of 
presentation of sore throat at the clinic, thus reducing potential bias which may come from 
patients knowing that they are being followed for repeated episodes of pharyngitis.  Also, 
the passive approach to participant recruitment made it less likely that GAS carriers would 
have been inadvertently enrolled.   
However, limitations in this study as far as enrolment is concerned include a likelihood of 
missing children who are privately insured for medical treatment, or missing children who 
sought health care after hours, given that our study was limited to normal office hours.  
However, this was likely to be minimal.  Another limitation in this study was the 
changeover of nursing staff, with four nurses participating in the study over the study 
period.  Again, though we expect this effect to be minimal given that the latest nurse has 
been on the project for > 2 years. 
These data confirm that the complaint of sore throat is common, particularly amongst 
younger children.  While relatively lower than prevalence and incidence rates of GAS 
reported elsewhere, the numbers nevertheless call attention to the need for vigilance on the 
correct management of sore throat.   
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6 CLINICAL PREDICTION OF GAS PHARYNGITIS: STUDY FOUR  
 
STREPTOCOCCAL PHARYNGITIS IN CHILDREN PRESENTING WITH 
SORE THROAT:  EVALUATION OF EXISTING CLINICAL PREDICTION 
RULES AND DEVELOPMENT OF A CAPE TOWN STREP THROAT SCORE  
 
6.1 INTRODUCTION 
Antibiotic therapy for acute streptococcal pharyngitis has been proven to be effective in 
decreasing the complication of ARF:  in a meta-analysis of 10 studies involving in excess of 
7500 participants, Robertson et al determined a 68% risk reduction in the incidence of 
ARF in those receiving antibiotics compared with controls (Robertson et al., 2005a).  As 
discussed previously (Section 1.6), in South Africa, the management of pharyngitis 
(including tonsillitis) is based on a diagnosis of streptococcal pharyngitis  made  on  
suggestive  clinical  features, without the benefit of microbiological culture confirmation or 
rapid antigen testing (Department of Health, 1999).  Thus, a risk assessment using an 
accurate, objective model of clinical prediction derived from health facility-based data is of 
vital importance to the primary-care physicians and nursing practitioners in making 
management decisions. 
As reviewed in Section 1.4, it is preferable that a clinical prediction rule (CPR) is tested or 
validated before being adopted into practice (Wasson et al., 1985, McGinn et al., 2003).  
An evaluation of CPRs for the management of streptococcal pharyngitis developed largely 
in industrialised nations showed poor performance in populations different from those in 
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which they were developed especially in low-income regions of the world (Fischer Walker 
et al., 2006, Rimoin et al., 2005).  A recent systematic review of fifteen studies confirmed 
the inability of a selection of five CPRs to confidently rule in a diagnosis of streptococcal 
pharyngitis (Shaikh et al., 2011).  No decision rules have been developed in sub-Saharan 
Africa and thus, it is imperative to evaluate existing CPRs for GAS pharyngitis within the 
local context.  
The objective of this study was twofold:  first, we wished to test the generalizability of three 
existing CPRs namely, the World Health Organisation (WHO) Acute Respiratory 
Infection (ARI) case management strategy (WHO, 1995), the 3-variable Steinhoff rule 
(Steinhoff et al., 2005) developed in an outpatient facility in Cairo (and thus bearing 
resemblance to African conditions and the McIsaac Rule (McIsaac et al., 1998) in patients 
aged 3-15 years presenting with pharyngitis in the primary care setting;  second, to develop 
a locally applicable CPR to assist primary care physicians and nursing practitioners in 
identifying children, aged 3-15 years, who are at risk for streptococcal pharyngitis.   
 
6.2 PATIENTS AND METHODS 
The methods are described in detail in Section 2.3 ‘Rationale and Design of the studies”. 
6.2.1 Participant	  Recruitment	  	  
Participants for this prospective study were recruited over four years from May 2008 from 
three clinics serving the Vanguard community of Cape Town following informed consent 
according to a standard protocol.   Prior to obtaining the throat swab, the research nurse 
recorded, in addition to the demographic characteristics of participants, recent antibiotic 
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usage, the date of presentation at the clinic and symptoms evaluated at the time of clinical 
examination.  Together with age and gender, the following 10 symptoms and signs were 
recorded as absent or present:  cough, rhinorrhoea, hoarseness, temperature above 38°C, 
tonsillar erythema and swelling, presence of exudate on the pharynx or tonsils, 
oropharyngeal candidiasis, tenderness of an anterior cervical lymph node on palpation, 
presence of an anterior cervical lymph node greater than 1.5cm in diameter and/or 
presence of a rash.   
Microbiological procedures have been described previously in Section 2.3.6 (Specimen 
Collection, Transport and Handling).   
6.2.2 Data	  Analyses	  	  
Statistical analysis was performed using Stata version 11.0 (SPSS Inc., Chicago, IL, USA)  
Proportions or means were calculated to describe the baseline characteristics of the study 
population.  Laboratory-confirmed GAS culture positivity was regarded as being indicative 
of streptococcal pharyngitis in assessing the respective rules.  Based on the prospective data 
collected, we generated scores as defined in the respective rules to estimate the probability 
of a GAS positive culture (Box 1.2).  The WHO rule predicts GAS positivity on the 
presence of exudate on the pharynx and a large tender anterior cervical node on palpation 
while for the Steinhoff rule, a score is calculated from 1-3, one point being given for each of 
enlarged cervical node, absence of rhinitis or absence of rash.  We used the recommended 
cut-off of 2, which corresponds to a sensitivity of 92% and specificity 38% for the detection 
of GAS positivity.  The McIsaac rule which renders a score from zero to five, in addition to 
the clinical variables of temperature > 38oC, tender anterior cervical adenopathy, tonsillar 
swelling or exudate and absence of cough, also incorporates the age of the patient into the 
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decision-making with under 15 years of age, 15-44 years and ≥ 45 years contributing scores 
of 1, 0 and -1 respectively. For each rule, we calculated sensitivity (“true positive rate”) and 
specificity (“true negative rate”), the positive predictive value (PPV) and negative predictive 
value (NPV), although these have the limitation of fluctuating as the prevalence of disease 
and likelihood ratios in a population change. In addition, we determined the numbers of 
missed streptococcal cases (MDx) and unnecessarily treated non-cases (WDx) in order to 
calculate the ratio of MDx / WDx (Steinhoff et al., 2005).  The lower the MDx/WDx, the 
better the performance of the test. 
For developing the CPR, we required 10 events per candidate predictor (index test) 
(Peduzzi et al., 1996).  For illustration purposes, we calculated univariable odds ratios with 
95% confidence intervals to examine the relationship between each individual predictor 
with the primary outcome measure, i.e. a laboratory-confirmed GAS culture from the 
throat swab specimen.  For continuous predictors, the form of association with the outcome 
was checked using restricted cubic splines, to find the proper transformation if needed 
(Harrell, 2001).  No selection of predictors was made on these given the potential of 
creating unstable prediction models (Sun et al., 1996). We then entered all the candidate 
predictors (index tests) into a multivariable logistic regression model, with GAS as the 
primary outcome measure, to identify which of the candidate predictors independently 
contributed to the inclusion or exclusion of the diagnosis GAS positivity.  Age was 
modelled as a dichotomous variable below or above the median value.  A backward 
elimination modelling technique was used, with a significance limit for removal from the 
model of P>0.10 on the basis of the likelihood ratio test.  We chose not to use a p-value of 
< 0.05 as a cut-off given the potential for poor model performance when tested on new 
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patients (Janssen et al., 2010).  The new CPR rule was constructed incorporating previously 
described methods (Zuithoff et al., 2009, McIsaac et al., 1998) where the logistic formula 
was transformed into a ready to use score chart. Beta coefficients were divided by a 
constant;  predictors with a negative association were inverted and evaluated as positive 
entities;  the total score was then compared to the observed proportion of GAS positivity in 
our cohort.  Receiver operating curves (ROC), together with a plot of sensitivity versus 
specificity were generated to evaluate the predictive power of the model. 
6.2.3 External	  Validity	  
To determine generalizability of the new CPR to new patients, the rule was applied to both 
the derivation set and a new data set comprising children from a subsequent period in the 
same group of clinics (validation set) as per recommendations in the literature (Bleeker et 
al., 2003). For comparison purposes, we also applied the same CPRs originally evaluated 
on the derivation set as discussed above.  Data collection, definition of clinical variables, 
and laboratory procedures to determine GAS status among the validation cohort were 




Over the first three years of our study, 720 children with pharyngitis were examined by the 
study nurse across the three study clinic sites.  Of these, informed consent was obtained for 
666 participants who met the inclusion criteria and were recruited into the study;  this 
cohort was used to evaluate the existing CPRs and derive the new CPR (derivation set).  
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Reasons for exclusion were antibiotic treatment in the preceding 30 days, incorrect age and 
refusal by the child to allow a throat swab to be taken.  The age of the patients ranged from 
3-15 years with a mean age of 8.3 years (sd, 2.37 years).  The proportion of males was 
43.4%.   Males and females differed as regards the mean age of presentation (males 7.96 
years vs females 8.61 years; p<0.01).  A laboratory-confirmed diagnosis of GAS was 
reported in 142 patients (21.3%), which exceeded the 115 cases as per the sample size 
calculated to develop a CPR (Section 2.3.8.2).  Tonsillar erythema and swelling were 
present in more than 80% of participants, while oral candidiasis was seen rather 
infrequently (<5%).   
Validation set 
Participants recruited from May 2011 until April 2012 constituted the validation set, 
comprising 172 participants recruited in the same manner, which was used to evaluate the 
performance of the newly derived CPR.  The age of participants ranged from 3-15 years 
with a mean age of 7.45 years (sd, 2.93 years).  Of these, a positive GAS diagnosis was 
reported in 38 (22.1%) participants. Tonsillar swelling and tonsillar erythema were the 
predominant clinical symptoms, while presence of an exudate on the pharynx and 
oropharyngeal candidiasis were absent.  The baseline characteristics of the participants 
from the derivation and validation sets are presented in Table 6.1. The baseline 
characteristics amongst the validation cohort were not significantly different from the 
derivation set. 
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Table 6.1:   Comparison of the characteristics of patients presenting with pharyngitis in the derivation and 
validation sets 
    
DataSet Derivation  Validation p-value 
Sample Size 666 172  
Baseline Characteristics n (%) n (%)  
Age > 8 years  305 (45.8) 66 (38.4) 0.081 
Male Gender 289 (43.4) 86 (50.0) 0.120 
Laboratory-confirmed Group A Streptococcus + 142 (21.3) 38 (22.1) 0.826 
    Clinical Symptoms    
Cough 455 (68.3) 120 (69.8) 0.715 
Rhinorrhea 394 (59.2) 94 (54.7) 0.285 
Hoarseness 162 (24.3) 2 (1.2) <0.001 
Temperature > 38 oC  134 (20.1) 105 (61.1) <0.001 
Tonsillar erythema  547 (82.1) 171 (99.4) <0.001 
Tonsillar swelling 545 (81.8) 172 (100) <0.001 
Presence of exudate on the pharynx 76 (11.4) 0 (0.0) - 
Presence of exudate on the tonsils 327 (49.1) 102 (59.3) 0.017 
Oropharyngeal candidiasis 28 (4.2) 0 (0.0) 0.006 
Tenderness of an anterior cervical node  348 (52.3) 123 (71.5) <0.001 
Presence of an anterior cervical lymph node  
greater than 1.5 cm in diameter  
153 (22.9 125 (72.7) <0.001 
Presence of a rash. 
 
114 (17.1) 4 (2.3) <0.001 
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6.3.1 Evaluation	  of	  Existing	  CPRs	  	  	  
A summary of the diagnostic performance of three decision rules in the 666 children 
comprising the derivation set is provided in (Table 6.2).  Compared with laboratory-
confirmed culture results, the following values were obtained for sensitivity and specificity 
respectively: 8.5% and 93.3% for the WHO ARI guideline, 54.9% and 54.2% for the 
Steinhoff rule and 38.0% and 77.5% for the McIsaac rule.   The Steinhoff rule showed the 
best performance with a positive likelihood ratio of 1.20. 
 
6.3.2 Development	  of	  a	  Locally	  Applicable	  CPR	  
Table 6.3 shows the results of the association between throat culture results and clinical 
findings of all 14 variables in the derivation data set.  Tonsillar swelling (P <0.001), was the 
strongest univariate predictor of a positive GAS culture.  A further four variables were 
significant predictors for GAS positivity:  a temperature > 38 oC (P=0.007), presence of 
exudate on the tonsils (P=0.001), tenderness of an anterior cervical node on palpation 
(P=0.026) and the presence of an anterior cervical lymph node > 1.5 cm in diameter 
(P=0.036).  Strong predictors inversely associated with GAS positivity were cough (P 
<0.001), rhinorrhoea (P=0.002), and presence of a rash (P = 0.039). 
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Table 6.2:  Performance of 3 clinical decision rules for streptococcal pharyngitis in children aged 3-15 years comprising the derivation set 
(n=666) from the Vanguard Demonstration Site 
Decision Rule Sens Spec PPV NPV LR+ MDx (%) WDx (%) MDx/WDx 
WHO Rule 8.5  93.3 25.5 79.0 1.27 130 (91) 35 (7) 3.71 
Steinhoff rule  (at cut-off 2) 54.9 54.2 24.5 81.6 1.20 64 (45) 240 (46) 0.27 
McIsaac Rule (at score ≥ 4) 38.0 77.5 31.4 82.2.0 1.69 88 (62) 118 (23) 0.75 
Sens, sensitivity; Spec, specificity; PPV, positive predictor value; NPV, negative predictive value all expressed as percentages; MDx, number of missed 
streptococcal cases;  WDx, number of unnecessarily treated non-cases. 
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Table 6.3:   Results of Univariable Analysis of Potential Predictive Variables for GAS in children aged 3-15 years with 
pharyngitis:  Derivation Set  
Variable GAS+ Patients with 
variable, n (%) 
Unadjusted OR for GAS+ 
(95% CI) 
P value 
Age > 8 years  72 (50.7) 1.28 (0.87 – 1.86) 0.186 
Male Gender  55 (38.7) 1.27 (0.87 – 1.86) 0.291 
Cough  78 (54.9) 0.47 (0.32 – 0.70) 
 
< 0.001 
Rhinorrhea  68 (47.9) 0.56 (0.38 – 0.81) 0.002 
Hoarseness  29 (20.4) 0.75 (0.48 – 1.19) 0.22 
Pyrexia  > 38 oC  40 (28.2) 1.79 (1.16 – 2.75) 0.007 
Tonsillitis erythema 126 (88.7) 1.92 (1.09 – 3.38) 0.022 
 swelling 132 (92.9) 3.55 (1.80 – 6.98) < 0.001 
 exudate 88 (61.9) 1.94 (1.33 – 2.84) 0.001 
Exudate on the pharynx  16 (11.3) 0.98 (0.55 – 1.76) 0.952 
Oropharyngeal candidiasis  6 (4.2) 1.00 (0.40 – 2.53) 0.93 
Cervical glands Enlarged  42 (29.6) 1.56 (1.03 – 2.37) 0.036 
Tenderness  86 (60.6) 1.54 (1.05 – 2.24) 0.026 
Presence of a rash.  16 (11.3) 0.55 (0.31– 0.97) 0.039 
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Table 6.4 details the multivariate analysis describing the variables and the corresponding 
odds ratio, as well as the beta-coefficients and p values. Our multivariable logistic 
regression model consisted of the following predictors:  cough (OR, 0.59, 95% CI 0.40 – 
0.90), rhinorrhoea (OR, 0.66, 95% CI 0.45;0.99), tonsillar swelling (OR, 2.98, 95% CI 
1.49;5.93), tenderness of an anterior cervical node on palpation (OR, 1.55, 95% CI 
1.05;2.32) and rash (OR, 0.54, 95% CI 0.30;0.99).   The area under the curve of the model 
was 0.67.   
Table 6.4:  Multivariable Analysis of Potential Predictive Variables for GAS in children aged 5-15 years 
with pharyngitis  
 
Variable Adjusted  
Odds Ratio (95% CI) 
Beta  (P value) 
Tonsillar swelling 2.98 (1.49 – 5.93) 1.091 0.002 
Tender anterior cervical node  1.55 (1.05 – 2.32) 0.443 0.029 
Rhinorrhea 0.66 (0.45 – 0.99) - 0.406 0.046 
Cough 0.59 (0.40 – 0.90) - 0.514  0.013 
Rash 0.54 (0.30 – 0.99) - 0.611 0.042 
     
Table 6.5 illustrates the scoring system developed to calculate the risk of GAS positivity in a 
child presenting with sore throat. Clinical predictors were weighted equally with a simple 
one-point being allocated for each predictor value, and summed into a score out of 5.  The 
observed proportions of patients with GAS positivity and corresponding score categories in 
each of our derivation and validation cohorts are  shown  in  column ‘observed proportion’  
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Table 6.5: Scorecard based on multivariable analysis model to calculate the 
probability of GAS positivity in children aged 3 - 15 years with pharyngitis  
Clinical sign Score 
Presence of tonsillar swelling 1 
Presence of tender anterior cervical node  1 
Absence of cough 1 
Absence of rhinorrhea 1 
Absence of rash 1 
Maximum Score 5 
 
in Table 6.6.  Using the validation set, 71.05%  of all patients obtained a score ≥ 3 using 
the newly-derived scorecard;  thus, we evaluated the discriminatory ability of the new rule 
at a cut-off of ≥ 3.  We also contrasted these findings with the existing rules evaluated in 
the derivation set of our study (Table 6.7). 
 
Table 6.6:   Observed percentage of GAS-positive patients within a specific range of scores  
Total Score Derivation set (n=666) Validation set (n=172) 
GAS Count (%) % of all patients  
with score 
GAS Count (%) % of all patients  
with score 
5  21 (14.8) 14.8 2 (5.26) 5.26 
4  48 (33.8) 48.6 9 (23.68) 28.95 
3 43 (30.3) 78.9 16 42.11) 71.05 
2 26 (18.3) 97.2 11 (28.95) 100.0 
1 4 (2.8) 100.0       - - 
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Table 6.7:  Performance of the Cape Town Clinical Prediction Rule for streptococcal pharyngitis using a cut-off score of ≥ 3 in children  
aged 3 - 15 years in the Vanguard population validation set.  Existing rules were evaluated as a comparison. 
Decision Rule Sens (95% CI) Spec (95% CI) PPV NPV LR+ MDx (%) WDx (%) MDx/WDx 
VDS rule (at cut-off 3) 71.1 (54.1; 84.6) 12.7 (7.6; 19.5) 18.8 60.7 0.81 11 (29) 117 (87) 0.09 
 
Steinhoff rule  (at cut-off 2) 65.8  (48.6; 80.4) 13.4  (8.2; 20.3) 
 
 
17.7 58.1 0.76 13 (34) 116 (87) 0.11 
 
McIsaac Rule  (at score ≥ 4) 28.9 (15.4; 45.9) 32.8 (24.9;41.5) 10.9 62.0 0.43 27 (71) 90 (67) 0.30 
Sens, sensitivity; Spec, specificity; CI, confidence interval;  PPV, positive predictor value; NPV, negative predictive value all expressed as percentages; 
MDx (%), number of missed streptococcal cases; WDx, number of unnecessarily treated non-cases.  
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6.4 DISCUSSION  
The potential of reducing ARF in areas of high incidence requires the appropriate 
diagnosis and treatment of streptococcal pharyngitis without necessarily relying on 
laboratory confirmation of GAS positivity (Karthikeyan and Mayosi, 2009).  A number of 
CPRs for predicting streptococcal pharyngitis have been published and tested over the 
years with varying results in different populations.  This study, the first in sub-Saharan 
Africa, sought to evaluate and compare the effectiveness of three existing clinical rules for 
managing children with GAS-positive pharyngitis, and if found to have low sensitivity, to 
develop a locally applicable CPR.  The existing CPRs have a low sensitivity for detecting 
GAS pharyngitis in Cape Town.  We have developed a new CPR with high sensitivity  that 
may be more applicable in sub-Saharan Africa 
We chose three CPRs purported to identify patients with GAS positivity:  the ARI 
guideline advocated by the WHO (WHO, 1995), the McIsaac rule which incorporates 
variables which were included in our study (McIsaac et al., 1998), and the Steinhoff rule, 
which was developed in a low-income setting (Steinhoff et al., 2005), and the only rule 
developed on the African continent and bearing resemblance to our setting.  In evaluating 
effectiveness of these, we used sensitivity and specificity as the main measure of 
performance.  We provide the positive predictive and negative predictive values as well as 
the numbers and percentages of failed diagnostic cases and incorrectly treated non-cases.  
In addition, we also calculated the ratio of missed diagnosis cases (MDx) to incorrectly 
treated non-cases (WDx) to allow comparison amongst the rules and with published data.  
Of the three rules tested, the McIsaac Rule using a cut-off of ≥ 4, had the highest positive 
predictive value, but missed 62% of the culture-positive children who should have been 
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treated.  By the same criteria, 22.5% of non-cases would have been prescribed antibiotics 
thus, increasing inappropriate use of antibiotics.  The Steinhoff rule had the best positive 
likelihood ration (LR+) with a sensitivity of 54.9% in our cohort;  however, in excess of 
45% of patients would have been unnecessarily treated.   Our findings regarding the dismal 
performance of the WHO guideline were similar to previous reports from low-resource 
settings (Rimoin et al., 2005).  
We performed logistic regression to determine the potential contribution of various clinical 
parameters in aiding a diagnosis of GAS pharyngitis amongst our participants.  Not all of 
the clinical parameters in our study, which were compiled from a variety of existing clinical 
prediction rules, were included in the multivariate model.  Our analysis identified five 
clinical considerations to be taken into account when determining the likelihood of GAS 
positivity in the absence of laboratory confirmation;  these included the presence of 
tonsillar swelling, a tender anterior cervical lymph node, absence of cough, absence of 
rhinorrhoea, and absence of rash.   These variables were largely similar to those 
incorporated within the three rules evaluated.  The presence of exudate on the pharynx 
and a temperature > 38oC, criteria in the WHO guideline and the McIsaac rule 
respectively were however, not included in the final model.    
The proposed score chart was externally validated with participants from a different time 
period than the derivation set.  To allow for comparison, we also included the existing rules 
tested earlier on the derivation set.  The WHO guideline, unfortunately, could not be 
included since the participants in the validation set showed no symptoms of exudate on the 
pharynx, a requirement for the WHO rule.   Our newly-derived Cape Town Clinical 
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Prediction Rule for GAS pharyngitis (at a cut-off of 3) had a sensitivity of 71% and a LR+ 
of 0.81 which, in comparison to the existing rules, proved to be the best performer.   
There is debate as to the acceptable level of false-negative rates of CPRs for GAS 
pharyngitis. Taking into account the rarity of reports of penicillin anaphylaxis and absence 
of microbial resistance, it is desirable to employ CPRs demonstrating a low MDx/WDx 
ratio which indicates favouring less missed diagnosis over incorrectly treated non-cases.  
We included the MDx/WDx ratio to allow us to compare the different CPRs against each 
other.  In both our derivation and validation cohorts, of the three existing rules evaluated, 
the Steinhoff rule had the lowest MDx/WDx ratio confirming its suitability for our context 
despite the potential selection bias in their cohort where pharyngeal erythema needed to be 
present.  In line with our expectation though, the Cape Town Clinical Prediction Rule (at a 
cut-off of 3) had the lowest MDx/WDx ratio when considering the Steinhoff and McIsaac 
rules.  
This study had a variety of strengths:  sufficient events were included in developing the 
rule;  the datasets were complete and no imputation for missing data was needed;  model 
assessment was conducted on a separate dataset, the validation set comprising participants 
enrolled from the same area and with the same protocol as for the derivation set, thus 
ensuring continuity in the examination procedure.    
Furthermore, given that participants were enrolled from amongst symptomatic patients 
seeking care at the community clinic, the probability of having enrolled asymptomatic 
patients is reduced.  Thus, there is no need to establish the carrier rate in asymptomatic 
individuals from the sampled population proposed by others (McGinn et al., 2000).   
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In conclusion, we developed a prediction model for GAS pharyngitis in children aged 3-15 
years in low-resource settings.  The model development fulfils many of the 
recommendations for building a multivariate prognostic model using regression techniques 
with empirical data.  While prospective studies utilising health practitioners in primary 
health care clinics are required to evaluate applicability in other low-resource settings, our 
rule nevertheless proved vastly superior to the recommended WHO ARI guideline.  
Furthermore, our rule also performed marginally better than the Steinhoff rule, the only 
other rule developed on the African continent in a similar setting to ours.  Using such a 
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7 PREVALENCE OF RHD:  STUDY FIVE 
 
PREVALENCE OF RHEUMATIC HEART DISEASE IN THE VANGUARD 
COMMUNITY DEMONSTRATION SITE, SOUTH AFRICA 
	  
7.1 INTRODUCTION 
The literature review for this chapter is covered in details in Section 1.5.3.  Mortality rates 
for RHD range from 1.2 to 23.8 per 100,000, being highest among the indigenous 
communities of Australia and lowest in industrialised countries (Jackson et al., 2011).  In 
addition, up to 80 million people are affected with RHD (Paar et al., 2010), and 1 million 
are in need of open-heart surgery and valve replacement, which is often not feasible in 
many developing countries with a heavy burden of RHD (Mocumbi, 2012).   
7.1.1 Echo-­‐Based	  School	  Screening	  Studies	  
Six studies from seven countries have documented an echocardiography-based approach to 
screening asymptomatic school children for RHD (Anabwani and Bonhoeffer, 1996, 
Carapetis et al., 2008, Marijon et al., 2007, Paar et al., 2010, Bhaya et al., 2010, Beaton et 
al., 2012) (Table 1.2).  These studies reported prevalence rates for definite or probable 
RHD from 2.7/1000 to 50/1000 school children with respective sample sizes ranging from 
1059 to 5053 participants.  The criteria used to assess the participants in these studies were 
based on the guidelines formulated by a working group convened and supported by the 
U.S. National Institutes of Health and the World Health Organization (Carapetis JP et al., 
2006), except for Marijon, who developed a set of consensus guidelines among the 
participating centres and Anabwani who conducted the first echocardiography-based 
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screening study by colour-flow Doppler.  The approach in all of these studies however, 
called for confirmation of the diagnosis of RHD by a cardiologist, who may not be 
available in a vast majority of African countries.   
7.1.2 Previous	  Studies	  in	  South	  Africa	  	  
Previous studies in South Africa have been reviewed in more detail in Section 1.5.3.  
Briefly, there are four studies on the prevalence of RHD among school children in South 
Africa.  Two studies conducted in schools on the outskirts of Johannesburg reported a 
prevalence per 1,000 of between 5 and 10 in 428 children (Pocock et al., 1968) and 6.9 in 
12,050 children (McLaren et al., 1975). The remaining studies reported prevalence rates of 
6.9 (n=1150) and 1.0 (n = 4408) from schools in Hout Bay, Cape Town (Bundred, 1986) 
and from Inanda, Durban (Maharaj et al., 1987).  All of these studies employed cardiac 
auscultation in initial screening of the children and thus, the findings are likely to be an 
underestimate, given the consistent demonstration of the superiority of echocardiography 
over auscultation in detecting subclinical RHD (Carapetis et al., 2008, Marijon et al., 
2008).  
The paucity of epidemiological data from developing countries on the burden of 
streptococcal disease has been described (Carapetis et al., 2005b).   Given that screening of 
asymptomatic school-age children is a useful strategy to identify new cases of RHD in 
regions of high prevalence (Carapetis et al., 2008), we conducted this echocardiography-
based study of the prevalence of RHD in school children in the Vanguard community of 
Cape Town, given the greater yield of echocardiography over auscultation (Marijon et al., 
2008).  For this study, a new set of criteria was introduced which focused on the 
echocardiograph as a screening tool without the concomitant use of clinical examination in 
the screening phase (Zuhlke and Mayosi, 2009).  
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7.2 PATIENTS AND METHODS 
The methods are described in detail in Section 2.4 on ‘Rationalé and Design of the 
studies”.  As discussed, the evaluation procedures used in the previous school screening 
studies relied upon cardiologists; instead, we conducted our study according to 
echocardiographic protocols suitable for use by echocardiographic technicians within a 
setting such as South Africa (Zuhlke and Mayosi, 2009).  RHD-positive participants were 
categorised following the screening procedure as having definite, probable or possible 
disease on screening echocardiograms according in to the criteria in Box 7.1.  A 
cardiologist reviewed the first 798 echocardiograms to test for agreement with the 
echocardiography technologist.  
 
Box 7.1.  Definitions of definite, probable and possible RHD used in the Cape Town 
study as per the echocardiographic criteria published by Zuhlke et al. for use where 
there is no cardiologist (Zuhlke and Mayosi, 2009). 
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7.3 RESULTS 
Two thousand, seven hundred and twenty healthy (as per self-reporting) school children 
were examined from 23 government schools in the two school districts of Bonteheuwel and 
Langa.  Pairwise kappa test showed fair agreement between the echocardiographic 
technician and the cardiologist (agreement, 93.11%; ϰ = 0.3; SE = 0.0329). 
Participants had a mean age of 12.2 years (range, 4 – 24 years) with all age categories well 
represented (Figure 7.1).    The school districts did not differ with regard to gender, but 
learners from Bonteheuwel had a significantly lower mean age (mean difference = -1.814 
years, 95% CI -2.12; -1.51).  Older age groups tended to be female children (p < 0.05).  
Three hundred and nineteen participants (11.7%) were aged 18 years or older.  Table 7.1 
presents the baseline characteristics according to school district.  
Figure 7.1.  Age and Gender Distribution of participants from the Bonteheuwel and 
















Age	  Category,	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Male	  	  
Female	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Table 7.1.  Characteristics of the participants  
 School District  
 Bonteheuwel 
(n = 1,303) 
Langa 
(n = 1,417) 
Combined 
(n = 2,720) 
Baseline Characteristic    
Age:  Mean (SD), y 11.2 (3.76) 13.1 (4.33) 12.2 (4.17) 
Range 4 – 21  4 – 24  4 – 24 
Median 11 13 12 
Age breakdown, y    
 ≤ 8 355 264 619 
9 - 11 302 258 560 
12 -14 360 337 697 
15 -17 233 292 525 
≥ 18 53 266 319 
    
Males, n (%) 555 (42.59) 561 (39.59) 1116 (41.03) 
    
Cases of RHD, n    
Definite 5 11 16 
Possible 182 162 344 
Probable 23 39 62 
Total  28 50 78 
    
n, number;  SD, standard deviation; y, years;  CI, confidence interval;   examined by echocardiography;  pr, 
prevalence;  CI, confidence interval 
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Using echocardiography, we detected RHD in 78 children overall, 16 of whom were 
classified as definite RHD and 62, as probable RHD as per our protocol (Table 7.2.), 
Table 7.2. Prevalence rates of echocardiography-confirmed definite and probable RHD 
among asymptomatic school children  
 School District  
 Bonteheuwel 
(n = 1,303) 
Langa 
(n = 1,417) 
Combined 
(n = 2,720) 
Prevalence of RHD /1000 (95% CI) 21.5 (14.3 – 31.0) 35.3 (26.3 – 46.2) 28.7 (22.7 – 35.7) 
       Prevalence by gender    
             Boys 16.2 (7.4 – 30.6) 32.1 (19.1 – 50.2) 24.2 (16.0 – 35.0) 
             Girls 25.4 (15.4 – 39.4) 37.4 (25.7 – 52.4) 31.8 (23.7 – 41.6) 
       Prevalence by Age (y) Strata    
 ≤ 8 5.63 (0.7 – 20.2) 11.36 (2.3 – 32.9) 8.08 (2.6 -18.7) 
9 - 11 36.42 (18.3 – 64.2) 27.13 (11.0 – 55.1) 32.14 (19.2 – 50.3) 
27.26 (16.5 – 42.2) 12 -14 25.0 (11.5 – 46.9) 29.67 (14.3 – 53.9) 
15 -17 17.17 (4.7 – 43.4) 41.10 (21.4 – 70.7) 30.48 (17.5 – 49.0) 
≥ 18 37.74 (4.6 – 129.8) 67.67 (40.6 – 104.8) 62.70 (38.7 – 95.2) 
    
Children under 18 years of age    
Prevalence / 1,000 20.80 (13.6 – 30.3) 27.80 (19.1 – 39.0) 24.16 (18.4 – 31.1) 
Estimated No. of Cases, n (95% CI)    
Vanguard School District 288 (256 – 323) 262 (232 – 295) 563 (518 – 611) 
South Africa 
 
  353,581  
(325,235 – 383,367) 
n, number; CI, confidence interval;    y, years;  examined by echocardiography;  pr, prevalence;  CI, confidence interval.  
*Number of cases was estimated by applying the observed prevalence in our sample to the whole population of under 
18 years of age in the respective suburbs. 
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which corresponds to a prevalence of 28.7 per 1,000 (95% CI, 22.7 – 35.7 per 1,000). 
Based on the 2003 census data, we estimate the number of prevalent cases to be 288 and 
262 in Bonteheuwel and Langa school districts respectively, which translates to 350,000 
cases nationally.  The overall prevalence of RHD was higher in female children 
(31.8/1,000 vs 24.2/1,000 in males).  Concerning age, a peak prevalence of 32.1/1,000 
(95% CI 19.2 – 50.3/1,000) was observed in the 9 – 11 years old age group.   
Of the 16 participants classified as having definite RHD, 11 (68.8%) were from the Langa 
school district. Those from Langa were significantly older with a mean of 15.5 years vs 9.8 
years in Bonteheuwel (p=0.004) and more likely to be female (p=0.02).  The respective 
prevalence rates for definite (95% CIs/1,000) are as follows:  Bonteheuwel 3.8/1,000 (1.2 – 
8.9), Langa 7.8/1,000 (3.88 – 13.85) giving a combined prevalence rate of 5.88/1,000 (3.37 




This is the first echocardiography-based investigation of the prevalence of RHD in 
asymptomatic school children in South Africa. Screening was conducted in two school 
districts of Cape Town by echocardiography technicians using WHO criteria modified for 
school-based screening without the need for interpretation by a cardiologist (Zuhlke and 
Mayosi, 2009).  Thus, we demonstrate the value of screening performed primarily by a 
technologist. 
The prevalence of RHD amongst school children in our population was found to be 28.7 
per 1,000.  School children in our cohort included a significant proportion above the age of 
18 years;  on excluding these participants from the analysis, 58 children out of 2401 had 
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definite or probable RHD, corresponding to a prevalence of  24.2 / 1,000 children under 
the age of 18 years.  The prevalence increased four-fold from 0.8% among children aged 8 
years and younger to 3.2% among those aged 9 – 11 years, which follows closely the 
expected pattern of a true reflection of prevalent cases in a population (Carapetis et al., 
2005b).   
Of the 16 participants classified as having definite RHD, 11 (68.8%) were from the Langa 
school district. Those from Langa were significantly older with a mean of 15.5 years vs 9.8 
years in Bonteheuwel (p=0.004).  This finding thus highlights the risk associated with a 
lower socio-economic status (Beaton et al., 2012).  Also, females were more likely to have 
definite RHD (p=0.02), a finding which confirms those reported in other studies (Saxena et 
al., 2011, Marijon et al., 2009). 
Figure 7.2 shows the relative prevalence (according to WHO criteria for definite RHD or 
probable RHD) across recent studies which used echocardiography for screening school 
children.  The prevalence for Mozambique are according to the authors’ revision of the 
original data using the WHO criteria (Marijon et al., 2009).  In comparison, our results fall 
below the range of previously reported prevalence rates in similar populations in Tonga, 
33.2/1,000 (Carapetis et al., 2008) and India, 50/1,000 (Bhaya et al., 2010).  One reason 
for this may relate to the relative stable nature of the communities from where our 
participants were selected which, despite their lower socioeconomic status, have reasonable 
access to primary health care facilities for treatment of pharyngitis. 
Earlier studies in South Africa reported prevalence rates of up to 7 per 1000 in school 
children from lower socioeconomic circumstances (Pocock et al., 1968, Maharaj et al., 
1987, Bundred, 1986).  We report a fourfold increase, a finding that is more likely to be 
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accurate given the superiority of screening by echocardiography and the lower likelihood of 
subjectivity in diagnosis. 
 
This study has a number of strengths including that it was adequately powered given the 
good level of enrolment.  A clustered sampling approach using the classes as the unit of 
randomisation proved successful with almost everyone approached agreeing to participate, 
thereby resulting in good representation in all age groups and across both school districts.  
Furthermore, consistency in procedures was optimal given that the echocardiography was 
performed almost exclusively by one of two echo technologists using one of two 
Figure 7.2.  Prevalence of echocardiographically-confirmed RHD based on WHO or WHO 
modified criteria for Definite and Probable RHD in school children aged < 18 years.  





















CHAPTER	  7:	  	  Prevalence	  Of	  RHD	  
PhD	  Thesis:	  	  Mark	  E	  Engel	  	   	   |	  Page	  147	  
echocardiography machines.  A limitation of this work was that we did not use the World 
Heart Federation echocardiography criteria in evaluating our screening echocardiographic 
images, given that these were only recently introduced (Remenyi et al., 2012).  In addition, 
amongst the higher grades, there was a skewing of gender towards female learners, thus 
giving rise to the potential of having missed male learners with asymptomatic disease.   
In conclusion, this is the first screening study, to the best of our knowledge, that reports 
screening being conducted completely by an echo technologist.  Given the dearth of 
cardiologists in many developing countries where RHD is prevalent, we strongly suggest 
that similar studies be conducted to confirm the feasibility of echo technologist-led 
screening programmes.  This study emphasizes the increased risk of contracting RHD in 
marginalised peri-urban communities, thus lending support to the importance of adopting 
primary antibiotic prophylaxis strategies, especially in areas of high prevalence, in an effort 
to reduce the global burden of RHD (Karthikeyan and Mayosi, 2009). 
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8 CONCLUSION AND FUTURE DIRECTION 
 
SUMMARY AND CONCLUSIONS 
IMPLICATIONS FOR POLICY, PRACTICE AND FUTURE RESEARCH 
This thesis has resulted in a series of five linked studies on the determinants and prevalence 
of RHD in Cape Town.  The synopsis below reflects the novel contributions made by the 
various studies in addressing the original aims of the thesis.  Implications for policy and 
practice, as well as recommendations for future research are presented. 
8.1 ORIGINALITY / NOVEL INSIGHT 
The first study in this thesis identified and summarized all studies reporting on the 
concordance of ARF amongst twin pairs, and is the first to provide a quantitative effect of 
the size of the genetic effect of ARF.  The study provides strong justification for whole 
genome studies of the genetic basis of ARF and RHD.  
This next study was the first investigation of pharyngeal carriage of β-haemolytic 
streptococci among school children in South Africa in more than 30 years.  Carriage of 
group A streptococci in the Vanguard Community was found to be remarkably low overall.  
Nevertheless, participants enrolled from two communities comprising Vanguard differing 
with regard to socioeconomic status, and from a wide age range showed that rate of GAS 
carriage is significantly associated with socioeconomic factors prevalent in poorer 
communities.  This finding also confirms reports elsewhere indicating an environmental 
influence in GAS pharyngeal carriage.  In addition, this was the first study in South Africa, 
and only the second in Africa, to conduct molecular characterisation of emm strains 
associated with GAS carriage in Africa, showing that only around 46%  of  carriage  strains 
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 are included in the putative 30-valent vaccine currently under development. 
Another noteworthy contribution of this thesis is the first prospective incidence study of 
acute GAS pharyngitis in 3- to 15- year old children with pharyngitis in South Africa.  
Younger children were observed to have twice the period prevalence and incidence rates of 
older children, confirming results from studies elsewhere.  
Next, this thesis provided the first South African Clinical Prediction Rule for GAS 
pharyngitis developed using data from local communities.  CPRs for GAS pharyngitis that 
had been developed abroa, including the diagnostic algorithm promoted by the WHO, 
were shown to be inadequate at predicting GAS pharyngitis amongst our children,.  
Finally, this thesis provides the first estimate, using an echocardiography-based screening 
approach, of the burden of RHD in South African school children.  In our setting, 
technologist-driven screening was shown to be feasible.  There was a clear socio-economic 
gradient in the prevalence of severe RHD, resulting in a higher prevalence of definite 
RHD in the Langa community.  
8.2 IMPLICATIONS FOR POLICY AND PRACTICE 
This thesis emphasizes the need for primordial prevention of RHD through addressing the 
needs related to socioeconomic status such as adequate housing, overcrowding and 
impoverished living conditions.    
Furthermore, access to adequate health care facilities where staff are trained in the 
implementation of guidelines, assisted by the newly-developed CPR, in order to recognise 
the clinical signs of GAS pharyngitis, in the absence of microbiological culture needs to be 
prioritized.    
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Finally, the high burden of RHD amongst asymptomatic school children lays the basis for 
studies of cost-effectiveness of screening in programmes to prevent ARF and RHD. 
	  
8.3 IMPLICATIONS FOR FUTURE RESEARCH 
The evidence provided for genetic susceptibility for RHD provides justification for the 
launch of whole genome studies of ARF and RHD. 
A follow-up study in those participants identified as GAS pharyngeal carriers would render 
valuable information on the persistence of strain types in our population.  In particular, 
there is a need to monitor carriers in order to ascertain whether they switch emm types 
during episodes of active GAS pharyngeal infection.   
There is a need to conduct emm strain typing on GAS isolates from patients presenting with 
pharyngitis at primary health care facilities in order to compare strains with those isolated 
from carriers.   This information will provide valuable insight into vaccine development. 
The CPR for pharyngitis developed during this thesis needs further validation, given the 
relatively small number of patients available at the time of this study. 
The recent revision of the World Heart Federation echocardiographic criteria for screening 
requires the re-examination and scoring of the echocardiograms according to the new 
standard, which would allow comparison with other studies.   
Finally, given that echocardiography-based school-screening has been proven to be feasible 
in our setting, there is a need to conduct a cost-effectiveness analysis of such screening in 
order to provide justification for adopting policy in this regard. 
	  
References	  
PhD	  Thesis:	  	  Mark	  E	  Engel	  	   	   |	  Page	  151	  
9 REFERENCES	  
ABDISSA,	  A.,	  ASRAT,	  D.,	  KRONVALL,	  G.,	  SHITTU,	  B.,	  ACHIKO,	  D.,	  ZEIDAN,	  M.,	  YAMUAH,	  L.	  K.	  &	  
ASEFFA,	  A.	  2006.	  High	  diversity	  of	  group	  A	  streptococcal	  emm	  types	  among	  healthy	  
schoolchildren	  in	  Ethiopia.	  Clin	  Infect	  Dis,	  42,	  1362-­‐7.	  
ABDISSA,	  A.,	  ASRAT,	  D.,	  KRONVALL,	  G.,	  SHITU,	  B.,	  ACHIKO,	  D.,	  ZEIDAN,	  M.,	  YAMUAH,	  L.	  K.	  &	  
ASEFFA,	  A.	  2011.	  Throat	  carriage	  rate	  and	  antimicrobial	  susceptibility	  pattern	  of	  group	  A	  
Streptococci	  (GAS)	  in	  healthy	  Ethiopian	  school	  children.	  Ethiop	  Med	  J,	  49,	  125-­‐30.	  
AHLBOM,	  A.,	  LICHTENSTEIN,	  P.,	  MALMSTROM,	  H.,	  FEYCHTING,	  M.,	  HEMMINKI,	  K.	  &	  PEDERSEN,	  N.	  
L.	  1997.	  Cancer	  in	  twins:	  genetic	  and	  nongenetic	  familial	  risk	  factors.	  J	  Natl	  Cancer	  Inst,	  
89,	  287-­‐93.	  
ALLAN,	  C.	  L.,	  CARDNO,	  A.	  G.,	  RIJSDIJK,	  F.	  V.,	  KALIDINDI,	  S.,	  FARMER,	  A.,	  MURRAY,	  R.	  M.	  &	  
MCGUFFIN,	  P.	  2009.	  Twin	  study	  of	  illness	  history	  variables	  in	  psychosis.	  Schizophr	  Res,	  
115,	  237-­‐44.	  
ALTMAN,	  D.	  G.,	  VERGOUWE,	  Y.,	  ROYSTON,	  P.	  &	  MOONS,	  K.	  G.	  2009.	  Prognosis	  and	  prognostic	  
research:	  validating	  a	  prognostic	  model.	  BMJ,	  338,	  b605.	  
ANABWANI,	  G.	  M.	  &	  BONHOEFFER,	  P.	  1996.	  Prevalence	  of	  heart	  disease	  in	  school	  children	  in	  rural	  
Kenya	  using	  colour-­‐flow	  echocardiography.	  East	  African	  medical	  journal,	  73,	  215-­‐7.	  
ATTIA,	  M.	  W.,	  ZAOUTIS,	  T.,	  KLEIN,	  J.	  D.	  &	  MEIER,	  F.	  A.	  2001.	  Performance	  of	  a	  predictive	  model	  for	  
streptococcal	  pharyngitis	  in	  children.	  Arch	  Pediatr	  Adolesc	  Med,	  155,	  687-­‐91.	  
AZEVEDO,	  P.	  M.,	  PEREIRA,	  R.	  R.	  &	  GUILHERME,	  L.	  2012.	  Understanding	  rheumatic	  fever.	  
Rheumatology	  International,	  32,	  1113-­‐20.	  
BEALL,	  B.,	  FACKLAM,	  R.	  &	  THOMPSON,	  T.	  1996.	  Sequencing	  emm-­‐specific	  PCR	  products	  for	  
routine	  and	  accurate	  typing	  of	  group	  A	  streptococci.	  J	  Clin	  Microbiol,	  34,	  953-­‐8.	  
BEALL,	  B.,	  GHERARDI,	  G.,	  LOVGREN,	  M.,	  FACKLAM,	  R.	  R.,	  FORWICK,	  B.	  A.	  &	  TYRRELL,	  G.	  J.	  2000.	  
emm	  and	  sof	  gene	  sequence	  variation	  in	  relation	  to	  serological	  typing	  of	  opacity-­‐factor-­‐
positive	  group	  A	  streptococci.	  Microbiology,	  146	  (	  Pt	  5),	  1195-­‐209.	  
BEATON,	  A.,	  OKELLO,	  E.,	  LWABI,	  P.,	  MONDO,	  C.,	  MCCARTER,	  R.	  &	  SABLE,	  C.	  2012.	  
Echocardiography	  screening	  for	  rheumatic	  heart	  disease	  in	  Ugandan	  schoolchildren.	  
Circulation,	  125,	  3127-­‐32.	  
BENEVOLENSKAIA,	  L.	  I.,	  BOLOTINA,	  A.	  &	  MIAKOTKIN,	  V.	  A.	  1973.	  [Some	  infectious	  (streptococcal)	  
and	  genetic	  aspects	  of	  familial	  rheumatic	  fever].	  Vopr	  Revm,	  13,	  33-­‐7.	  
BENEVOLENSKAIA,	  L.	  I.	  &	  MIAKOTKIN,	  V.	  A.	  1980.	  [Role	  of	  heredity	  and	  environment	  in	  
rheumatism].	  Vopr	  Revm,	  26-­‐30.	  
BERDELI,	  A.,	  CELIK,	  H.	  A.,	  OZYUREK,	  R.	  &	  AYDIN,	  H.	  H.	  2004.	  Involvement	  of	  immunoglobulin	  
FcgammaRIIA	  and	  FcgammaRIIIB	  gene	  polymorphisms	  in	  susceptibility	  to	  rheumatic	  fever.	  
Clin	  Biochem,	  37,	  925-­‐9.	  
BERDELI,	  A.,	  CELIK,	  H.	  A.,	  OZYUREK,	  R.,	  DOGRUSOZ,	  B.	  &	  AYDIN,	  H.	  H.	  2005.	  TLR-­‐2	  gene	  Arg753Gln	  
polymorphism	  is	  strongly	  associated	  with	  acute	  rheumatic	  fever	  in	  children.	  J	  Mol	  Med,	  
83,	  535-­‐41.	  
BHAYA,	  M.,	  PANWAR,	  S.,	  BENIWAL,	  R.	  &	  PANWAR,	  R.	  B.	  2010.	  High	  prevalence	  of	  rheumatic	  heart	  
disease	  detected	  by	  echocardiography	  in	  school	  children.	  Echocardiography,	  27,	  448-­‐53.	  
BISNO,	  A.	  L.,	  GERBER,	  M.	  A.,	  GWALTNEY,	  J.	  M.,	  JR.,	  KAPLAN,	  E.	  L.	  &	  SCHWARTZ,	  R.	  H.	  1997.	  
Diagnosis	  and	  management	  of	  group	  A	  streptococcal	  pharyngitis:	  a	  practice	  guideline.	  
Infectious	  Diseases	  Society	  of	  America.	  Clin	  Infect	  Dis,	  25,	  574-­‐83.	  
BLAND,	  E.	  F.	  &	  DUCKETT	  JONES,	  T.	  1951.	  Rheumatic	  fever	  and	  rheumatic	  heart	  disease;	  a	  twenty	  
year	  report	  on	  1000	  patients	  followed	  since	  childhood.	  Circulation,	  4,	  836-­‐43.	  
References	  
PhD	  Thesis:	  	  Mark	  E	  Engel	  	   	   |	  Page	  152	  
BLEEKER,	  S.	  E.,	  MOLL,	  H.	  A.,	  STEYERBERG,	  E.	  W.,	  DONDERS,	  A.	  R.,	  DERKSEN-­‐LUBSEN,	  G.,	  GROBBEE,	  
D.	  E.	  &	  MOONS,	  K.	  G.	  2003.	  External	  validation	  is	  necessary	  in	  prediction	  research:	  a	  
clinical	  example.	  Journal	  of	  Clinical	  Epidemiology,	  56,	  826-­‐32.	  
BOBYLEV,	  V.	  &	  MEN'SHOVA,	  K.	  I.	  1972.	  [Familial	  rheumatic	  fever].	  Vopr	  Okhr	  Materin	  Det,	  17,	  20-­‐
3.	  
BONOW,	  R.	  O.	  &	  BRAUNWALD,	  E.	  2012.	  Braunwald's	  heart	  disease	  :	  a	  textbook	  of	  cardiovascular	  
medicine,	  Philadelphia,	  Pa.,	  Elsevier	  Saunders.	  
BREESE,	  B.	  B.	  1977.	  A	  simple	  scorecard	  for	  the	  tentative	  diagnosis	  of	  streptococcal	  pharyngitis.	  Am	  
J	  Dis	  Child,	  131,	  514-­‐7.	  
BRYANT,	  P.	  A.,	  ROBINS-­‐BROWNE,	  R.,	  CARAPETIS,	  J.	  R.	  &	  CURTIS,	  N.	  2009.	  Some	  of	  the	  People,	  
Some	  of	  the	  Time	  Susceptibility	  to	  Acute	  Rheumatic	  Fever.	  Circulation,	  119,	  742-­‐753.	  
BUNDRED,	  P.	  E.	  1986.	  The	  place	  of	  primary	  care	  in	  the	  prevention	  and	  control	  of	  rheumatic	  fever	  
and	  rheumatic	  heart	  disease	  in	  Southern	  Africa.	  M.D.	  Thesis	  -­‐	  University	  of	  London,	  
London.	  
CARAPETIS	  JP,	  PAAR	  J	  &	  T.,	  C.	  2006.	  Standardization	  of	  epidemiologic	  protocols	  for	  surveillance	  of	  
post-­‐streptococcal	  sequelae:	  acute	  rheumatic	  fever,	  rheumatic	  heart	  disease	  and	  acute	  
post-­‐streptococcal	  glomerulonephritis.	  National	  Institute	  of	  Allergy	  and	  Infectious	  
Diseases.	  2006.	  http://	  
www.niaid.nih.gov/topics/strepThroat/Documents/groupasequelae.pdf.	  (Last	  accessed	  
15/08/2012).	  
CARAPETIS,	  J.	  R.,	  CURRIE,	  B.	  J.	  &	  GOOD,	  M.	  F.	  1996.	  Towards	  understanding	  the	  pathogenesis	  of	  
rheumatic	  fever.	  Scandinavian	  journal	  of	  rheumatology,	  25,	  127-­‐31;	  discussion	  132-­‐3.	  
CARAPETIS,	  J.	  R.,	  HARDY,	  M.,	  FAKAKOVIKAETAU,	  T.,	  TAIB,	  R.,	  WILKINSON,	  L.,	  PENNY,	  D.	  J.	  &	  STEER,	  
A.	  C.	  2008.	  Evaluation	  of	  a	  screening	  protocol	  using	  auscultation	  and	  portable	  
echocardiography	  to	  detect	  asymptomatic	  rheumatic	  heart	  disease	  in	  Tongan	  
schoolchildren.	  Nature	  clinical	  practice.	  Cardiovascular	  medicine,	  5,	  411-­‐7.	  
CARAPETIS,	  J.	  R.,	  MCDONALD,	  M.	  &	  WILSON,	  N.	  J.	  2005a.	  Acute	  rheumatic	  fever.	  Lancet,	  366,	  155-­‐
68.	  
CARAPETIS,	  J.	  R.,	  STEER,	  A.	  C.,	  MULHOLLAND,	  E.	  K.	  &	  WEBER,	  M.	  2005b.	  The	  global	  burden	  of	  
group	  A	  streptococcal	  diseases.	  Lancet	  Infect	  Dis,	  5,	  685-­‐94.	  
CARLQUIST,	  J.	  F.,	  WARD,	  R.	  H.,	  MEYER,	  K.	  J.,	  HUSEBYE,	  D.,	  FEOLO,	  M.	  &	  ANDERSON,	  J.	  L.	  1995.	  
Immune	  response	  factors	  in	  rheumatic	  heart	  disease:	  meta-­‐analysis	  of	  HLA-­‐DR	  
associations	  and	  evaluation	  of	  additional	  class	  II	  alleles.	  J	  Am	  Coll	  Cardiol,	  26,	  452-­‐7.	  
CDC	  PROTOCOL	  FOR	  EMM	  TYPING	  AVAILABLE	  AT	  
HTTP://WWW.CDC.GOV/NCIDOD/BIOTECH/STREP/M-­‐PROTEINGENE_TYPING.HTM	  
Protocol	  for	  emm	  typing.	  Centres	  for	  Disease	  Control	  and	  Prevention.	  	  Available	  at:	  
http://www.cdc.gov/ncidod/biotech/strep/M-­‐ProteinGene_typing.htm	  Accessed	  20	  
August	  	  2012.	  
CENTOR,	  R.	  M.	  2009.	  Expand	  the	  Pharyngitis	  Paradigm	  for	  Adolescents	  and	  Young	  Adults.	  Annals	  
of	  Internal	  Medicine,	  151,	  812-­‐815.	  
CHIAPPINI,	  E.,	  PRINCIPI,	  N.,	  MANSI,	  N.,	  SERRA,	  A.,	  DE	  MASI,	  S.,	  CAMAIONI,	  A.,	  ESPOSITO,	  S.,	  
FELISATI,	  G.,	  GALLI,	  L.,	  LANDI,	  M.,	  SPECIALE,	  A.	  M.,	  BONSIGNORI,	  F.,	  MARCHISIO,	  P.	  &	  DE	  
MARTINO,	  M.	  2012.	  Management	  of	  acute	  pharyngitis	  in	  children:	  summary	  of	  the	  Italian	  
National	  Institute	  of	  Health	  guidelines.	  Clin	  Ther,	  34,	  1442-­‐1458	  e2.	  
CHOU,	  H.	  T.,	  CHEN,	  C.	  H.,	  TSAI,	  C.	  H.	  &	  TSAI,	  F.	  J.	  2004a.	  Association	  between	  transforming	  growth	  
factor-­‐beta1	  gene	  C-­‐509T	  and	  T869C	  polymorphisms	  and	  rheumatic	  heart	  disease.	  Am	  
Heart	  J,	  148,	  181-­‐6.	  
CHOU,	  H.	  T.,	  TSAI,	  C.	  H.	  &	  TSAI,	  F.	  J.	  2004b.	  Association	  between	  angiotensin	  I-­‐converting	  enzyme	  
gene	  insertion/deletion	  polymorphism	  and	  risk	  of	  rheumatic	  heart	  disease.	  Jpn	  Heart	  J,	  
45,	  949-­‐57.	  
References	  
PhD	  Thesis:	  	  Mark	  E	  Engel	  	   	   |	  Page	  153	  
CUNNINGHAM,	  M.	  W.	  2000.	  Pathogenesis	  of	  group	  A	  streptococcal	  infections.	  Clin	  Microbiol	  Rev,	  
13,	  470-­‐511.	  
DAGNELIE,	  C.	  F.,	  TOUW-­‐OTTEN,	  F.	  W.,	  KUYVENHOVEN,	  M.	  M.,	  ROZENBERG-­‐ARSKA,	  M.	  &	  DE	  
MELKER,	  R.	  A.	  1993.	  Bacterial	  flora	  in	  patients	  presenting	  with	  sore	  throat	  in	  Dutch	  
general	  practice.	  Family	  practice,	  10,	  371-­‐7.	  
DALE,	  J.	  B.	  2008.	  Current	  status	  of	  group	  A	  streptococcal	  vaccine	  development.	  Advances	  in	  
experimental	  medicine	  and	  biology,	  609,	  53-­‐63.	  
DALE,	  J.	  B.,	  PENFOUND,	  T.	  A.,	  CHIANG,	  E.	  Y.	  &	  WALTON,	  W.	  J.	  2011.	  New	  30-­‐valent	  M	  protein-­‐
based	  vaccine	  evokes	  cross-­‐opsonic	  antibodies	  against	  non-­‐vaccine	  serotypes	  of	  group	  A	  
streptococci.	  Vaccine,	  29,	  8175-­‐8.	  
DANCHIN,	  M.	  H.,	  ROGERS,	  S.,	  KELPIE,	  L.,	  SELVARAJ,	  G.,	  CURTIS,	  N.,	  CARLIN,	  J.	  B.,	  NOLAN,	  T.	  M.	  &	  
CARAPETIS,	  J.	  R.	  2007.	  Burden	  of	  acute	  sore	  throat	  and	  group	  A	  streptococcal	  pharyngitis	  
in	  school-­‐aged	  children	  and	  their	  families	  in	  Australia.	  Pediatrics,	  120,	  950-­‐7.	  
DANCHIN,	  M.	  H.,	  ROGERS,	  S.,	  SELVARAJ,	  G.,	  KELPIE,	  L.,	  RANKIN,	  P.,	  VORICH,	  R.,	  HOWSON,	  M.,	  
CARLIN,	  J.	  B.,	  CURTIS,	  N.,	  NOLAN,	  T.	  M.	  &	  CARAPETIS,	  J.	  R.	  2004.	  The	  burden	  of	  group	  A	  
streptococcal	  pharyngitis	  in	  Melbourne	  families.	  The	  Indian	  journal	  of	  medical	  research,	  
119	  Suppl,	  144-­‐7.	  
DAVUTOGLU,	  V.	  &	  NACAK,	  M.	  2005.	  Influence	  of	  angiotensin-­‐converting	  enzyme	  gene	  
insertion/deletion	  polymorphism	  on	  rheumatic	  valve	  involvement,	  valve	  severity	  and	  
subsequent	  valve	  calcification.	  J	  Heart	  Valve	  Dis,	  14,	  277-­‐81.	  
DENBOW,	  C.	  E.,	  BARTON,	  E.	  N.	  &	  SMIKLE,	  M.	  F.	  1999.	  The	  prophylaxis	  of	  acute	  rheumatic	  fever	  in	  
a	  pair	  of	  monozygotic	  twins.	  The	  public	  health	  implications.	  West	  Indian	  Med	  J,	  48,	  242-­‐3.	  
DENNY,	  F.	  W.	  1987.	  T.	  Duckett	  Jones	  and	  rheumatic	  fever	  in	  1986.	  T.	  Duckett	  Jones	  Memorial	  
Lecture.	  Circulation,	  76,	  963-­‐70.	  
DEPARTMENT	  OF	  HEALTH,	  S.	  A.	  1999.	  National	  Guidelines	  on	  the	  Primary	  Prevention	  and	  
Prophylaxis	  of	  Rheumatic	  Fever	  and	  Rheumatic	  Heart	  Disease	  for	  Health	  Professionals	  at	  
Primary	  Level.	  Pretoria:	  DOH,	  1999.	  	  http://www.doh.gov.za/docs/facts-­‐f.html	  (Last	  
accessed	  12/11/2003).	  
DEPARTMENT	  OF	  HEALTH,	  S.	  A.	  2002a.	  Child	  Health	  National	  School	  Health	  Policy	  And	  
Implementation	  Guidelines.	  Pretoria:	  DOH,	  2002.	  	  
http://ci.org.za/depts/ci/pubs/pdf/health/poldraft/schealthpol.pdf.	  (Last	  accessed	  
15/08/2012).	  
DEPARTMENT	  OF	  HEALTH,	  S.	  A.	  2002b.	  Modernisation	  of	  tertiary	  care	  services.	  Report	  on	  the	  
paediatric	  cardiology	  workshop.	  Strand,	  South	  Africa,	  26	  -­‐	  27	  September	  2002.	  Pretoria:	  
DOH,	  2002.	  	  http://www.doh.gov.za/mts/reports/cardiology01.html	  (Last	  accessed	  
22/1/2009).	  
DEPARTMENT	  OF	  HEALTH,	  S.	  A.	  2006.	  Standard	  Treatment	  Guidelines	  and	  Essential	  Drugs	  List	  for	  
South	  Africa:	  	  PRIMARY	  HEALTH	  CARE	  2003	  EDITION.	  Pretoria:	  DOH,	  2006.	  
http://www.doh.gov.za/docs/policy/2006/stg&edl2006.pdf	  (Last	  accessed	  20/09/2012).	  
DIXON,	  A.	  S.	  1969.	  Twins	  with	  rheumatic	  diseases.	  Bristol	  Med	  Chir	  J,	  84,	  125-­‐9.	  
DUBEN,	  J.,	  JELINKOVA,	  J.,	  JELINEK,	  J.	  &	  ROTTA,	  J.	  1979.	  Prospective	  study	  on	  streptococcal	  
pharyngitis	  among	  a	  town	  population.	  Journal	  of	  hygiene,	  epidemiology,	  microbiology,	  
and	  immunology,	  23,	  159-­‐67.	  
DUMRE,	  S.	  P.,	  SAPKOTA,	  K.,	  ADHIKARI,	  N.,	  ACHARYA,	  D.,	  KARKI,	  M.,	  BISTA,	  S.,	  BASANYAT,	  S.	  R.	  &	  
JOSHI,	  S.	  K.	  2009.	  Asymptomatic	  throat	  carriage	  rate	  and	  antimicrobial	  resistance	  pattern	  
of	  Streptococcus	  pyogenes	  in	  Nepalese	  school	  children.	  Kathmandu	  Univ	  Med	  J	  (KUMJ),	  7,	  
392-­‐6.	  
EUROPEAN	  SOCIAL	  SURVEY	  EDUCATION	  NET.	  Sampling	  with	  Probability	  Proportional	  to	  Size.	  
Available	  at:	  http://essedunet.nsd.uib.no/cms/topics/weight/2/6.html	  	  Accessed	  16	  May	  
2012.	  
References	  
PhD	  Thesis:	  	  Mark	  E	  Engel	  	   	   |	  Page	  154	  
FACKLAM,	  R.	  R.	  1997.	  Screening	  for	  streptococcal	  pharyngitis:	  current	  technology.	  Infect	  Med,	  14,	  
891-­‐8-­‐7.	  
FARRER	  LA,	  C.	  L.	  1998.	  Determining	  the	  genetic	  component	  of	  a	  disease.	  In:	  HAINES	  JL,	  P.-­‐V.	  M.	  
(ed.)	  Approaches	  to	  gene	  mapping	  in	  complex	  human	  diseases.	  New	  York:	  Wiley-­‐Liss.	  
FISCHER	  WALKER,	  C.	  L.,	  RIMOIN,	  A.	  W.,	  HAMZA,	  H.	  S.	  &	  STEINHOFF,	  M.	  C.	  2006.	  Comparison	  of	  
clinical	  prediction	  rules	  for	  management	  of	  pharyngitis	  in	  settings	  with	  limited	  resources.	  
J	  Pediatr,	  149,	  64-­‐71.	  
FISCHETTI,	  V.	  A.	  1989.	  Streptococcal	  M	  protein:	  molecular	  design	  and	  biological	  behavior.	  Clinical	  
microbiology	  reviews,	  2,	  285-­‐314.	  
FLOSSMANN,	  E.,	  SCHULZ,	  U.	  G.	  &	  ROTHWELL,	  P.	  M.	  2004.	  Systematic	  review	  of	  methods	  and	  
results	  of	  studies	  of	  the	  genetic	  epidemiology	  of	  ischemic	  stroke.	  Stroke,	  35,	  212-­‐27.	  
GALVIN,	  J.	  E.,	  HEMRIC,	  M.	  E.,	  WARD,	  K.	  &	  CUNNINGHAM,	  M.	  W.	  2000.	  Cytotoxic	  mAb	  from	  
rheumatic	  carditis	  recognizes	  heart	  valves	  and	  laminin.	  The	  Journal	  of	  clinical	  
investigation,	  106,	  217-­‐24.	  
GERBER,	  M.	  A.	  &	  SHULMAN,	  S.	  T.	  2004.	  Rapid	  diagnosis	  of	  pharyngitis	  caused	  by	  group	  A	  
streptococci.	  Clinical	  microbiology	  reviews,	  17,	  571-­‐80,	  table	  of	  contents.	  
GIANNINI,	  G.	  &	  ROMANI,	  L.	  1967.	  [Epidemiological	  data	  and	  importance	  of	  constitutional,	  familial,	  
nutritional	  and	  environmental	  factors	  in	  rheumatic	  fever].	  G	  Mal	  Infett	  Parassit,	  19,	  105-­‐
8.	  
GUEDEZ,	  Y.,	  KOTBY,	  A.,	  EL-­‐DEMELLAWY,	  M.,	  GALAL,	  A.,	  THOMSON,	  G.,	  ZAHER,	  S.,	  KASSEM,	  S.	  &	  
KOTB,	  M.	  1999.	  HLA	  class	  II	  associations	  with	  rheumatic	  heart	  disease	  are	  more	  evident	  
and	  consistent	  among	  clinically	  homogeneous	  patients.	  Circulation,	  99,	  2784-­‐90.	  
GUILHERME,	  L.,	  FAE,	  K.,	  OSHIRO,	  S.	  E.	  &	  KALIL,	  J.	  2005.	  Molecular	  pathogenesis	  of	  rheumatic	  fever	  
and	  rheumatic	  heart	  disease.	  Expert	  Rev	  Mol	  Med,	  7,	  1-­‐15.	  
GUILHERME,	  L.,	  KOHLER,	  K.	  F.	  &	  KALIL,	  J.	  2011.	  Rheumatic	  heart	  disease:	  mediation	  by	  complex	  
immune	  events.	  Adv	  Clin	  Chem,	  53,	  31-­‐50.	  
GUILHERME,	  L.,	  RAMASAWMY,	  R.	  &	  KALIL,	  J.	  2007.	  Rheumatic	  fever	  and	  rheumatic	  heart	  disease:	  
genetics	  and	  pathogenesis.	  Scandinavian	  journal	  of	  immunology,	  66,	  199-­‐207.	  
GUNNARSSON,	  R.	  K.,	  HOLM,	  S.	  E.	  &	  SODERSTROM,	  M.	  1997.	  The	  prevalence	  of	  beta-­‐haemolytic	  
streptococci	  in	  throat	  specimens	  from	  healthy	  children	  and	  adults.	  Implications	  for	  the	  
clinical	  value	  of	  throat	  cultures.	  Scand	  J	  Prim	  Health	  Care,	  15,	  149-­‐55.	  
HAFEZ,	  M.,	  CHAKRAVARTI,	  A.,	  EL-­‐SHENNAWY,	  F.,	  EL-­‐MORSI,	  Z.,	  EL-­‐SALLAB,	  S.	  H.	  &	  AL-­‐TONBARY,	  Y.	  
1985.	  HLA	  antigens	  and	  acute	  rheumatic	  fever:	  evidence	  for	  a	  recessive	  susceptibility	  
gene	  linked	  to	  HLA.	  Genet	  Epidemiol,	  2,	  273-­‐82.	  
HARRELL,	  F.	  E.	  2001.	  Regression	  modeling	  strategies	  :	  with	  applications	  to	  linear	  models,	  logistic	  
regression,	  and	  survival	  analysis,	  New	  York	  ;	  London,	  Springer.	  
HERNANDEZ-­‐PACHECO,	  G.,	  AGUILAR-­‐GARCIA,	  J.,	  FLORES-­‐DOMINGUEZ,	  C.,	  RODRIGUEZ-­‐PEREZ,	  J.	  
M.,	  PEREZ-­‐HERNANDEZ,	  N.,	  ALVAREZ-­‐LEON,	  E.,	  REYES,	  P.	  A.	  &	  VARGAS-­‐ALARCON,	  G.	  
2003a.	  MHC	  class	  II	  alleles	  in	  Mexican	  patients	  with	  rheumatic	  heart	  disease.	  Int	  J	  Cardiol,	  
92,	  49-­‐54.	  
HERNANDEZ-­‐PACHECO,	  G.,	  FLORES-­‐DOMINGUEZ,	  C.,	  RODRIGUEZ-­‐PEREZ,	  J.	  M.,	  PEREZ-­‐
HERNANDEZ,	  N.,	  FRAGOSO,	  J.	  M.,	  SAUL,	  A.,	  ALVAREZ-­‐LEON,	  E.,	  GRANADOS,	  J.,	  REYES,	  P.	  A.	  
&	  VARGAS-­‐ALARCON,	  G.	  2003b.	  Tumor	  necrosis	  factor-­‐alpha	  promoter	  polymorphisms	  in	  
Mexican	  patients	  with	  rheumatic	  heart	  disease.	  J	  Autoimmun,	  21,	  59-­‐63.	  
HIGGINS,	  J.	  P.	  T.,	  GREEN,	  S.	  &	  (EDITORS).	  2009.	  Cochrane	  Handbook	  for	  Systematic	  Reviews	  of	  
Interventions.	  Version	  5.0.2	  [updated	  September	  2009].	  The	  Cochrane	  Collaboration,	  2009.	  
Available	  from	  www.cochrane-­‐handbook.org.	  
HONEYMAN,	  M.	  S.	  &	  DAVIS,	  E.	  1971.	  A	  genetic	  study	  of	  rheumatic	  fever	  clustering	  in	  families.	  
Acta	  Genet	  Med	  Gemellol	  (Roma),	  20,	  189-­‐98.	  
IRVINE-­‐JONES,	  E.	  1933.	  Acute	  rheumatism	  as	  a	  familial	  disease.	  Am.	  J.	  Dis.	  Child,	  45,	  1184-­‐95.	  
References	  
PhD	  Thesis:	  	  Mark	  E	  Engel	  	   	   |	  Page	  155	  
JACKSON,	  S.	  J.,	  STEER,	  A.	  C.	  &	  CAMPBELL,	  H.	  2011.	  Systematic	  Review:	  Estimation	  of	  global	  burden	  
of	  non-­‐suppurative	  sequelae	  of	  upper	  respiratory	  tract	  infection:	  rheumatic	  fever	  and	  
post-­‐streptococcal	  glomerulonephritis.	  Tropical	  medicine	  &	  international	  health	  :	  TM	  &	  IH,	  
16,	  2-­‐11.	  
JANSSEN,	  K.	  J.,	  MOONS,	  K.	  G.	  &	  HARRELL,	  F.	  E.,	  JR.	  2010.	  Prediction	  rules	  must	  be	  developed	  
according	  to	  methodological	  guidelines.	  Annals	  of	  Internal	  Medicine,	  152,	  263;	  author	  
reply	  263-­‐4.	  
JASIR,	  A.,	  NOORANI,	  A.,	  MIRSALEHIAN,	  A.	  &	  SCHALEN,	  C.	  2000.	  Isolation	  rates	  of	  Streptococcus	  
pyogenes	  in	  patients	  with	  acute	  pharyngotonsillitis	  and	  among	  healthy	  school	  children	  in	  
Iran.	  Epidemiol	  Infect,	  124,	  47-­‐51.	  
JIN,	  Z.,	  JI,	  Z.	  &	  HU,	  J.	  2001.	  [Mannose-­‐binding	  lectin	  gene	  site	  mutations	  and	  the	  susceptibility	  of	  
rheumatic	  heart	  disease].	  Zhonghua	  Yi	  Xue	  Za	  Zhi,	  81,	  1284-­‐6.	  
JOACHIM,	  L.,	  CAMPOS,	  D.,	  JR.	  &	  SMEESTERS,	  P.	  R.	  2010.	  Pragmatic	  scoring	  system	  for	  pharyngitis	  
in	  low-­‐resource	  settings.	  Pediatrics,	  126,	  e608-­‐14.	  
KARTHIKEYAN,	  G.	  &	  MAYOSI,	  B.	  M.	  2009.	  Is	  primary	  prevention	  of	  rheumatic	  fever	  the	  missing	  link	  
in	  the	  control	  of	  rheumatic	  heart	  disease	  in	  Africa?	  Circulation,	  120,	  709-­‐13.	  
KARTHIKEYAN,	  G.,	  ZÜHLKE,	  L.,	  ENGEL,	  M.	  E.	  &	  AL.,	  E.	  2011.	  Rationalé	  and	  Design	  of	  A	  Global	  
Rheumatic	  Heart	  Disease	  Registry:	  The	  REMEDY	  Study.	  American	  Heart	  Journal,	  
Submitted.	  
KATENDE-­‐KYENDA,	  N.	  L.,	  LUBBE,	  M.	  S.,	  SERFONTEIN,	  J.	  H.	  &	  TRUTER,	  I.	  2006.	  Inappropriateness	  of	  
antimicrobial	  prescription	  in	  private	  primary	  health	  care	  settings	  in	  South	  Africa.	  S	  Afr	  
Med	  J,	  96,	  704-­‐5.	  
KATSI,	  V.,	  RAFTOPOULOS,	  L.,	  AGGELI,	  C.,	  VLASSEROS,	  I.,	  FELEKOS,	  I.,	  TOUSOULIS,	  D.,	  STEFANADIS,	  
C.	  &	  KALLIKAZAROS,	  I.	  2012.	  Tricuspid	  regurgitation	  after	  successful	  mitral	  valve	  surgery.	  
Interactive	  cardiovascular	  and	  thoracic	  surgery,	  15,	  102-­‐8.	  
KAUFFMAN,	  O.	  &	  SCHREERER,	  E.	  1938.	  Uber	  die	  Erblichkeit	  akuten	  Gelenkrheumatismus.	  Z.	  ges.	  
Anat.	  2.Z.	  KonstLehre,	  21,	  687.	  
KAUFMAN,	  J.	  S.,	  COOPER,	  R.	  S.	  &	  MCGEE,	  D.	  L.	  1997.	  Socioeconomic	  status	  and	  health	  in	  blacks	  
and	  whites:	  the	  problem	  of	  residual	  confounding	  and	  the	  resiliency	  of	  race.	  Epidemiology,	  
8,	  621-­‐8.	  
KERDEMELIDIS,	  M.,	  LENNON,	  D.,	  ARROLL,	  B.	  &	  PEAT,	  B.	  2009.	  Guidelines	  for	  sore	  throat	  
management	  in	  New	  Zealand.	  N	  Z	  Med	  J,	  122,	  10-­‐8.	  
KHOURY,	  M.	  J.	  1998.	  Genetic	  Epidemiology.	  In:	  ROTHMAN	  K	  &	  GREENLAND	  S	  (eds.)	  Modern	  
Epidemiology.	  2nd	  ed.	  Philadelphia,	  PA:	  Lippincott-­‐Raven	  Publishers.	  
KIM,	  S.	  &	  LEE,	  N.	  Y.	  2004.	  Epidemiology	  and	  antibiotic	  resistance	  of	  group	  A	  streptococci	  isolated	  
from	  healthy	  schoolchildren	  in	  Korea.	  J	  Antimicrob	  Chemother,	  54,	  447-­‐50.	  
KUDAT,	  H.,	  TELCI,	  G.,	  SOZEN,	  A.	  B.,	  OGUZ,	  F.,	  AKKAYA,	  V.,	  OZCAN,	  M.,	  ATILGAN,	  D.,	  CARIN,	  M.	  &	  
GUVEN,	  O.	  2006.	  The	  role	  of	  HLA	  molecules	  in	  susceptibility	  to	  chronic	  rheumatic	  heart	  
disease.	  Int	  J	  Immunogenet,	  33,	  41-­‐4.	  
KUMAR,	  R.,	  VOHRA,	  H.,	  CHAKRABORTY,	  A.,	  SHARMA,	  Y.	  P.,	  BANDHOPADHYA,	  S.,	  DHANDA,	  V.,	  
SAGAR,	  V.,	  SHARMA,	  M.,	  SHAH,	  B.	  &	  GANGULY,	  N.	  K.	  2009a.	  Epidemiology	  of	  group	  A	  
streptococcal	  pharyngitis	  &	  impetigo:	  a	  cross-­‐sectional	  &	  follow	  up	  study	  in	  a	  rural	  
community	  of	  northern	  India.	  The	  Indian	  journal	  of	  medical	  research,	  130,	  765-­‐71.	  
KUMAR,	  R.,	  VOHRA,	  H.,	  CHAKRABORTY,	  A.,	  SHARMA,	  Y.	  P.,	  BANDHOPADHYA,	  S.,	  DHANDA,	  V.,	  
SAGAR,	  V.,	  SHARMA,	  M.,	  SHAH,	  B.	  &	  GANGULY,	  N.	  K.	  2009b.	  Epidemiology	  of	  group	  A	  
streptococcal	  pharyngitis	  &	  impetigo:	  a	  cross-­‐sectional	  &	  follow	  up	  study	  in	  a	  rural	  
community	  of	  northern	  India.	  Indian	  J	  Med	  Res,	  130,	  765-­‐71.	  
LANCEFIELD,	  R.	  C.	  1941.	  Specific	  relationships	  of	  cell	  composition	  to	  biologic	  activity	  of	  hemolytic	  
streptococci.	  Harvey	  Lectures.,	  36,	  251-­‐265.	  
References	  
PhD	  Thesis:	  	  Mark	  E	  Engel	  	   	   |	  Page	  156	  
LAPENTA,	  D.,	  RUBENS,	  C.,	  CHI,	  E.	  &	  CLEARY,	  P.	  P.	  1994.	  Group	  A	  streptococci	  efficiently	  invade	  
human	  respiratory	  epithelial	  cells.	  Proceedings	  of	  the	  National	  Academy	  of	  Sciences	  of	  the	  
United	  States	  of	  America,	  91,	  12115-­‐9.	  
LAUPACIS,	  A.,	  SEKAR,	  N.	  &	  STIELL,	  I.	  G.	  1997.	  Clinical	  prediction	  rules.	  A	  review	  and	  suggested	  
modifications	  of	  methodological	  standards.	  JAMA	  :	  the	  journal	  of	  the	  American	  Medical	  
Association,	  277,	  488-­‐94.	  
LITTLE,	  J.	  &	  HIGGINS,	  J.	  2006.	  The	  HuGENet™	  HuGE	  Review	  Handbook,	  version	  1.0.	  
http://www.hugenet.ca.	  
LLOYD,	  C.	  A.,	  JACOB,	  S.	  E.	  &	  MENON,	  T.	  2006.	  Pharyngeal	  carriage	  of	  group	  A	  streptococci	  in	  
school	  children	  in	  Chennai.	  Indian	  J	  Med	  Res,	  124,	  195-­‐8.	  
MACK,	  T.	  M.,	  HAMILTON,	  A.	  S.,	  PRESS,	  M.	  F.,	  DIEP,	  A.	  &	  RAPPAPORT,	  E.	  B.	  2002.	  Heritable	  breast	  
cancer	  in	  twins.	  Br	  J	  Cancer,	  87,	  294-­‐300.	  
MAHARAJ,	  B.,	  DYER,	  R.	  B.,	  LEARY,	  W.	  P.,	  ARBUCKLE,	  D.	  D.,	  ARMSTRONG,	  T.	  G.	  &	  PUDIFIN,	  D.	  J.	  
1987.	  Screening	  for	  rheumatic	  heart	  disease	  amongst	  black	  schoolchildren	  in	  Inanda,	  
South	  Africa.	  J	  Trop	  Pediatr,	  33,	  60-­‐1.	  
MALHOTRA-­‐KUMAR,	  S.,	  LAMMENS,	  C.,	  COENEN,	  S.,	  VAN	  HERCK,	  K.	  &	  GOOSSENS,	  H.	  2007.	  Effect	  
of	  azithromycin	  and	  clarithromycin	  therapy	  on	  pharyngeal	  carriage	  of	  macrolide-­‐resistant	  
streptococci	  in	  healthy	  volunteers:	  a	  randomised,	  double-­‐blind,	  placebo-­‐controlled	  study.	  
Lancet,	  369,	  482-­‐90.	  
MALTEZOU,	  H.	  C.,	  TSAGRIS,	  V.,	  ANTONIADOU,	  A.,	  GALANI,	  L.,	  DOUROS,	  C.,	  KATSAROLIS,	  I.,	  
MARAGOS,	  A.,	  RAFTOPOULOS,	  V.,	  BISKINI,	  P.,	  KANELLAKOPOULOU,	  K.,	  FRETZAYAS,	  A.,	  
PAPADIMITRIOU,	  T.,	  NICOLAIDOU,	  P.	  &	  GIAMARELLOU,	  H.	  2008.	  Evaluation	  of	  a	  rapid	  
antigen	  detection	  test	  in	  the	  diagnosis	  of	  streptococcal	  pharyngitis	  in	  children	  and	  its	  
impact	  on	  antibiotic	  prescription.	  The	  Journal	  of	  antimicrobial	  chemotherapy,	  62,	  1407-­‐
12.	  
MANYEMBA,	  J.	  &	  MAYOSI,	  B.	  M.	  2003.	  Intramuscular	  penicillin	  is	  more	  effective	  than	  oral	  
penicillin	  in	  secondary	  prevention	  of	  rheumatic	  fever-­‐-­‐a	  systematic	  review.	  S	  Afr	  Med	  J,	  
93,	  212-­‐8.	  
MARIJON,	  E.,	  CELERMAJER,	  D.	  S.,	  TAFFLET,	  M.,	  EL-­‐HAOU,	  S.,	  JANI,	  D.	  N.,	  FERREIRA,	  B.,	  MOCUMBI,	  
A.	  O.,	  PAQUET,	  C.,	  SIDI,	  D.	  &	  JOUVEN,	  X.	  2009.	  Rheumatic	  heart	  disease	  screening	  by	  
echocardiography:	  the	  inadequacy	  of	  World	  Health	  Organization	  criteria	  for	  optimizing	  
the	  diagnosis	  of	  subclinical	  disease.	  Circulation,	  120,	  663-­‐8.	  
MARIJON,	  E.,	  MIRABEL,	  M.,	  CELERMAJER,	  D.	  S.	  &	  JOUVEN,	  X.	  2012.	  Rheumatic	  heart	  disease.	  
Lancet,	  379,	  953-­‐64.	  
MARIJON,	  E.,	  OU,	  P.,	  CELERMAJER,	  D.	  S.,	  FERREIRA,	  B.,	  MOCUMBI,	  A.	  O.,	  JANI,	  D.,	  PAQUET,	  C.,	  
JACOB,	  S.,	  SIDI,	  D.	  &	  JOUVEN,	  X.	  2007.	  Prevalence	  of	  rheumatic	  heart	  disease	  detected	  by	  
echocardiographic	  screening.	  N	  Engl	  J	  Med,	  357,	  470-­‐6.	  
MARIJON,	  E.,	  TAFFLET,	  M.	  &	  JOUVEN,	  X.	  2008.	  Time	  to	  use	  ultrasound	  and	  not	  stethoscopes	  for	  
rheumatic	  heart	  disease	  screening.	  Nature	  clinical	  practice.	  Cardiovascular	  medicine,	  5,	  
E1-­‐3.	  
MARKOWITZ,	  M.,	  GERBER,	  M.	  A.	  &	  KAPLAN,	  E.	  L.	  1993.	  Treatment	  of	  streptococcal	  
pharyngotonsillitis:	  reports	  of	  penicillin's	  demise	  are	  premature.	  The	  Journal	  of	  pediatrics,	  
123,	  679-­‐85.	  
MARRES,	  H.	  A.	  2008.	  [The	  practice	  guideline	  'Sore	  throat'	  (second	  revision)	  from	  the	  Dutch	  College	  
of	  General	  Practitioners;	  a	  response	  from	  the	  perspective	  of	  otorhinolaryngology].	  Ned	  
Tijdschr	  Geneeskd,	  152,	  421-­‐2.	  
MARTIN,	  J.	  M.,	  GREEN,	  M.,	  BARBADORA,	  K.	  A.	  &	  WALD,	  E.	  R.	  2004.	  Group	  A	  streptococci	  among	  
school-­‐aged	  children:	  clinical	  characteristics	  and	  the	  carrier	  state.	  Pediatrics,	  114,	  1212-­‐9.	  
MATTHYS,	  J.,	  DE	  MEYERE,	  M.,	  VAN	  DRIEL,	  M.	  L.	  &	  DE	  SUTTER,	  A.	  2007.	  Differences	  among	  
international	  pharyngitis	  guidelines:	  not	  just	  academic.	  Ann	  Fam	  Med,	  5,	  436-­‐43.	  
References	  
PhD	  Thesis:	  	  Mark	  E	  Engel	  	   	   |	  Page	  157	  
MAYOSI,	  B.,	  ROBERTSON,	  K.,	  VOLMINK,	  J.,	  ADEBO,	  W.,	  AKINYORE,	  K.,	  AMOAH,	  A.,	  BANNERMAN,	  
C.,	  BIESMAN-­‐SIMONS,	  S.,	  CARAPETIS,	  J.,	  CILLIERS,	  A.,	  COMMERFORD,	  P.,	  CROASDALE,	  A.,	  
DAMASCENO,	  A.,	  DEAN,	  J.,	  DEAN,	  M.,	  DE	  SOUZA,	  R.,	  FILIPE,	  A.,	  HUGO-­‐HAMMAN,	  C.,	  
JURGENS-­‐CLUR,	  S.	  A.,	  KOMBILA-­‐KOUMBA,	  P.,	  KOTZENBERG,	  C.,	  LAWRENSON,	  J.,	  MANGA,	  
P.,	  MATENGA,	  J.,	  MATHIVHA,	  T.,	  MNTLA,	  P.,	  MOCUMBI,	  A.,	  MOKONE,	  T.,	  OGOLA,	  E.,	  
OMOKHODION,	  S.,	  PALWENI,	  C.,	  PEARCE,	  A.,	  SALO,	  A.,	  THOMAS,	  B.,	  WALKER,	  K.,	  
WIYSONGE,	  C.	  &	  ZAHER,	  S.	  2006.	  The	  Drakensberg	  declaration	  on	  the	  control	  of	  
rheumatic	  fever	  and	  rheumatic	  heart	  disease	  in	  Africa.	  S	  Afr	  Med	  J,	  96,	  246.	  
MCDONALD,	  M.,	  BROWN,	  A.,	  NOONAN,	  S.	  &	  CARAPETIS,	  J.	  R.	  2005.	  Preventing	  recurrent	  
rheumatic	  fever:	  the	  role	  of	  register	  based	  programmes.	  Heart,	  91,	  1131-­‐3.	  
MCDONALD,	  M.	  I.,	  TOWERS,	  R.	  J.,	  ANDREWS,	  R.	  M.,	  BENGER,	  N.,	  CURRIE,	  B.	  J.	  &	  CARAPETIS,	  J.	  R.	  
2006.	  Low	  rates	  of	  streptococcal	  pharyngitis	  and	  high	  rates	  of	  pyoderma	  in	  Australian	  
aboriginal	  communities	  where	  acute	  rheumatic	  fever	  is	  hyperendemic.	  Clinical	  infectious	  
diseases	  :	  an	  official	  publication	  of	  the	  Infectious	  Diseases	  Society	  of	  America,	  43,	  683-­‐9.	  
MCGINN,	  T.	  G.,	  DELUCA,	  J.,	  AHLAWAT,	  S.	  K.,	  MOBO,	  B.	  H.,	  JR.	  &	  WISNIVESKY,	  J.	  P.	  2003.	  Validation	  
and	  modification	  of	  streptococcal	  pharyngitis	  clinical	  prediction	  rules.	  Mayo	  Clin	  Proc,	  78,	  
289-­‐93.	  
MCGINN,	  T.	  G.,	  GUYATT,	  G.	  H.,	  WYER,	  P.	  C.,	  NAYLOR,	  C.	  D.,	  STIELL,	  I.	  G.	  &	  RICHARDSON,	  W.	  S.	  
2000.	  Users'	  guides	  to	  the	  medical	  literature:	  XXII:	  how	  to	  use	  articles	  about	  clinical	  
decision	  rules.	  Evidence-­‐Based	  Medicine	  Working	  Group.	  JAMA,	  284,	  79-­‐84.	  
MCISAAC,	  W.	  J.,	  WHITE,	  D.,	  TANNENBAUM,	  D.	  &	  LOW,	  D.	  E.	  1998.	  A	  clinical	  score	  to	  reduce	  
unnecessary	  antibiotic	  use	  in	  patients	  with	  sore	  throat.	  CMAJ,	  158,	  75-­‐83.	  
MCLAREN,	  M.	  J.,	  HAWKINS,	  D.	  M.,	  KOORNHOF,	  H.	  J.,	  BLOOM,	  K.	  R.,	  BRAMWELL-­‐JONES,	  D.	  M.,	  
COHEN,	  E.,	  GALE,	  G.	  E.,	  KANAREK,	  K.,	  LACHMAN,	  A.	  S.,	  LAKIER,	  J.	  B.,	  POCOCK,	  W.	  A.	  &	  
BARLOW,	  J.	  B.	  1975.	  Epidemiology	  of	  rheumatic	  heart	  disease	  in	  black	  schoolchildren	  of	  
Soweto,	  Johannesburg.	  Br	  Med	  J,	  3,	  474-­‐8.	  
MIAKOTKIN,	  V.	  A.	  &	  BENEVOLENSKAIA,	  L.	  I.	  2008.	  [Genetics	  of	  osteoporosis].	  Vestn	  Ross	  Akad	  
Med	  Nauk,	  37-­‐41.	  
MOCUMBI,	  A.	  O.	  2012.	  The	  challenges	  of	  cardiac	  surgery	  for	  African	  children.	  Cardiovascular	  
Journal	  of	  Africa,	  23,	  165-­‐7.	  
MOHER,	  D.,	  LIBERATI,	  A.,	  TETZLAFF,	  J.	  &	  ALTMAN,	  D.	  G.	  2009.	  Preferred	  reporting	  items	  for	  
systematic	  reviews	  and	  meta-­‐analyses:	  the	  PRISMA	  Statement.	  Open	  medicine	  :	  a	  peer-­‐
reviewed,	  independent,	  open-­‐access	  journal,	  3,	  e123-­‐30.	  
MR	  PAULSEN	  PERSONAL	  COMMUNICATION	  Mr	  Paulsen,	  Chairman	  of	  Bonteheuwel	  Principals’	  
forum.	  
MZOUGHI,	  R.,	  BOUALLEGUE,	  O.,	  SELMI,	  H.,	  BEN	  SAID,	  H.,	  ESSOUSSI,	  A.	  S.	  &	  JEDDI,	  M.	  2004.	  Group	  
A	  streptococci	  in	  children	  with	  acute	  pharyngitis	  in	  Sousse,	  Tunisia.	  East	  Mediterr	  Health	  J,	  
10,	  488-­‐93.	  
NANDI,	  S.,	  KUMAR,	  R.,	  RAY,	  P.,	  VOHRA,	  H.	  &	  GANGULY,	  N.	  K.	  2001.	  Group	  A	  streptococcal	  sore	  
throat	  in	  a	  periurban	  population	  of	  northern	  India:	  a	  one-­‐year	  prospective	  study.	  Bulletin	  
of	  the	  World	  Health	  Organization,	  79,	  528-­‐33.	  
NKGUDI,	  B.,	  ROBERTSON,	  K.	  A.,	  VOLMINK,	  J.	  &	  MAYOSI,	  B.	  M.	  2006.	  Notification	  of	  rheumatic	  
fever	  in	  South	  Africa	  -­‐-­‐	  evidence	  for	  underreporting	  by	  health	  care	  professionals	  and	  
administrators.	  S	  Afr	  Med	  J,	  96,	  206-­‐8.	  
NOEL,	  T.	  P.,	  ZABRISKIE,	  J.,	  MACPHERSON,	  C.	  N.	  &	  PERROTTE,	  G.	  2005.	  Beta-­‐haemolytic	  
streptococci	  in	  school	  children	  5-­‐15	  years	  of	  age	  with	  an	  emphasis	  on	  rheumatic	  fever,	  in	  
the	  tri-­‐island	  state	  of	  Grenada.	  West	  Indian	  Med	  J,	  54,	  22-­‐7.	  
OLIVIER,	  L.	  &	  DE	  GRAAD,	  G.	  1978.	  Streptococcal	  sore	  throat.	  South	  African	  medical	  journal	  =	  Suid-­‐
Afrikaanse	  tydskrif	  vir	  geneeskunde,	  54,	  1082.	  
OMURZAKOVA,	  N.	  A.,	  YAMANO,	  Y.,	  SAATOVA,	  G.	  M.,	  MIRZAKHANOVA,	  M.	  I.,	  SHUKUROVA,	  S.	  M.,	  
KYDYRALIEVA,	  R.	  B.,	  JUMAGULOVA,	  A.	  S.,	  SEISENBAEV,	  A.,	  NISHIOKA,	  K.	  &	  NAKAJIMA,	  T.	  
References	  
PhD	  Thesis:	  	  Mark	  E	  Engel	  	   	   |	  Page	  158	  
2009.	  High	  incidence	  of	  rheumatic	  fever	  and	  rheumatic	  heart	  disease	  in	  the	  republics	  of	  
Central	  Asia.	  Int	  J	  Rheum	  Dis,	  12,	  79-­‐83.	  
PAAR,	  J.	  A.,	  BERRIOS,	  N.	  M.,	  ROSE,	  J.	  D.,	  CACERES,	  M.,	  PENA,	  R.,	  PEREZ,	  W.,	  CHEN-­‐MOK,	  M.,	  
JOLLES,	  E.	  &	  DALE,	  J.	  B.	  2010.	  Prevalence	  of	  rheumatic	  heart	  disease	  in	  children	  and	  young	  
adults	  in	  Nicaragua.	  The	  American	  journal	  of	  cardiology,	  105,	  1809-­‐14.	  
PAUL,	  J.	  R.	  1941.	  The	  Epidemiology	  of	  Rheumatic	  Fever.	  Am	  J	  Public	  Health	  Nations	  Health,	  31,	  
611-­‐8.	  
PAUL,	  J.	  R.	  &	  SALINGER,	  R.	  1931.	  The	  spread	  of	  rheumatic	  fever	  through	  families.	  J	  Clin	  Invest,	  10,	  
33-­‐51.	  
PEDUZZI,	  P.,	  CONCATO,	  J.,	  KEMPER,	  E.,	  HOLFORD,	  T.	  R.	  &	  FEINSTEIN,	  A.	  R.	  1996.	  A	  simulation	  
study	  of	  the	  number	  of	  events	  per	  variable	  in	  logistic	  regression	  analysis.	  Journal	  of	  
Clinical	  Epidemiology,	  49,	  1373-­‐9.	  
PERRY,	  C.	  B.	  1940.	  Rheumatic	  Heart	  Disease	  in	  Identical	  Twins.	  Archives	  of	  Disease	  in	  Childhood.,	  
15,	  179.	  
PFOH,	  E.,	  WESSELS,	  M.	  R.,	  GOLDMANN,	  D.	  &	  LEE,	  G.	  M.	  2008.	  Burden	  and	  economic	  cost	  of	  group	  
A	  streptococcal	  pharyngitis.	  Pediatrics,	  121,	  229-­‐34.	  
PHILLIPS,	  D.	  I.	  1993.	  Twin	  studies	  in	  medical	  research.	  Lancet,	  342,	  52.	  
POCOCK,	  W.	  A.,	  CHESLER,	  E.	  &	  BARLOW,	  J.	  B.	  1968.	  A	  preliminary	  survey	  of	  428	  Black	  Soweto	  
schoolchildren	  aged	  2-­‐12	  years.	  Proceedings	  of	  the	  Southern	  Africa	  Cardiac	  Society	  
Conference.	  
PRASAD,	  S.	  1967.	  Observations	  on	  seasonal,	  socio-­‐economic,	  and	  heredo-­‐familial	  factors	  of	  
rheumatic	  heart	  disease	  in	  children.	  Indian	  Pediatr,	  4,	  290-­‐7.	  
QUINN,	  R.	  W.	  1989.	  Comprehensive	  review	  of	  morbidity	  and	  mortality	  trends	  for	  rheumatic	  fever,	  
streptococcal	  disease,	  and	  scarlet	  fever:	  the	  decline	  of	  rheumatic	  fever.	  Reviews	  of	  
infectious	  diseases,	  11,	  928-­‐53.	  
QUINN,	  R.	  W.	  &	  FEDERSPIEL,	  C.	  F.	  1967.	  Rheumatic	  fever	  and	  rheumatic	  heart	  disease.	  A	  five-­‐year	  
study	  of	  rheumatic	  and	  non-­‐rheumatic	  families.	  Am	  J	  Epidemiol,	  85,	  120-­‐36.	  
RAMMELKAMP,	  C.	  H.,	  JR.	  &	  STOLZER,	  B.	  L.	  1961.	  The	  latent	  period	  before	  the	  onset	  of	  acute	  
rheumatic	  fever.	  The	  Yale	  journal	  of	  biology	  and	  medicine,	  34,	  386-­‐98.	  
RAMMELKAMP,	  C.	  H.,	  WANNAMAKER,	  L.	  W.	  &	  DENNY,	  F.	  W.	  1952.	  The	  Epidemiology	  and	  
Prevention	  of	  Rheumatic	  Fever.	  Bulletin	  of	  the	  New	  York	  Academy	  of	  Medicine,	  28,	  321-­‐
34.	  
RANSOME,	  O.	  J.,	  ROODE,	  H.,	  SPECTOR,	  I.	  &	  REINACH,	  S.	  G.	  1983.	  Pharyngeal	  carriage	  of	  group	  A	  
beta-­‐haemolytic	  streptococci	  in	  coloured	  and	  Indian	  schoolchildren.	  S	  Afr	  Med	  J,	  64,	  779-­‐
81.	  
RASHED,	  M.	  M.,	  NAGM,	  M.	  A.,	  GALAL,	  M.	  K.	  &	  RAGAB,	  N.	  M.	  2007.	  Clinical	  And	  Histopathologic	  
Study	  Of	  Surgically	  Excised	  Mitral	  Valves	  In	  Children.	  .	  2007	  Volume	  5	  Number	  2.	  DOI:	  
10.5580/1f6d.	  The	  Internet	  Journal	  of	  Pathology.	  	  ,	  5,	  DOI:	  10.5580/1f6d.	  
RAY,	  D.,	  BANERJEE,	  S.,	  BHATTACHARYA,	  S.,	  SINHA,	  S.,	  BANDYOPADHYAY,	  D.,	  GHOSAL,	  C.,	  GUPTA,	  
S.,	  MAJUMDAR,	  P.	  K.,	  SAHA,	  S.	  &	  BHATTACHARYA,	  B.	  2010.	  A	  hospital-­‐based	  study	  to	  
evaluate	  the	  incidence	  pattern	  of	  group	  A	  streptococcal	  throat	  infections	  from	  different	  
age	  group	  patients.	  J	  Indian	  Med	  Assoc,	  108,	  81-­‐3.	  
REED,	  S.	  1964.	  Parenthood	  and	  Heredity,	  New	  York,	  John	  Wiley	  and	  Sons,	  Inc.	  
REEVES,	  B.	  M.,	  KADO,	  J.	  &	  BROOK,	  M.	  2011.	  High	  prevalence	  of	  rheumatic	  heart	  disease	  in	  Fiji	  
detected	  by	  echocardiography	  screening.	  Journal	  of	  paediatrics	  and	  child	  health,	  47,	  473-­‐
8.	  
REMENYI,	  B.,	  WILSON,	  N.,	  STEER,	  A.,	  FERREIRA,	  B.,	  KADO,	  J.,	  KUMAR,	  K.,	  LAWRENSON,	  J.,	  
MAGUIRE,	  G.,	  MARIJON,	  E.,	  MIRABEL,	  M.,	  MOCUMBI,	  A.	  O.,	  MOTA,	  C.,	  PAAR,	  J.,	  SAXENA,	  
A.,	  SCHEEL,	  J.,	  STIRLING,	  J.,	  VIALI,	  S.,	  BALEKUNDRI,	  V.	  I.,	  WHEATON,	  G.,	  ZUHLKE,	  L.	  &	  
CARAPETIS,	  J.	  2012.	  World	  Heart	  Federation	  criteria	  for	  echocardiographic	  diagnosis	  of	  
References	  
PhD	  Thesis:	  	  Mark	  E	  Engel	  	   	   |	  Page	  159	  
rheumatic	  heart	  disease-­‐-­‐an	  evidence-­‐based	  guideline.	  Nature	  reviews.	  Cardiology,	  9,	  
297-­‐309.	  
RIMOIN,	  A.	  W.,	  HAMZA,	  H.	  S.,	  VINCE,	  A.,	  KUMAR,	  R.,	  WALKER,	  C.	  F.,	  CHITALE,	  R.	  A.,	  DA	  CUNHA,	  A.	  
L.,	  QAZI,	  S.	  &	  STEINHOFF,	  M.	  C.	  2005.	  Evaluation	  of	  the	  WHO	  clinical	  decision	  rule	  for	  
streptococcal	  pharyngitis.	  Arch	  Dis	  Child,	  90,	  1066-­‐70.	  
ROBERTS,	  S.,	  KOSANKE,	  S.,	  TERRENCE	  DUNN,	  S.,	  JANKELOW,	  D.,	  DURAN,	  C.	  M.	  &	  CUNNINGHAM,	  
M.	  W.	  2001.	  Pathogenic	  mechanisms	  in	  rheumatic	  carditis:	  focus	  on	  valvular	  endothelium.	  
The	  Journal	  of	  infectious	  diseases,	  183,	  507-­‐11.	  
ROBERTSON,	  K.	  A.,	  VOLMINK,	  J.	  A.	  &	  MAYOSI,	  B.	  M.	  2005a.	  Antibiotics	  for	  the	  primary	  prevention	  
of	  acute	  rheumatic	  fever:	  a	  meta-­‐analysis.	  BMC	  Cardiovasc	  Disord,	  5,	  11.	  
ROBERTSON,	  K.	  A.,	  VOLMINK,	  J.	  A.	  &	  MAYOSI,	  B.	  M.	  2005b.	  Lack	  of	  adherence	  to	  the	  national	  
guidelines	  on	  the	  prevention	  of	  rheumatic	  fever.	  S	  Afr	  Med	  J,	  95,	  52-­‐6.	  
ROBERTSON,	  K.	  A.,	  VOLMINK,	  J.	  A.	  &	  MAYOSI,	  B.	  M.	  2006.	  Towards	  a	  uniform	  plan	  for	  the	  control	  
of	  rheumatic	  fever	  and	  rheumatic	  heart	  disease	  in	  Africa-­‐-­‐the	  Awareness	  Surveillance	  
Advocacy	  Prevention	  (A.S.A.P.)	  Programme.	  S	  Afr	  Med	  J,	  96,	  241.	  
ROYSTON,	  P.,	  MOONS,	  K.	  G.,	  ALTMAN,	  D.	  G.	  &	  VERGOUWE,	  Y.	  2009.	  Prognosis	  and	  prognostic	  
research:	  Developing	  a	  prognostic	  model.	  BMJ,	  338,	  b604.	  
SADOH,	  A.	  E.	  &	  OMOKHODION,	  S.	  I.	  2007.	  Streptococcal	  Throat	  Isolates	  In	  School	  Children	  In	  An	  
Urban	  Centre	  In	  Nigeria	  -­‐	  Are	  There	  Other	  Rheumatogenic	  Strains?	  Nigerian	  journal	  of	  
Cardiology,	  4,	  50-­‐5.	  
SALLAKCI,	  N.,	  AKCURIN,	  G.,	  KOKSOY,	  S.,	  KARDELEN,	  F.,	  UGUZ,	  A.,	  COSKUN,	  M.,	  ERTUG,	  H.	  &	  YEGIN,	  
O.	  2005.	  TNF-­‐alpha	  G-­‐308A	  polymorphism	  is	  associated	  with	  rheumatic	  fever	  and	  
correlates	  with	  increased	  TNF-­‐alpha	  production.	  J	  Autoimmun,	  25,	  150-­‐4.	  
SARKAR,	  S.,	  BISWAS,	  R.,	  GAUR,	  S.	  D.,	  SEN,	  P.	  C.	  &	  REDDY,	  D.	  C.	  1988.	  A	  study	  on	  sore	  throat	  and	  
beta	  haemolytic	  streptococcal	  pharyngitis	  among	  rural	  school	  children	  in	  Varanasi,	  with	  
reference	  to	  age	  and	  season.	  Indian	  journal	  of	  public	  health,	  32,	  190-­‐8.	  
SAXENA,	  A.,	  RAMAKRISHNAN,	  S.,	  ROY,	  A.,	  SETH,	  S.,	  KRISHNAN,	  A.,	  MISRA,	  P.,	  KALAIVANI,	  M.,	  
BHARGAVA,	  B.,	  FLATHER,	  M.	  D.	  &	  POOLE-­‐WILSON,	  P.	  P.	  2011.	  Prevalence	  and	  outcome	  of	  
subclinical	  rheumatic	  heart	  disease	  in	  India:	  the	  RHEUMATIC	  (Rheumatic	  Heart	  Echo	  
Utilisation	  and	  Monitoring	  Actuarial	  Trends	  in	  Indian	  Children)	  study.	  Heart,	  97,	  2018-­‐22.	  
SCOTT,	  J.	  R.,	  PULLIAM,	  W.	  M.,	  HOLLINGSHEAD,	  S.	  K.	  &	  FISCHETTI,	  V.	  A.	  1985.	  Relationship	  of	  M	  
protein	  genes	  in	  group	  A	  streptococci.	  Proceedings	  of	  the	  National	  Academy	  of	  Sciences	  of	  
the	  United	  States	  of	  America,	  82,	  1822-­‐6.	  
SECKELER,	  M.	  D.	  &	  HOKE,	  T.	  R.	  2011.	  The	  worldwide	  epidemiology	  of	  acute	  rheumatic	  fever	  and	  
rheumatic	  heart	  disease.	  Clin	  Epidemiol,	  3,	  67-­‐84.	  
SHAIKH,	  N.,	  LEONARD,	  E.	  &	  MARTIN,	  J.	  M.	  2010.	  Prevalence	  of	  streptococcal	  pharyngitis	  and	  
streptococcal	  carriage	  in	  children:	  a	  meta-­‐analysis.	  Pediatrics,	  126,	  e557-­‐64.	  
SHAIKH,	  N.,	  SWAMINATHAN,	  N.	  &	  HOOPER,	  E.	  G.	  2011.	  Accuracy	  and	  precision	  of	  the	  signs	  and	  
symptoms	  of	  streptococcal	  pharyngitis	  in	  children:	  a	  systematic	  review.	  J	  Pediatr,	  160,	  
487-­‐493	  e3.	  
SHOHAT,	  M.,	  LIVNEH,	  A.,	  ZEMER,	  D.,	  PRAS,	  M.	  &	  SOHAR,	  E.	  1992.	  Twin	  studies	  in	  familial	  
Mediterranean	  fever.	  Am	  J	  Med	  Genet,	  44,	  179-­‐82.	  
SHRESTHA,	  N.	  R.,	  PILGRIM,	  T.,	  KARKI,	  P.,	  BHANDARI,	  R.,	  BASNET,	  S.,	  TIWARI,	  S.,	  DHAKAL,	  S.	  S.	  &	  
URBAN,	  P.	  2012.	  Rheumatic	  heart	  disease	  revisited:	  patterns	  of	  valvular	  involvement	  from	  
a	  consecutive	  cohort	  in	  eastern	  Nepal.	  Journal	  of	  cardiovascular	  medicine.	  
SILVA-­‐COSTA,	  C.,	  FRIAES,	  A.,	  RAMIREZ,	  M.	  &	  MELO-­‐CRISTINO,	  J.	  2012.	  Differences	  between	  
macrolide	  resistant	  and	  susceptible	  Streptococcus	  pyogenes:	  the	  importance	  of	  clonal	  
properties	  in	  addition	  to	  antibiotic	  consumption.	  Antimicrobial	  agents	  and	  chemotherapy.	  
SLIWA,	  K.,	  CARRINGTON,	  M.,	  MAYOSI,	  B.	  M.,	  ZIGIRIADIS,	  E.,	  MVUNGI,	  R.	  &	  STEWART,	  S.	  2010.	  
Incidence	  and	  characteristics	  of	  newly	  diagnosed	  rheumatic	  heart	  disease	  in	  urban	  African	  
adults:	  insights	  from	  the	  heart	  of	  Soweto	  study.	  European	  heart	  journal,	  31,	  719-­‐27.	  
References	  
PhD	  Thesis:	  	  Mark	  E	  Engel	  	   	   |	  Page	  160	  
SMEESTERS,	  P.	  R.,	  CAMPOS,	  D.,	  JR.,	  VAN	  MELDEREN,	  L.,	  DE	  AGUIAR,	  E.,	  VANDERPAS,	  J.	  &	  
VERGISON,	  A.	  2006.	  Pharyngitis	  in	  low-­‐resources	  settings:	  a	  pragmatic	  clinical	  approach	  to	  
reduce	  unnecessary	  antibiotic	  use.	  Pediatrics,	  118,	  e1607-­‐11.	  
SMEESTERS,	  P.	  R.,	  MCMILLAN,	  D.	  J.,	  SRIPRAKASH,	  K.	  S.	  &	  GEORGOUSAKIS,	  M.	  M.	  2009.	  Differences	  
among	  group	  A	  streptococcus	  epidemiological	  landscapes:	  consequences	  for	  M	  protein-­‐
based	  vaccines?	  Expert	  review	  of	  vaccines,	  8,	  1705-­‐20.	  
SPAGNUOLO,	  M.	  &	  TARANTA,	  A.	  1968.	  Rheumatic	  fever	  in	  siblings.	  Similarity	  of	  its	  clinical	  
manifestations.	  N	  Engl	  J	  Med,	  278,	  183-­‐8.	  
SPECIAL	  WRITING	  GROUP	  OF	  THE	  COMMITTEE	  ON	  RHEUMATIC	  FEVER,	  A.	  1992.	  Guidelines	  for	  the	  
diagnosis	  of	  rheumatic	  fever.	  Jones	  Criteria,	  1992	  update.	  Special	  Writing	  Group	  of	  the	  
Committee	  on	  Rheumatic	  Fever,	  Endocarditis,	  and	  Kawasaki	  Disease	  of	  the	  Council	  on	  
Cardiovascular	  Disease	  in	  the	  Young	  of	  the	  American	  Heart	  Association.	  JAMA	  :	  the	  
journal	  of	  the	  American	  Medical	  Association,	  268,	  2069-­‐73.	  
SPIEGELHALTER,	  D.	  J.	  1986.	  Probabilistic	  prediction	  in	  patient	  management	  and	  clinical	  trials.	  
Statistics	  in	  medicine,	  5,	  421-­‐33.	  
STATISTICS	  SOUTH	  AFRICA	  2003.	  Population	  Census	  2001:	  	  Community	  Profile	  Databases:	  
Pretoria.	  	  Available	  at:	  http://www.statssa.gov.za.	  
STEER,	  A.	  C.	  &	  CARAPETIS,	  J.	  R.	  2009.	  Prevention	  and	  treatment	  of	  rheumatic	  heart	  disease	  in	  the	  
developing	  world.	  Nature	  reviews.	  Cardiology,	  6,	  689-­‐98.	  
STEER,	  A.	  C.,	  CARAPETIS,	  J.	  R.,	  NOLAN,	  T.	  M.	  &	  SHANN,	  F.	  2002.	  Systematic	  review	  of	  rheumatic	  
heart	  disease	  prevalence	  in	  children	  in	  developing	  countries:	  the	  role	  of	  environmental	  
factors.	  J	  Paediatr	  Child	  Health,	  38,	  229-­‐34.	  
STEER,	  A.	  C.,	  DANCHIN,	  M.	  H.	  &	  CARAPETIS,	  J.	  R.	  2007.	  Group	  A	  streptococcal	  infections	  in	  
children.	  J	  Paediatr	  Child	  Health,	  43,	  203-­‐13.	  
STEER,	  A.	  C.,	  JENNEY,	  A.	  W.,	  KADO,	  J.,	  GOOD,	  M.	  F.,	  BATZLOFF,	  M.,	  MAGOR,	  G.,	  RITIKA,	  R.,	  
MULHOLLAND,	  K.	  E.	  &	  CARAPETIS,	  J.	  R.	  2009.	  Prospective	  surveillance	  of	  streptococcal	  
sore	  throat	  in	  a	  tropical	  country.	  Pediatr	  Infect	  Dis	  J,	  28,	  477-­‐82.	  
STEINHOFF,	  M.	  C.,	  WALKER,	  C.	  F.,	  RIMOIN,	  A.	  W.	  &	  HAMZA,	  H.	  S.	  2005.	  A	  clinical	  decision	  rule	  for	  
management	  of	  streptococcal	  pharyngitis	  in	  low-­‐resource	  settings.	  Acta	  Paediatr,	  94,	  
1038-­‐42.	  
STERNE	  JAC,	  BRADBURN	  MJ	  &	  EGGER	  M	  2001.	  Meta-­‐analysis	  in	  Stata.	  In:	  EGGER	  M,	  DAVEY	  SMITH	  
G	  &	  ALTMAN	  DG	  (eds.)	  Systematic	  reviews	  in	  healthcare:	  meta-­‐analysis	  in	  context.	  2nd	  ed.	  
London:	  BMJ	  Publishing	  Group.	  
STEVENSON,	  A.	  C.	  &	  CHEESEMAN,	  E.	  A.	  1953.	  Heredity	  and	  rheumatic	  fever;	  a	  study	  of	  462	  
families	  ascertained	  by	  an	  affected	  child	  and	  51	  families	  ascertained	  by	  an	  affected	  
mother.	  Ann	  Eugen,	  17,	  177-­‐210.	  
STEYERBERG,	  E.	  W.,	  EIJKEMANS,	  M.	  J.,	  HARRELL,	  F.	  E.,	  JR.	  &	  HABBEMA,	  J.	  D.	  2000.	  Prognostic	  
modelling	  with	  logistic	  regression	  analysis:	  a	  comparison	  of	  selection	  and	  estimation	  
methods	  in	  small	  data	  sets.	  Statistics	  in	  medicine,	  19,	  1059-­‐79.	  
STOLLERMAN,	  G.	  H.	  1975.	  Rheumatic	  fever	  and	  streptococcal	  infection,	  New	  York,	  Grune	  &	  
Stratton.	  
STOLLERMAN,	  G.	  H.	  1995.	  Penicillin	  for	  streptococcal	  pharyngitis:	  has	  anything	  changed?	  Hospital	  
practice,	  30,	  80-­‐3.	  
STOLLERMAN,	  G.	  H.	  2001.	  Rheumatic	  fever	  in	  the	  21st	  century.	  Clin	  Infect	  Dis,	  33,	  806-­‐14.	  
STRUSBERG,	  A.	  M.,	  HALAC,	  J.	  L.	  &	  RISEMBERG,	  A.	  1968.	  [Familial	  rheumatic	  fever].	  Rev	  Fac	  Cienc	  
Med	  Cordoba,	  26,	  219-­‐22.	  
SUN,	  G.	  W.,	  SHOOK,	  T.	  L.	  &	  KAY,	  G.	  L.	  1996.	  Inappropriate	  use	  of	  bivariable	  analysis	  to	  screen	  risk	  
factors	  for	  use	  in	  multivariable	  analysis.	  Journal	  of	  Clinical	  Epidemiology,	  49,	  907-­‐16.	  
SYROGIANNOPOULOS,	  G.	  A.,	  BOZDOGAN,	  B.,	  GRIVEA,	  I.	  N.,	  EDNIE,	  L.	  M.,	  KRITIKOU,	  D.	  I.,	  
KATOPODIS,	  G.	  D.,	  BERATIS,	  N.	  G.	  &	  APPLEBAUM,	  P.	  C.	  2004.	  Two	  dosages	  of	  
clarithromycin	  for	  five	  days,	  amoxicillin/clavulanate	  for	  five	  days	  or	  penicillin	  V	  for	  ten	  
References	  
PhD	  Thesis:	  	  Mark	  E	  Engel	  	   	   |	  Page	  161	  
days	  in	  acute	  group	  A	  streptococcal	  tonsillopharyngitis.	  The	  Pediatric	  infectious	  disease	  
journal,	  23,	  857-­‐65.	  
TARANTA,	  A.,	  TOROSDAG,	  S.,	  METRAKOS,	  J.,	  JEGIER,	  W.	  &	  UCHIDA,	  I.	  A.	  1959.	  Rheumatic	  fever	  in	  
monozygotic	  and	  dizygotic	  twins.	  Circulation,	  20,	  778.	  
TIEMSTRA,	  J.	  &	  MIRANDA,	  R.	  L.	  2009.	  Role	  of	  non-­‐group	  a	  streptococci	  in	  acute	  pharyngitis.	  
Journal	  of	  the	  American	  Board	  of	  Family	  Medicine	  :	  JABFM,	  22,	  663-­‐9.	  
TURNER,	  J.	  C.,	  HAYDEN,	  F.	  G.,	  LOBO,	  M.	  C.,	  RAMIREZ,	  C.	  E.	  &	  MURREN,	  D.	  1997.	  Epidemiologic	  
evidence	  for	  Lancefield	  group	  C	  beta-­‐hemolytic	  streptococci	  as	  a	  cause	  of	  exudative	  
pharyngitis	  in	  college	  students.	  Journal	  of	  Clinical	  Microbiology,	  35,	  1-­‐4.	  
URIBARRI,	  G.,	  MARTINEZ	  GASTEY,	  A.	  &	  FERNANDEZ	  PIZARRO,	  J.	  P.	  1965.	  [Familial	  rheumatic	  fever.	  
(Preliminary	  note)].	  Rev	  Clin	  Esp,	  97,	  410-­‐2.	  
US	  DEPARTMENT	  OF	  HHS.	  Basic	  HHS	  Policy	  for	  Protection	  of	  Human	  Research	  Subjects.	  Available	  
at:	  http://www.hhs.gov/ohrp/humansubjects/guidance/45cfr46.html	  Accessed	  Accessed	  
20	  June	  2012.	  
VAN	  STADEN,	  D.	  A.,	  NEL,	  W.	  &	  VAN	  ZYL,	  M.	  L.	  1982.	  Groep	  A	  B-­‐hemolitiese	  streptockokke	  in	  'n	  
tradisionele	  Swart	  gemeenskap.	  S	  Afr	  Med	  J,	  62,	  569-­‐70.	  
VAN	  ZYL,	  M.	  L.,	  VAN	  STADEN,	  D.	  A.	  &	  POTGIETER,	  M.	  D.	  1981.	  [Beta-­‐hemolytic	  streptococci	  as	  a	  
cause	  of	  sore	  throat	  in	  the	  Pretoria	  area].	  South	  African	  medical	  journal	  =	  Suid-­‐Afrikaanse	  
tydskrif	  vir	  geneeskunde,	  59,	  783-­‐4.	  
VEASY,	  L.	  G.	  &	  HILL,	  H.	  R.	  1997.	  Immunologic	  and	  clinical	  correlations	  in	  rheumatic	  fever	  and	  
rheumatic	  heart	  disease.	  The	  Pediatric	  infectious	  disease	  journal,	  16,	  400-­‐7.	  
VISENTAINER,	  J.	  E.,	  PEREIRA,	  F.	  C.,	  DALALIO,	  M.	  M.,	  TSUNETO,	  L.	  T.,	  DONADIO,	  P.	  R.	  &	  
MOLITERNO,	  R.	  A.	  2000.	  Association	  of	  HLA-­‐DR7	  with	  rheumatic	  fever	  in	  the	  Brazilian	  
population.	  J	  Rheumatol,	  27,	  1518-­‐20.	  
WACHTLER,	  H.	  &	  CHENOT,	  J.	  F.	  2011.	  [Guidelines	  for	  the	  management	  of	  sore	  throat	  from	  the	  
German	  Society	  of	  General	  Practice	  and	  Family	  Medicine].	  HNO,	  59,	  480-­‐4.	  
WALD,	  E.	  R.,	  GREEN,	  M.	  D.,	  SCHWARTZ,	  B.	  &	  BARBADORA,	  K.	  1998.	  A	  streptococcal	  score	  card	  
revisited.	  Pediatr	  Emerg	  Care,	  14,	  109-­‐11.	  
WANI,	  B.	  A.	  1997.	  Study	  of	  HLA-­‐A,	  B,	  C,	  DR,	  DQ	  profile	  of	  patients	  with	  established	  rheumatic	  
heart	  disease	  in	  Kashmir.	  Indian	  Heart	  J,	  49,	  152-­‐4.	  
WANNAMAKER,	  L.	  W.	  1972.	  Perplexity	  and	  precision	  in	  the	  diagnosis	  of	  streptococcal	  pharyngitis.	  
American	  Journal	  of	  Diseases	  of	  Children,	  124,	  352-­‐8.	  
WASSON,	  J.	  H.,	  SOX,	  H.	  C.,	  NEFF,	  R.	  K.	  &	  GOLDMAN,	  L.	  1985.	  Clinical	  prediction	  rules.	  Applications	  
and	  methodological	  standards.	  N	  Engl	  J	  Med,	  313,	  793-­‐9.	  
WATKINS,	  D.	  A.,	  ZUHLKE,	  L.	  J.,	  ENGEL,	  M.	  E.	  &	  MAYOSI,	  B.	  M.	  2009.	  Rheumatic	  fever:	  neglected	  
again.	  Science,	  324,	  37.	  
WHO	  1995.	  The	  management	  of	  acute	  respiratory	  infections	  in	  children:	  practical	  guidelines	  for	  
outpatient	  care.	  World	  Health	  Organisation,	  Geneva,	  31-­‐3.	  
WHO	  2004.	  Rheumatic	  Fever	  and	  Rheumatic	  Heart	  Disease.	  	  Report	  of	  a	  WHO	  Expert	  Consultation.	  
WILSON,	  M.	  G.	  &	  SCHWEITZER,	  M.	  D.	  1937.	  Rheumatic	  fever	  as	  a	  familial	  disease.	  Environment,	  
communicability	  and	  heredity	  in	  their	  relation	  to	  the	  observed	  familial	  incidence	  of	  the	  
disease.	  J	  Clin	  Invest,	  16,	  555-­‐70.	  
WORLD	  BANK	  2012.	  World	  Development	  Indictors	  (14	  June	  2012/April	  WDI	  2012	  edtion).	  	  	  
Available	  at	  	  http://dx.doi.org/10.5257/wb/wdi/2012-­‐04.	  
WORLD	  HEALTH	  ORGANIZATION.	  2004.	  Rheumatic	  fever	  and	  rheumatic	  heart	  disease	  :	  report	  of	  a	  
WHO	  Expert	  Consultation	  :	  Geneva,	  29	  October	  -­‐	  1	  November	  2001,	  Geneva,	  World	  Health	  
Organization.	  
ZAJICEK,	  M.	  &	  GAJOVA,	  B.	  1966.	  [Familial	  rheumatic	  fever	  and	  glomerulonephritis].	  Cesk	  Pediatr,	  
21,	  250-­‐2.	  
References	  
PhD	  Thesis:	  	  Mark	  E	  Engel	  	   	   |	  Page	  162	  
ZAOUTIS,	  T.,	  ATTIA,	  M.,	  GROSS,	  R.	  &	  KLEIN,	  J.	  2004.	  The	  role	  of	  group	  C	  and	  group	  G	  streptococci	  
in	  acute	  pharyngitis	  in	  children.	  Clinical	  microbiology	  and	  infection	  :	  the	  official	  publication	  
of	  the	  European	  Society	  of	  Clinical	  Microbiology	  and	  Infectious	  Diseases,	  10,	  37-­‐40.	  
ZIETSMAN,	  I.	  L.	  &	  A.J.,	  B.	  2011.	  National	  surveillance	  of	  private	  sector	  respiratory	  tract	  pathogens	  
in	  South	  Africa,	  2010.	  South	  Afr	  J	  Epidemiol	  Infect,	  26,	  51-­‐3.	  
ZUHLKE,	  L.	  J.	  &	  MAYOSI,	  B.	  2009.	  The	  challenge	  of	  screening	  for	  asymptomatic	  rheumatic	  heart	  
disease	  in	  South	  Africa.	  SA	  Heart,	  6,	  100-­‐3.	  
ZUITHOFF,	  N.	  P.,	  VERGOUWE,	  Y.,	  KING,	  M.,	  NAZARETH,	  I.,	  HAK,	  E.,	  MOONS,	  K.	  G.	  &	  GEERLINGS,	  M.	  
I.	  2009.	  A	  clinical	  prediction	  rule	  for	  detecting	  major	  depressive	  disorder	  in	  primary	  care:	  
the	  PREDICT-­‐NL	  study.	  Fam	  Pract,	  26,	  241-­‐50.	  
ZWEIG,	  M.	  H.	  &	  CAMPBELL,	  G.	  1993.	  Receiver-­‐operating	  characteristic	  (ROC)	  plots:	  a	  fundamental	  
evaluation	  tool	  in	  clinical	  medicine.	  Clinical	  chemistry,	  39,	  561-­‐77.	  
	  
Appendices	  
PhD	  Thesis:	  	  Mark	  E	  Engel	  	   	   	  	  	  |	  Page	  163	  
10 APPENDICES 
10.1 	  	  Appendix	  1:	  	  PRISMA	  Checklist	  
Section/topic  # Checklist item  Reported on page #  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.   
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility 
criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions 
and implications of key findings; systematic review registration number.  
 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.   
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, interventions, 
comparisons, outcomes, and study design (PICOS).  
 
METHODS   
Protocol and 
registration  
5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide 
registration information including registration number.  
 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-­‐up) and report characteristics (e.g., years considered, 
language, publication status) used as criteria for eligibility, giving rationale.  
 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify 
additional studies) in the search and date last searched.  
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Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, 
included in the meta-­‐analysis).  
 
Data collection process  10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any 
processes for obtaining and confirming data from investigators.  
 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and 
simplifications made.  
 
Risk of bias in individual 
studies  
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was 
done at the study or outcome level), and how this information is to be used in any data synthesis.  
 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).   
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including measures of 
consistency (e.g., I2) for each meta-­‐analysis.  
 
 




Section/topic  # Checklist item  Reported on page #  
Risk of bias across 
studies  
15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective 
reporting within studies).  
 
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, 
indicating which were pre-­‐specified.  
 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions 
at each stage, ideally with a flow diagram.  
 
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) 
and provide the citations.  
 
Risk of bias within 
studies  
19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).   
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Results of individual 
studies  
20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each 
intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.  
 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of consistency.   
Risk of bias across 
studies  
22 Present results of any assessment of risk of bias across studies (see Item 15).   
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).   
DISCUSSION   
Summary of evidence  24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance 
to key groups (e.g., healthcare providers, users, and policy makers).  
 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of 
identified research, reporting bias).  
 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for future research.   
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for 
the systematic review.  
 
 
From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): 
e1000097. doi:10.1371/journal.pmed1000097  
For more information, visit: www.prisma-­‐statement.org.  
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Parental Information Sheet: 
 
The Molecular Epidemiology of Streptococcus pyogenes sore throat among Children 
in the Vanguard Community (Bonteheuwel/Langa), Cape Town, South Africa and 
The Development of a Clinical Prediction Rule for Streptococcal sore throat 
 
Principal Investigator: Bongani M. Mayosi, D.Phil. Groote Schuur Hospital 
Tel:  27-21-406-6200 
Email: bongani.mayosi@uct.ac.za  
 
Co-Investigators:       David Beatty, M.D.   
Red Cross War Memorial Children’s Hospital 
 
                                     Karen Cohen, M.B., Ch.B., M.Sc. (Epid.) 
Groote Schuur Hospital and University of Cape Town 
 
Mark Engel, BSc (Hons), MPH (Epid/Bios) 
                                    Groote Schuur Hospital and University of Cape Town 
 
Ronald Gounden, M.B.,Ch.B. 
                           Groote Schuur Hospital and University of Cape Town 
                                     
Gary Maartens, M.B., Ch.B. 
            Groote Schuur Hospital and University of Cape Town 
                                        
  Andrew Whitelaw, M.B., Ch.B. 





Your child has been asked to participate in this research study because he or she has a sore throat.  We are 
asking for your permission for your child to participate.   
 
This form provides information about the study and the risks and benefits of being involved in this study.  
Please read it carefully and then ask the study doctors or nurse any questions that you may have. 
 
Your child does not have to take part in the study.  If you choose not to take part, your child will still be 
treated for his/ her sore throat. You will not be penalised for not participating in this study.   
 
WHY ARE WE DOING THIS STUDY? 
 
There are many causes of sore throat.  Most often a sore throat is caused by a virus.  A virus is a germ 
which can cause illnesses, for example colds and flu.  Antibiotics do not work against viruses.  Antibiotics 
should only be used when a doctor or clinical nurse believes that a patient’s illness is caused by a 
bacterium, which is a different kind of germ which can be killed by antibiotics. 
 
If antibiotics are used too often and incorrectly, bacteria become resistant to the antibiotics.  This means 
that antibiotics no longer work against them and so in future, we may be unable to treat infections caused 
by these bacteria.    
 
A particular type of bacterium called Streptococcus pyogenes can cause sore throat.  As a complication of 
this type of sore throat, a small percentage of children can later develop disease of the heart valves 
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(Rheumatic heart disease) or kidney disease.  Antibiotics can prevent children from developing these 
complications. 
 
When a child has a sore throat, the doctor or clinical nurse has to decide whether the likely cause is a 
virus or a streptococcal infection, in order to decide whether or not antibiotics should be prescribed. There 
are certain symptoms and signs which may help the doctor or nurse to decide what is the most likely 
cause of a particular sore throat.  Doctors and nurses ask the patient and their caregiver questions, and 
examine the child to look for these signs. In previous studies, these symptoms and signs have been 
combined into “Clinical prediction rules”- a scoring system which helps the doctor or nurse to decide 
whether or not a sore throat is due to streptococcal infection. 
 
These scoring systems have been studied in other parts of the world to see how good they are at 
identifying children who have streptococcal sore throat. Their performance in South African children has 
not previously been studied.  
 
In this study, we will test the performance of existing prediction rules in South African children, and 
develop a clinical prediction rule for use in South African children. 
This information will be very helpful to healthcare workers who can use this to make decisions about the 
need for an antibiotic.  
 
There are many different genetic types of Streptococcus pyogenes and it is not known which types of this 
bacterium are most common in your area. In the study, we will take throat swabs which will be sent to a 
laboratory in the United States to examine the genetic structure of the bacteria. The genes of the bacteria, 
and not your child, will be investigated. 
 
It is hoped that if we know which genetic types are most common, it will help researchers to produce an 
effective vaccine against S pyogenes.  A vaccine is a substance that is used to protect a healthy person 
from developing an infection. 
 
 
IF WE PARTICIPATE, WHAT WILL BE EXPECTED OF US?  
 
If you agree to participate in the study, the study nurse or doctor will ask you questions about your child 
and their illness.  
   
After the questions, your child’s neck and throat will be examined.   
 
A throat swab will then be performed.  Using a long plastic stick with cotton wool at the end (much like 
an earbud) a sample of the mucous or pus from the back of the throat will be taken.  This sample will be 
sent to a laboratory where we will look for the presence of Streptococcus pyogenes.    
 
Afterward, the clinic doctor or nurse will examine and treat your child as usual. 
 
WHAT WILL HAPPEN TO MY CHILD'S THROAT SWAB AT THE END OF THE STUDY?  
 
Throat swabs collected from your child during this study will be labelled with a unique code. It will not 
be possible to determine your child's identity from this information.  Should your child’s swab contain 
bacteria, the sample will be stored.  We may study these bacteria further at a later date.  You will not be 
informed of any results of these studies, nor benefit financially from any medicines or vaccines which are 
produced by these studies.   
 
Any future research with your child's samples will be reviewed by the University of Cape Town and the 
University of Tennessee Institutional Review Board before the research can begin. Your permission is 
required for these later studies.    
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If you do not agree to the storage and later investigations of the bacteria, you can still be involved in the 
rest of the study procedures.  
 
 
WHAT ARE THE RISKS OF BEING INVOLVED IN THE STUDY? 
 
Taking the throat swab can be uncomfortable, especially for younger children.  Touching the back of the 
throat may make your child feel nauseous for a little while.  We will try to make the procedure as quick 
and comfortable as possible. 
 
 
WHAT ARE THE BENEFITS OF TAKING PART IN THIS STUDY? 
 
The results of the laboratory diagnosis of your child’s swab will be made available to the clinic staff to be 
added to your child’s folder.  Also, you will be helping us to produce a guideline to assist nurses and 
primary care doctors in deciding which people with sore throats need antibiotics.  Such a rule would be of 
benefit to future patients with sore throat as it will help doctors and nurses treat patients appropriately.  
You will also possibly be helping researchers to produce a vaccine that is effective in our setting and 
which may one day help in the prevention of the complications of sore throat. 
 
  
HAS THIS STUDY BEEN APPROVED? 
 
This study is being performed by investigators from the Department of Medicine and the Department of 
Medical Microbiology at Groote Schuur Hospital.   
 
The study has been approved by the Human Research Ethics Committee of the University of Cape Town. 
If you have any problem with this study, please contact this committee at 021 406 6338. 
 
 
YOUR RIGHTS AS A PARTICIPANT IN THIS STUDY 
 
You have the right to refuse to participate in this trial.  Your child will still be treated in the same way if 




All information collected during the course of this study will be kept securely and confidentially.  Reports 
about the study and results that may be published in scientific journals will not include any information 
which identifies you or your child personally.  
 
If the investigators have any questions about any of your child’s medical information which is important 
for this study, we may need to find the clinic folder to gather information.  This information will be 
treated as confidential. 
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INFORMED CONSENT: The Molecular Epidemiology of Streptococcus pyogenes pharyngitis 
Among Children in the Vanguard Community (Bonteheuwel/Langa), Cape Town, South Africa and 
The Development of a Locally Applicable Clinical Prediction Rule for Streptococcal Pharyngitis  
 
 
 I hereby confirm that I have been informed about the purpose, benefits and risks of 
allowing my child to participate in this study. 
 
 I am aware that some information regarding my child’s health will be used anonymously 
by the investigators and researchers. 
 
 I have been informed that participation is voluntary. 
 
 I have had an opportunity to ask questions and these have been answered 
 
 I have read and understood the contents of this document.  
 
 
I agree to the storage and later investigations of bacterial specimens obtained from my child’s throat.             









Parent or legal guardian:: 
 
________________________________________________________________________ 
Printed name                                      Signature                                                    Date 
 
 
Study Doctor or Research Nurse: 
 
 






Printed Name                                     Signature                                                     Date  
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DMID07-0056 App02 Assent.English.doc 
Assent Form 
 
The Molecular Epidemiology of Streptococcus pyogenes pharyngitis Among 
Children in the Vanguard Community (Bonteheuwel/Langa), Cape Town, 
South Africa And The Development of a Clinical Prediction Rule for 
Streptococcal Pharyngitis  
 
We are doctors and nurses from Groote Schuur Hospital and we are doing a study of sore throat 
in children.  Sore throat can be caused by many kinds of germs. 
 
We would like to ask you and your parent / legal guardian a few questions about your sore 
throat.  After that, the nurse will ask to look inside your mouth at your throat and feel your neck 
for swollen glands. 
 
To find out if you have a germ in your throat, we will use a long soft stick (like an earbud) and 
lightly touch the back of your throat.  This will not hurt at all and is very quick, but may be a 
little uncomfortable.  This stick will then be sent away to test for a germ that causes sore throat.   
 
If you allow us to examine you, you will be helping doctors understand sore throat better. Your 
information will help doctors and nurses to learn how to treat sore throat in children. 
 
You are allowed to say that you don’t want to be in the study.  Nobody will be angry with you if 
you say no. The clinic nurses will still treat your sore throat if you don’t want to be in the study. 
 
Before you decide, you can ask us questions.  If you want to be in the study, you must write your 





Printed name                                      Signature                                                     Date 
 
Study doctor or research nurse: 
 
________________________________________________________________________ 





Printed name                                       Signature                                                    Date 
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10.3 	  Appendix	  3:	  	  Case	  Report	  Form	  used	  in	  the	  Clinic-­‐based	  Studies	  
	  
	  
DMID 07-0056 Data Management Plan Version 1.2 
University of Cape Town 30April 2008 
 
DMID07-0056 CRF V1.2.doc     Page 1 of 2 




I.  General Information 
 
1 Enrolment Date d d m m y y 2 Clinic name    VAN / NET / LAN 
 3 Clinic folder #         
4 Date of birth d d m m y y 5 Age    
6 Gender m f  7 Race  Black White Ind Col 
8 Place of residence B L Oth  Other 
 
Has the patient used antibiotics within the last 30 days?                   
If yes, do not continue 
Y N 
 
Informed consent obtained                 










Mark the signs and symptoms obtained from history and examination of the child: 
 
 Y N   Y N 
1 Cough  1 0 2 Rhinorrhoea          1 0 
3 Hoarseness  1 0  4 Temperature > 38°C 1 0 
5 Tonsillar erythema  1 0  6 Tonsillar swelling 1 0 
7 Exudate on the pharynx 1 0  8 Exudate on the tonsils  1 0 
9 Oropharyngeal candidiasis 1 0  10 Tender anterior cervical node 1 0 
11 Anterior cervical node > 1.5cm in diameter  1 0  12 Rash 1 0 
 
 
Time of swab collection    _________________________ 
 
 
Person completing form    (Name)  _________________________ 
  
   (Signature)  _________________________ 
Screening Number:     
Participant  Number:     
Appendices	  
PhD	  Thesis:	  	  Mark	  E	  Engel	  	   	   	  	  	  |	  Page	  169	  
10.4 Appendix	  4:	  	  Standard	  Operating	  Protocol:	  	  Throat	  Swab	  Collection	  
	  
Collection  of  specimens.    
All  throat  swab  specimens will  be  collected  by  study staff using a standard procedure. 
For each throat specimen, a single sterile individual cotton swab will be slowly swiped 
across one tonsil or  tonsillar fossa, then across the posterior pharynx, and finally across the 
opposite  tonsil or  tonsillar  fossa. The collector will avoid touching the tongue or  the 
mouth with  the  swab. Swabs with liquid media tips will be used (Culturette or equivalent). 
These swabs will be returned to their sheaths following swabbing. The sheath contains a 
transport medium at the tip for the swab.   
 
Transport of specimens.  
Swabs collected at the clinical sites will be transported to the National Health Laboratory 
Service (NHLS) microbiology laboratory at Groote Schuur Hospital  for  incubation.  
Specimens  will  be  kept  in  an  insulated  bag  for specimens directly to the Groote 
Schuur Hospital laboratory where the culture will be performed.   In the unlikely event of 
the study nurse/ coordinator being unable to transport the specimens, another member of 
the research team will take on that responsibility.  
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Handling  of  specimens.    
Swabs will  be  received  by  the microbiology  laboratory and  logged  in  according  to  
routine  procedures.  Specimens received as appropriately labelled swabs will be plated 
onto 4% sheep blood agar plates  in a standard fashion. Every effort will be made to place 
specimens in an incubator no later than 4 hours from  the  time  of  collection.    Time of 
collection and  time  of plating will  be  recorded.   Plates will be  inverted  and  incubated  
anaerobically  at 35°C. After 18 to 24 hours, the plates will be read by the microbiology 
technician, under the supervision of one of the investigators, Dr Andrew Whitelaw. All 
cultures of beta-haemolytic colonies will be further  identified by Gram stain, catalase, and 
serogrouping, as appropriate.  A single colony will be picked off with a sterile wire loop, 
and  sub-cultured  for purity.   Pure  colonies of beta-haemolytic  streptococci identified as 
group A, C or G will be removed from  the plates  in a sterile fashion and placed in 
trypticase soy broth with glycerol for storage. Triplicate vials will be made  for each  isolate. 
The  cryovials will be  labelled with  identifier numbers and placed in the 70°C freezer. 
The report containing the microbiologic data indicating the  presence  or  absence  of  beta  
haemolytic  streptococci  (group  A,  C  or  G  in particular) and the storage identification 
number will be affixed  to the case report form. 
Appendices	  
PhD	  Thesis:	  	  Mark	  E	  Engel	  	   	   |	  Page	  171	  
10.5 Appendix	  5:	  	  Consent	  Form	  used	  in	  the	  School	  Screening	  Study	  
 
 
Prevalence of RHD in Cape Town 
 
A.S.A.P. Team, Dept of Medicine, University Of Cape Town, Ph:021-406-6361;   Fax: 021-406-6617 
PRHeDICT consent English v1.1 - swab   November 11, 2008 
A.S.A.P. 
Awareness   ♦  Surveillance   ♦  Advocacy  ♦  Prevention 
Rheumatic Fever & 
Rheumatic Heart Disease 
Name of Research Study:  Study of the Prevalence of Rheumatic Heart Disease in school 
children in the Vanguard Population in Cape Town, South Africa  
 
Principal Investigator: Bongani M. Mayosi, D.Phil. Groote Schuur Hospital 








This consent form contains information about the research study named above.  So we can be sure 
that you and your child are informed about being in this research study, we are asking you to read 
(or have read to you) this Consent Form.  You will also be asked to sign it (or place your thumb 
print in front of a witness).  You must sign this parental consent form and return it to the research 
staff before your daughter/son can take part in the research.  If your child is 8 years old or older, 
he/she will also be informed about the study and asked to agree to take part. We will give you a 
copy of this form.  This consent form might contain some words that are unfamiliar to you.  Please 
ask us to explain anything you may not understand.  
 
Why is the Study Being Done? 
A bacterium called Group A Streptococcus or “strep” is commonly found in the nose and throat of 
healthy adults and children, and can cause a wide variety of illnesses including sore throat, skin 
sores, and blood stream infections. These illnesses must be diagnosed and treated with the right 
medicine. If the streptococcus bacterium infects another part of the body one or more times, 
children may get Rheumatic heart disease (RHD). The valves of the heart can be affected which 
can lead to permanent damage. Some children may have RHD and not know it, because it may 
only cause problems later in life.  
 
This research is being done to study RHD. The main reason for the study is to see how many 
children between 5 – 17 years of age have RHD. We also want to find out how well the usual 
methods for detecting RHD are working. We hope that this study will collect information that will 
help to develop and bring vaccines that may prevent infections due to “strep” to Cape Town and 
other parts of the world in the future. 
 
What is involved in the Study? 
If you agree to have your child participate in this research, we will ask some general questions 
about your family and your child. Thereafter, your child will be examined and we will perform a 
throat swab.  Using a long plastic stick with cotton wool at the end (much like an earbud), we will 
rub over the skin at the back of the throat.  The swab will then be sent to a laboratory where we will 
look for the presence of a bacteria called Streptococcus pyogenes.  Afterward, the researcher will 
do a sound wave test of your child’s heart, called echocardiogram. This will tell us if your child 
might have a heart problem. If we find that your child already has heart disease or may be at risk to 
develop RHD, you will be referred to Red Cross Children’s Hospital for follow-up and treatment.  If 
we are not sure if the heart problem is RHD, we may ask your child to come back for a new 
echocardiogram in 6 months.  You will be asked to give permission for your child to continue in this 






A.S.A.P. Team, Dept of Medicine, University Of Cape Town, Ph:021-406-6361;   Fax: 021-406-6617 
PRHeDICT consent English v1.1 - swab   November 11, 2008 
A.S.A.P. 
Awareness ♦ Surveillance ♦ Advocacy ♦ Prevention 
Rheumatic Fever & 
Rheumatic Heart Disease 
About 3,000 children from Bonteheuwel and Langa will take part in this research. The entire study 
will take about 2 years. 
 
What will happen to my child's results at the end of the study?  
 
All information relating to your child during this study will be labeled with a unique code. It will not 
be possible to determine your child's identity from this information.  Should your child’s swab 
contain bacteria, the sample will be stored.  We may study these bacteria further at a later date.   
Any future research with your child's samples will be reviewed by the University of Cape Town’s 
Institutional Review Board before the research can begin. Your permission is required for these 
later studies.    
 
If you do not agree to the storage and later investigations of the bacteria, you can still be involved 
in the rest of the study procedures. 
 
What are the Possible Risks and Benefits of the Study?  
There is very little risk involved in taking part in this research.  The tests we will do will not hurt or 
pose any risk to your child. Taking the throat swab may be uncomfortable, especially for younger 
children since touching the back of the throat may make your child feel nauseous for a little while.  
We will try to make the procedure as quick and comfortable as possible.  
 
Your child may benefit from taking part in the research by referral for treatment if we detect a 
problem with his or her heart.  
 
What if I or My Child decides not to be in the Research? 
You and your child are free to refuse to be in this research study. No record will be kept of this, nor 
will it affect the health care your child would normally receive. 
 
Has this study been approved? 
This study is being performed by investigators from the Department of Medicine at Red Cross 
Children’s Hospital and Groote Schuur Hospital.  The study has been approved by the Human 
Research Ethics Committee of the University of Cape Town. If you have any problem with this 
study, please contact this committee at 021 406 6338. 
 
What about Confidentiality? 
You must sign this parental consent form and return it to the research staff before your 
daughter/son can take part in the research. We will protect information about your daughter/son 
and her/his taking part in this research to the best of our ability. Your child will be identified by a 
code on all study records. Personal information from his/her records will not be released without 
your written permission. If the results of this research are published, your child's name will not be 
shown. However, the staff of Red Cross Children’s and Groote Schuur Hospitals may sometimes 
look at records of those people who take part in the research study.   
 
Will we be Paid for Being in the Study? 
You or your daughter/son will not be paid for being in the research. 
 
What are the Costs? 
There will be no costs to you or your medical aid for procedures that are part of this study. 
 
How Long Will My Child be in the Study? 





A.S.A.P. Team, Dept of Medicine, University Of Cape Town, Ph:021-406-6361;   Fax: 021-406-6617 
PRHeDICT consent English v1.1 - swab   November 11, 2008 
A.S.A.P. 
Awareness ♦ Surveillance ♦ Advocacy ♦ Prevention 
Rheumatic Fever & 
Rheumatic Heart Disease 
Can My Child Leave the Research Study? 
Your child may leave the research study at any time without losing the benefits of any of the regular 
care he or she would normally receive. 
 
Also, your daughter/son may be asked to leave the research if  
• the research doctor/clinic staff or you feel it is best for her/him, or 
• the research is stopped. 
 
What are My Child’s Rights as a Study Participant? 
Taking part in this study is voluntary. You may choose not to let your child take part in the study, or 
you or your child may decide to leave the study early. This will not cause any problems with your 
child’s regular medical care.  
 
If you have any questions about your daughter/son's rights while taking part in the research you 
may contact the Human Research Ethics Committee of the University of Cape Town on  
(021) 406-6338.  
 
What if My Daughter/Son has a Problem? 
If your daughter/son has a problem that you or she/he thinks might be related to taking part in this 
research, please call our office on 021-406-6361.   
 
If your daughter/son is sick or has a health problem due to her/his participation in this research, you 





A.S.A.P. Team, Dept of Medicine, University Of Cape Town, Ph:021-406-6361;   Fax: 021-406-6617 
PRHeDICT consent English v1.1 - swab   November 11, 2008 
A.S.A.P. 
Awareness ♦ Surveillance ♦ Advocacy ♦ Prevention 
Rheumatic Fever & 




Name of Research Study:  Study of the Prevalence of Rheumatic Heart Disease in school 




1. STATEMENT BY PARENT/GUARDIAN AGREEING FOR HIS/HER CHILD TO PARTICIPATE 
IN THIS STUDY 
 
I have read this informed consent document describing the benefits, risks and procedures for the 
research study titled “Study of the Prevalence of Rheumatic Heart Disease in school children in the 
Vanguard Population in Cape Town, South Africa” or it was read to me.  I freely and voluntarily 




Name of participant: _________________________________________ 









2. IF THE PARENT/GUARDIAN CANNOT READ THE FORM THEMSELVES, A WITNESS 
MUST SIGN HERE: 
 
I was present while the informed consent document with benefits, risks and procedures were read 
to the parent/guardian and the participant.  The parent/guardian has freely and voluntarily agreed to 
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A.S.A.P. Team, Dept of Medicine, University Of Cape Town, Ph:021-406-6361;   Fax: 021-406-6617 
PRHeDICT consent English v1.1 - swab   November 11, 2008 
A.S.A.P. 
Awareness ♦ Surveillance ♦ Advocacy ♦ Prevention 
Rheumatic Fever & 
Rheumatic Heart Disease 
Assent Form for Children 8 years and older 
 
Name of Research Study:  Study of the Prevalence of Rheumatic Heart Disease in school 
children in the Vanguard Population in Cape Town, South Africa  
 
Principal Investigator: Bongani M. Mayosi, D.Phil. Groote Schuur Hospital 
Tel:  27-21-406-6200   Email: bongani.mayosi@uct.ac.za  
 
We are doctors and nurses from Groote Schuur Hospital and we are doing a study of hearts in 
children.  Some heart diseases are caused by a specific type of germ living in the throats of 
children.    
 
We would like to ask you a few questions about your health.  After that, the nurse will examine your 
skin and joints.  This will not hurt at all and is very quick. 
 
We also want to examine your throat to make sure that you do not have any germs living there.  
We will use a long soft stick (like an earbud) and lightly touch the back of your throat.  This will not 
hurt at all and is very quick, but may be a little uncomfortable.  This stick will then be sent away to 
test for the germ that causes sore throat.   
 
A special machine will be used to examine your heart.   This will not hurt at all and is very quick.   
 
If you allow us to examine you, you will be helping doctors to know how many healthy hearts and 
throats are present in the community. 
 
You are allowed to say that you don’t want to be in the study.  Nobody will be angry with you if you 
say no.  
 
Before you decide, you can ask us questions.  If you want to be in the study, you must write your 






Printed name                                      Signature                                                     Date 
 
 
Study doctor or research nurse: 
 
________________________________________________________________________ 






Printed name                                       Signature                                                    Date 
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10.7 Appendix	  7:	  	  	  Case	  Report	  Form	  used	  in	  the	  School	  Screening	  Study	  
CT (PRHeDICT) CRF, Version: 2.0         Updated    19 October 2012   Participant No.:                                           
A.S.A.P. SCREENING PROJECT:  Case Report Form   p1/7 
 
 
CASE RECORD FORM 
 








DIAGNOSTIC CATEGORY:   (CIRCLE ONE ONLY) To be completed at end of today’s examination 
 
1st Attack ARF                       = 01 
Recurrence of ARF without RHD    = 02 
Recurrence of ARF with RHD    = 03 
Chorea            = 04 
Insidious onset of rheumatic carditis    = 05 
Known diagnosis of Chronic Rheumatic Heart Disease       = 06 
School screening – normal     = 07 
School screening – possible rheumatic process    = 08 
School screening – probable rheumatic process   = 09 
School screening - 1st diagnosis of Chronic RHD           = 10  
School screening – Other (Specify _________________)    = 11               
Family screening - normal         = 12 
Family screening - abnormal                                                 = 13 
MODE OF DIAGNOSIS:  School screening 
  Family screening 
  Health care facility (Symptomatic) 
 
DATE:  
SIGNED:   
DESIGNATION: 
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PART I:  BASIC DATA 
 
 
 PARTICIPANT NUMBER:  
DATE OF BIRTH:  dd/mm/yyyy     eg: 16/05/1991 
SEX:  (0 = unknown; 1  = male, 2 = female) 
SUBURB:  
   
ETHNICITY:  Asian 
  Black 
  Coloured 
  White 
  Foreign Country:   
SCHOOL NAME:    






PART II:  PAST MEDICAL HISTORY (ALL PERSONS SCREENED) 
 
 
PRE-EXISTING DIAGNOSIS: 1. 2. 3. 
MONTH OF DIAGNOSIS:  MMM/YYYY   eg: JAN/1991, 0 = unknown 
DATE OF ADMISSION:  DD/MM/YYYY eg: 16/05/1991, 0 = unknown 
DATE OF DISCHARGE:  DD/MM/YYYY eg: 16/05/1991,  0 = unknown 
SYMPTOM TIME:  Days prior to presentation 
THERAPY PRIOR TO PRESENTATION / ADMISSION:  
0 = unknown, A = nil, 1 = Aspirin,  







Signed:_____________________________     Date: I__I__I / I__I__I / I 2 I 0 I 0 I__I 
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PART III. AUSCULTATION / SKIN EXAMINATION 
 
 PART IIIA. CONSENT AND ANTHROPOMETRIC MEASUREMENTS 
 
1. Participant Number                           I 1 I-I__I__I__I__I       
 
 
2. Initials:                                              I__I__I  /  I__I__I       
3. Site:                                          Name_________________________  
4. Site                                       Number I__I__I  
5. Date of Enrolment:                             I__I__I / I__I__I / I 2 I 0 I 0 I__I 
                                                                      dd            mm           yyyy 
6. Informed consent obtained?               o Yes     o No    IF NO DO NOT CONTINUE 
    If no; why not                                 ______________________________________ 
7. Height I__I__I__I.I__I                        8.  Weight I__I__I__I.I__I                    9.  AGE I__I__I                             
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 PART IV. ECHO SCREENING DATA COLLECTION FORM 
  
Participant number:   I 1 I-I__I__I__I__I       
 
Initials:    I    I__I / I__I__I       
 
Site:        Name ______________________   Number I__I__I 
     
Date of enrolment:  I__I__I / I__I__I / I 2 I 0 I 0 I__I 
 
Step 1: PLAX 2D  
Mitral valve:  Normal o   
Abnormal o  à  Elbow deformity of the amvl o  
Thickened amvl   o  
Thickened pmvl  o
 Elongation of amv chordae o  
Tethered pmvl   o  
                                   Not sure           o  
                                    Measured thickness of amvl at margin _______________mm 
                                                                                     Midleaflet _____________mm 
                                    Measured thickness of pmvl at margin _______________mm 
                                                                                  Midleaflet _______________mm 
Nodules:   oYes    o  No 
 
Aortic valve:   Normal o   
Abnormal oà Thickened right coronorary cusp         o  
                                                                       Thickened non-coronary cusp             o  
                                                                       Thickened ring                                     o  
                                                                       Thickened but not typically rheumatic o  
                                    Not sure          o  
Nodules:   oYes    o  No 
 
Step 2: PLAX M-MODE 
Measurements: At mitral valve tips:  IVSd  =   ___ 
LVIDd =  ___ 
LVPWd   ___ 
IVSs     ___ 
LVIDs   ___ 
LVPWs =   ___ 
EF =    ___ 
%FS =    ___ 
RVIDd =   ___ 
RVIDs  =  ___ 
 
At aortic cusp:  Ao (diam) =   ___   
LA (diam) =   ___ 
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Step 3: PLAX COLOR DOPPLER 
Mitral valve:  Normal  o    
Regurgitation o  à   Jet direction _______ 
       Pan-systolic o   
Measure jet __ __ cm 
                                    Not sure         o  
 
Aortic valve:   Normal  o     
Regurgitation o  à  Jet direction _______ 
                          Measure jet :   length    _____cm 
                          Measure jet :   width      _____cm 
                                   Not sure          o  
 
Step 4: PSAX 2D  
Mitral valve:    Normal  o  
   Abnormal o  à  Regurgitation o  à _____________  
   Stenotic  o  à _____________ 
   Not sure  o   
If stenotic or not sure must have PW Doppler 
 
 
Aortic valve:   Normal o   
Abnormal oà Thickened right coronorary cusp         o  
                                                                       Thickened non-coronary cusp             o  
                                                                       Thickened ring                                     o  
                                                                       Thickened but not typically rheumatic o  
 




Step 5: PSAX COLOR DOPPLER 
Mitral valve:  Normal o      
Regurgitation o  
                                    Not sure          o  
 
 
Aortic valve:   Normal o       
Regurgitation o  




Step 6: APICAL 2D 
Mitral valve:  Normal o   
Abnormal o  à  Elbow deformity of the amvl o  
Thickened amvl   o  
Thickened pmvl  o
 Elongation of amv chordae o  
Tethered pmvl   o  
                                    Not sure           o  
                                    
                                    Measured thickness of amvl at margin _______________mm 
                                                                                     Midleaflet _____________mm 
                                    Measured thickness of pmvl at margin _______________mm 
                                                                                  Midleaflet _______________mm 
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Aortic valve:   Normal o   
Abnormal oà Thickened right coronorary cusp         o  
                                                                       Thickened non-coronary cusp             o  
                                                                       Thickened ring                                     o  
                                                                       Thickened but not typically rheumatic o  
 
                                    Not sure          o  
 
 







 Normal   o     
 
Regurgitation à 
 Good spectral envelope? Y N 
 Jet reaches back atrial wall?  Y N 
 Measure Jet (cm)  











           
o  





 Normal    o     
 
Regurgitation à 
 Good spectral envelope? Y N 
 Jet direction Central Medial 
lateral eccentric 
  
Measure Jet (cm) length 
 










           
o  
  Measure Jet (m/s) PHT  




Step 8: APICAL PW/CW DOPPLER 
 
MV pressure half-time and MVA: _________seconds = MVA _____ cm2 
o  Not done 
 
If MS suspected:……………  MV mean pressure gradient:  _________mmHg 
                                                           o  Not done 
 
PW/CW Doppler of the AV:   _________m/s 
o  Not done 
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Step 10: summary 
 
ECHOCARDIOGRAPHIC FEATURES OF RHD 
   
Yes  o  If yes, continue below…   No    o  
 
Definite RHD: Significant MS (Mean Grad: >4mmHg) 
 Significant structural and functional changes involving both mitral AND aortic 
valves OR multiple valve disease 
 
Probable RHD: Significant structural AND functional changes involving either mitral OR aortic 
valves 
 Single valve disease 
 






Significant	  structural	  changes:	  	  
Thickness	  of	  mitral	  and	  aortic	  leaflets	  greater	  than	  4mm	  
Increased	  echogenicity	  of	  submitral	  structures	  
Rheumatic	  nodules	  giving	  a	  beaded	  appearance	  
Prolapse	  of	  mitral,	  aortic	  or	  tricuspid	  valves	  
Reduced	  mobility	  of	  leaflets	  
Chordal	  tears	  	  
Elbow	  or	  dog	   leg	  deformity	  of	   the	  anterior	  mitral	   valve	  
leaflet.	  
Fixed	  or	  markedly	  restricted	  motion	  of	  the	  posterior	  
mitral	  leaflet 
Significant	  functional	  changes:	  	  
Significant	  mitral	  regurgitation:	  
defined	  as	  a	  mitral	  regurgitant	  jet	  at	  least	  1	  cm.	  from	  
the	  coaptation	  point	  of	  the	  valve	  leaflets,	  seen	  in	  two	  
planes,	   high	   velocity	   (mosaic	   pattern)	   and	   persisting	  
throughout	   systole.	   Additional	   changes	   that	   may	   be	  
present	   include	   multiple	   regurgitant	   jets	   and/or	   a	  
posterolaterally-­‐directed	  jet	  
	  
Significant	  aortic	  regurgitation:	  	  
defined	  as	  an	  aortic	  regurgitant	  jet	  at	  least	  1	  cm	  from	  
the	   coaptation	   point	   of	   the	   valve	   leaflets,	   of	   high	  




Signed:_____________________________     Date: I__I__I / I__I__I / I 2 I 0 I 0 I__I 
                     Person completing section                      dd         mm             yyyy 
 
A.S.A.P. Team, Dept of Medicine, University Of Cape Town,        Ph:021-406-6361;   Fax: 021-406-6617 
PRHeDICT Throat CRF v1.docx.0  2010-01-20 
A.S.A.P. 
Awareness ♦ Surveillance ♦ Advocacy ♦ Prevention 
Rheumatic Fever & 
Rheumatic Heart Disease 




I.  General Information 
 
1 Enrolment Date       2 School     (Abbr) 
3 Date of birth       4 Age    
5 Gender m f  6 Race  Black White Ind Col 
7 Place of residence B L Oth  Other 
 
Has the participant used antibiotics within the last 30 days?                   





II.  Clinical Examination 
 
 
Mark the signs and symptoms obtained from history and examination of the child: 
 
 Y N   Y N 
1 Cough  1 0 2 Rhinorrhoea          1 0 
3 Hoarseness  1 0  4 Temperature > 38°C 1 0 
5 Tonsillar erythema  1 0  6 Tonsillar swelling 1 0 
7 Exudate on the pharynx 1 0  8 Exudate on the tonsils  1 0 
9 Oropharyngeal candidiasis 1 0  10 Tender anterior cervical node 1 0 
11 Anterior cervical node > 1.5cm in diameter  1 0  12 Rash 1 0 
 
 
Time of swab collection    _________________________ 
 
 
Person completing form    (Name)  _________________________ 
  
   (Signature)  _________________________ 
 
Participant Number:      
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10.8 Appendix	  8:	  	  	  emm	  Typing	  Protocol	  
Genomic DNA Extraction 
Isolates were subcultured from frozen stocks onto blood agar and incubated in presence of 5% CO2 for 
24 hours. Single colonies were suspended in 1 ml of autoclaved water in Eppendorf tubes (Eppendorf, 
Germany).  After emulsifying the colonies, the bacteria were pelleted using a microfuge for 1 minute at 
16500 x g (Eppendorf, Germany).  The supernatant was discarded and genomic DNA was extracted from the 
bacterial pellet using an InstaGene matrix DNA extraction kit (Bio-Rad, France) as recommended by the 
manufacturer.  Using a 1000 µl pipette tip, as instructed, InstaGene matrix was added to the pellet and 
incubated for 30 minutes at 56°C (Kendro, German).  After incubation, the tubes were vortexed at level 8 on 
a Vortex-2 Genie (Scientific Industries, USA) for 10 seconds and placed on a heating block (Techne LTD, 
USA) at 100°C for 8 minutes.  The Eppendorf tubes were then vortexed again at level 8 for 10 seconds 
followed by centrifugation in a microfuge at 16500 x g for 3 minutes.  The supernatant, containing the 
extracted DNA, was used as a template for PCR amplification. 
Polymerase Chain Reaction 
The emm gene was selectively amplified using PCR according to the CDC protocol.  This molecular 
method selectively amplifies a target gene or a portion of a gene.  The amplification is achieved by the use of 
sequence-specific oligonucleotides, often referred to as primers.  Primers work in pairs by binding on either 
strand of double-stranded DNA. The primers used in emm typing anneal to a conserved sequence internal to 
the emm gene.  The primers (Table) used in this assay were synthesized at the Department of Molecular and 
Cell Biology, University of Cape Town, South Africa.  Polymerase chain reaction amplification of DNA is 
achieved by the work of an enzyme called DNA polymerase I (Taq Polymerase) isolated from the bacterium 
Thermus aquaticus.  Taq Polymerase has the ability to withstand high temperatures during PCR cycles.   
 
To achieve a successful amplification of the emm gene, a combination of reagents were used at specific 
concentrations recommended by the CDC.  PCR reagents comprised 1X buffer, 1.5 mM MgCl2, 0.2 mM 
dNTP, 70 picomol/µl of the forward and reverse primers and 1.5U of SuperTherm Taq (JMR, Holdings, 
London UK) then brought to a final volume of 50 µl with DNAse-free water.  
 
Table.  Primers used for emm Typing 
Target gene Primer  Primer sequence 
emm gene Primer 1 (forward) TAT T(C/G) GCT TAG AAA ATT AA  
 Primer 2 (reverse) GCA AGT TCT TCA GCT TGT TT 
 Emmseq2 TAT TCG CTT AGA AAA TTA AAA ACA GG 
 
Cycling conditions for amplification of the emm gene involves the three basic principle amplification steps 
during PCR, namely; denaturation, annealing and elongation.  Cycling conditions for emm typing, as 
recommended by the CDC, begins with initial denaturation at 94ºC for a minute followed by 30 cycles of 
denaturation at 94ºC for 15 seconds, annealing at 46.5ºC for 30 seconds and extension at 72ºC for 75 
seconds.  Additional 20 cycles follow with denaturation at 94ºC, annealing at 46.5ºC for 30 seconds, 
extension at 72ºC for 75 seconds with a 10 second increment for each of the subsequent 19 cycles.  Final 
extension was carried out at 72ºC for 10 minutes. 
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Agarose Gel Electrophoresis 
Agarose gel electrophoresis is a technique used to separate DNA fragments based on their sizes when 
subjected to an electrical current.  DNA has a negative charge due to the phosphate groups on its sugar-
phosphate backbone and thus migrates to the positive end of the agarose gel when an electric current is 
passed through the gel.  The percentage of agarose within a gel determines the pore size; hence different 
percentages of gels are prepared based on the size of DNA fragments to be separated.  Larger DNA 
fragments migrate slower through an agarose gel than smaller fragments.  
 
Agarose gel electrophoresis was used to separate the DNA fragments following PCR. As the expected sizes 
of emm amplicons range from 750 bp to 1400 bp, a 2% agarose gel was used to separate the PCR products.  
Agarose (SeaKem® LE Agarose, Lanza, USA) was dissolved in 1X TAE buffer (Appendix A) and ethidium 
bromide (10 ng/µl), which intercalates between base pairs of DNA and fluoresces under ultraviolet light.  
Eight microliters of the PCR product was loaded into each well, with 2 µl of loading dye.  The fragments 
were separated by passing an electric current through the agarose for 3 hour of 60V to allow the negatively 
charged DNA fragments to migrate towards the positive electrode.  The rate of migration is inversely 
proportional to the size of the fragments. A molecular marker (HyperLadder IV, Bioline, UK) was included 
to enable estimation of emm amplicon sizes.  
DNA Purification 
The DNA sequencing assay is very sensitive and requires a purification step to minimise inhibition by PCR 
reagents within the sample.  The MinElute PCR purification kit (Qiagen, Valencia, CA, USA) incorporates 
spin-column technology using silica-gel membranes with selective binding properties to purify DNA directly 
from PCR products. 
 
Five volumes of PB buffer was added to one volume of PCR product and mixed as per manufacturer’s 
instructions.  To achieve a pH of 5.0 as recommended, 10 µl of 3 M sodium acetate was added and mixed.  
The mixture was then added to 2 ml MinElute columns and centrifuged in a microfuge (Eppendorf, German) 
for 1 minute at 17900 x g.  The flow through products were discarded and 750 µl of Buffer PE was added to 
the column which was again centrifuged for a minute at 17900 x g. Again, the flow through product was 
discarded and the column was centrifuged for a minute at 17900 x g.  MinElute columns were then 
transferred to sterile 1.5 ml Eppendorf tube and the DNA was eluted following the addition of 10 µl EB 
buffer to the centre of the column membranes and centrifuged for a minute at 17900 x g.  Purified DNA 
products were stored at 4ºC. 
 
Sequencing and Assigning emm Types 
Sequencing of purified DNA was done using the ABI Prism® BigDyeTM Terminator Cycle Sequencing kit 
(Applied Biosystems, USA) at Stellenbosch University, South Africa.  The DNA concentration was adjusted 
to 10 ng/µl for amplicon less than 1000-bp and 20 ng/µl for amplicons more than 1000-bp as recommended 
by the sequencing facility at the Stellenbosch University, South Africa.  Primer emmseq2 (Table), 
recommended by the CDC, was prepared to 1.1 ng/µl and used for sequencing reaction. Sequences generated 
were analysed using BioEdit v7.0.9 (Ibis Biosciences, USA).  The sequences were submitted electronically to 
the S. pyogenes emm sequence database centre at the CDC which assigned all the emm types and subtypes.  
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10.9 	  Appendix	  9:	  	  	  Search	  Strategy	  For	  Twin	  Studies	  of	  ARF	  and	  RHD	  
	  
Search	  performed	  on	  Pubmed	  
1	   RHEUMATIC	  FEVER	  OR	  RHEUMATIC	  HEART	  
2	   FAMIL*	  OR	  TWIN	  OR	  ADOPTION	  
3	   #1	  AND	  #2	  
	  
Search	  performed	  on	  EMBASE	  (www.embase.com)	  
1	   'RHEUMATIC	  FEVER'/SYN	  OR	  'RHEUMATIC	  HEART'	   	  
2	   FAMIL*	  OR	  'TWIN'/SYN	  OR	  'ADOPTION'/SYN	  	  
3	   #1	  AND	  #2	   	  
4	   #1	  AND	  #2	  AND	  [HUMANS]/LIM	  AND	  [EMBASE]/LIM	  
	  
